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Cortisol is a steroid hormone, which is produced in the cortex of the adrenal gland. 
Cortisol was first discovered by Edward Kendall, Tadeus Reichstein, and Philip Hench 
in the 1930s (1). After collecting 1,000 kg of adrenals from cattle, they extracted 25 
g of active substance, in which they discovered 29 different steroids. Twenty-four of 
these were still undiscovered previously, including cortisol. In 1950, they shared the 
‘Nobel prize in physiology or medicine’ for their discoveries relating to the hormones 
of the adrenal cortex, their structure, and biological effects (1).  
 
The biological effects of cortisol are derived from the evolutionary perspective of 
stress response control, and consequently, these effects are widespread throughout 
the human body. These include immunosuppressive functions, e.g. reduction of an 
inflammatory response, and prevention of an allergic reaction, as well as the modern 
use of cortisol in the prevention of rejection of organ transplants (2, 3). In addition, 
cortisol co-regulates metabolic functions, e.g. control of blood pressure, glucose 
metabolism, bone mineral density, and lipid metabolism (4, 5). Finally, cortisol 
controls psychological functions, e.g. regulation of mood, well-being, and cognitive 
function (6). Therefore, cortisol is released in response both to physical and mental 
stress (7, 8).  
 
In this chapter, the physiological and pathophysiological role of cortisol is explored, 
starting with the production and regulation of cortisol in healthy individuals. 
Subsequently, disruptions in the regulation of cortisol are discussed, including both 
states of cortisol excess (hypercortisolism) as well as cortisol deficiency 
(hypocortisolism), which is also known as adrenal insufficiency. Underlying causes, 
clinical features, and treatment options are presented. 
 
 
The hypothalamus-pituitary-adrenal axis  
 
Cortisol concentrations in the human body are controlled by the hypothalamus-
pituitary-adrenal (HPA) axis (Figure 1). The central circadian oscillator (pacemaker), 
which is located in the hypothalamic suprachiasmatic nucleus in the brain, regulates 
this HPA-axis under basal, non-stressed conditions. This pacemaker ensures a daily 
rhythm in the production of cortisol (the so-called circadian rhythm), which is 
externally synchronized by the light-dark cycle as its most important input. The 
pacemaker mainly influences the hypothalamus, driving the release of corticotropin-
releasing hormone (CRH) from the hypothalamic paraventricular nucleus. CRH 
stimulates the release of adrenocorticotropic hormone (ACTH) from the corticotroph 
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cells in the anterior pituitary gland. CRH also stimulates the production of new ACTH 
from its precursor POMC in the anterior pituitary, which is secreted after the initial 
fast release of pre-stored ACTH. ACTH is released from the anterior pituitary gland in 
around 40 pulses per 24 hours, with the highest amount of ACTH released in the 
morning around the time of waking. ACTH induces the release of cortisol from the 
adrenal cortex. Lowest concentrations of cortisol in the human body are found 
around midnight, and highest concentrations are found in the morning after the 




Figure 1: The hypothalamus-pituitary-adrenal (HPA) axis is regulated through the light-dark cycle via the 
retinohypothalamic tract (RHT), which in case of light inhibits the activity of the superior cervical ganglia 
(SCG). When dark, the SCG stimulates production of melatonin. Melatonin activates the suprachiasmatic 
nucleus (SCN) by the melatonin 1 and 2 receptors (MT1 and MT2), which in turn influences circadian rhythms 
including the HPA-axis. The SCN is modulated through daily behaviors and through serotonin from the raphe 
nucleus which acts at the serotonin receptor (5-HT2C) (A). The HPA-axis regulates production and release of 
glucocorticoids by excitatory control of the amygdala and inhibitory control of the hippocampus. The 
paraventricular nucleus in the hypothalamus produces corticotropin-releasing hormone (CRH), also known as 
corticotropin-releasing factor (CRF), which stimulates ACTH production and release from the pituitary, 
which in turn stimulates the adrenal cortex to synthesize and release glucocorticoids. Glucocorticoids inhibit 
the HPA-axis by negative feedback at various levels (B). Glucocorticoids have several metabolic influences in 
various tissues of the human body (C). Adapted from de Bodinat et al., Hyman, and Fernandez-Rodriguez et 




Cortisol controls the abovementioned immunosuppressive, metabolic, and 
psychological functions by binding to the glucocorticoid receptor and also to the 
mineralocorticoid receptor. In addition, cortisol regulates its own secretion by a 
negative feedback mechanism through glucocorticoid and mineralocorticoid receptors 
in the brain and in the anterior pituitary gland (10). 
 
Factors influencing cortisol concentrations  
Circulating cortisol concentrations are lower in premenopausal women than in men of 
corresponding age, but there is no difference in cortisol concentrations between 
postmenopausal women and men older than fifty years. Therefore, there appears to 
be no sex difference, but there seems to be an influence of female hormones on 
cortisol concentrations. In older age, the morning cortisol peak occurs later than in 
younger age (13, 14). Food consumption rapidly increases concentrations of cortisol, 
mainly during the daytime (15). Differences in cortisol concentrations between 
different ethnic groups in relation to differences in social activity and living habits, 
suggest that these habits influence the synchronization of daily cortisol rhythms. E.g. 
in Chinese people, the cortisol peak occurs two hours earlier than in Caucasians, 
which may be related to their habits of early awakening and going to sleep early (16).  
 
The morning cortisol peak after awakening is also known as the cortisol awakening 
response. This response seems to be influenced by both waking up as well as by 
daylight, as a smaller cortisol awakening response is seen after waking up in the 
afternoon than in the morning, and no cortisol awakening response is seen in the 
evening (17). Altered habits, such as lack of sleep, changes in meal pattern, and 
light-dark transitions, as may occur during travelling (jet lag) or shift work, affect the 
circadian rhythm in cortisol production, with complete inversion of cortisol rhythm 
when sleeping twelve hours out of phase with the usual sleep pattern (18). Circadian 
misalignment, by sleeping and eating at unusual times, reduces glucose tolerance in 
shift workers, increasing the risk of type 2 diabetes mellitus (19).  
 
In reaction to unforeseen changes in the environment called ‘stressors’, which can be 
both external (e.g. temperature changes, food deprivation, physical trauma, 
infection) and internal (e.g. psychological stress), the stress system is activated. This 
stress system senses environmental changes through sensory organs and adjusts the 
central nervous system and peripheral organ activity to improve the chance of 
survival through restoration of internal homeostasis. The stress system includes both 
activation of the autonomic nervous system and the HPA-axis, and therefore leads to 
increased production of catecholamines and cortisol, which in turn increases 
metabolism (e.g. glucose concentrations), as needed to cope with the stressor at 
hand (the ‘fight-or-flight response’) (20). 
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Measurement of hormone concentrations and testing the HPA-axis  
Approximately 95% of circulating cortisol is transported bound to cortisol-binding 
globulin (CBG). The remaining 5% is unbound, also called ‘free cortisol’, and is 
therefore available for executing the previously mentioned functions of cortisol by 
binding to the glucocorticoid and mineralocorticoid receptors (21). Cortisol bound to 
CBG can be released, depending on the saturation of the CBG (the percentage of CBG 
binding cortisol) and the affinity with which cortisol is bound to CBG. Cortisol-binding 
affinity is reduced locally in case of local inflammation and systemically in case of 
fever, leading to increased cortisol release from CBG (21).  
 
Nowadays, cortisol can be measured by immunoassay or mass spectrometry in serum, 
saliva, urine, and hair. Serum total cortisol is usually measured in the morning to 
provide the peak cortisol concentration (22). Salivary cortisol on the other hand is 
collected at midnight, to capture the physiologically lowest cortisol concentration 
(23). Urinary free cortisol is usually measured in 24 h urine samples to provide the 
mean cortisol excretion (24). Hair cortisol can be examined to determine long-term 
cortisol exposure, which is until now only performed in research settings (25). Serum 
ACTH concentrations are measured by immunoassay, and they are often measured 
accompanying the morning serum total cortisol (26). Both salivary and hair cortisol 
reflect free cortisol measurements. 
 
As cortisol concentrations vary during the day, single cortisol measurements provide 
limited information and are generally considered inadequate in determining normal 
functioning of the HPA-axis. Therefore, dynamic stimulation as well as suppression 
tests have been developed. In general, a rise in plasma glucocorticoids inhibits the 
ACTH secretion from the anterior pituitary gland, thereby suppressing the activity of 
the HPA-axis, whereas a fall in plasma glucocorticoids stimulates ACTH secretion 
from the anterior pituitary gland, thereby stimulating the activity of the HPA-axis. 
HPA-axis stimulation tests aim to maximize cortisol production from the adrenal 
cortex, whereas HPA-axis suppression tests aim to minimize cortisol production. 
 
The most commonly used stimulation test in clinical practice is the ACTH stimulation 
test, which is used to test the maximum potential function of the adrenal glands 
when insufficient functioning is clinically suspected. During the ACTH stimulation 
test, usually a high dose (250 µg), or alternatively a low dose (0.5-1.0 µg), of ACTH is 
administered, and cortisol is measured after 30 (and sometimes also after 60) 
minutes and compared to the baseline cortisol measurement. Another stimulation 
test is the CRH test, in which 100 µg of CRH is administered, and cortisol and ACTH 
are measured for maximum increase compared to baseline (27). The insulin tolerance 
(stress) test can be used to induce the physiological stress response by administering 




cortisol concentrations. However, as this is a potentially hazardous test in selected 
patients and uncomfortable for the patient, it is less commonly used (28). Finally, the 
overnight metyrapone stimulation test can be used to test the HPA-axis, in which 
patients are given a midnight metyrapone dose to inhibit the conversion of 11-
deoxycortisol to cortisol, resulting in increased ACTH secretion due to loss of negative 
feedback in case of intact hypothalamic-pituitary function (29).  
 
The low dose (1 mg) and high dose (8 mg) overnight dexamethasone suppression tests 
are available to test whether endogenous cortisol production can be suppressed. 
Because dexamethasone binds to the glucocorticoid receptor, both CRH and ACTH 
production and release are inhibited, and therefore also cortisol production is 
inhibited. Dexamethasone does not interfere with the assay used to measure cortisol 
concentrations. The high dose overnight dexamethasone suppression test is more 
potent in suppressing cortisol concentrations than the low dose test, but does not 
result in meaningful higher discriminatory power and is therefore not often necessary 
in the screening process of Cushing’s syndrome (27). 
 
 
Endogenous hypercortisolism  
 
Cortisol overproduction by the human body itself is called endogenous 
hypercortisolism. The combination of clinical symptoms accompanying endogenous 
hypercortisolism is now known as Cushing’s syndrome, and was first described in 1912 
by Harvey Cushing (30): 
 
“A syndrome of painful obesity, hypertrichosis, and amenorrhoea, with over-
development of secondary sexual characteristics accompanying a low grade of 
hydrocephalus and increased cerebral tension. Pituitary, adrenal, pineal or ovary?” 
 
An excess concentration of glucocorticoids induces specific metabolic changes and 
thereby alter body composition, including fat maldistribution, muscle wasting, insulin 
resistance, dyslipidemia, and hypercoagulability. Furthermore, risk of osteoporosis, 
hypertension, and neuropsychiatric disorders is increased by hypercortisolism (4, 31). 
Symptoms and signs associated with Cushing’s syndrome include weight gain (with 
central obesity, rounded ‘moon’ face, and increased dorsal and supraclavicular fat 
pads called ‘buffalo hump’), proximal muscle weakness, menstrual irregularities, loss 
of libido, depression, hirsutism, and thinness and fragility of the skin (with acne, 
purple striae, hyperpigmentation, and easy bruising) (Figure 2) (4, 32). Mortality is 
high in untreated severe Cushing’s syndrome, with an estimated five-year survival 
rate of only 50% (33). 
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Endogenous hypercortisolism can be caused by a variety of etiologies (Table 1). The 
majority of these etiologies are ACTH-dependent, meaning that ACTH secretion is 
increased along with cortisol, and a minority of these etiologies are ACTH-
independent, meaning that cortisol concentrations are increased without increase in 
ACTH concentrations (32). Cushing’s disease is the most common underlying cause of 
endogenous hypercortisolism, with an incidence of 1.2-1.7 patients per million 
persons each year (35), which accounts for approximately 70% of cases of endogenous 
hypercortisolism (36). Cushing’s disease is caused by an ACTH-secreting pituitary 
adenoma, which stimulates cortisol production by the cortex of the adrenal gland, 
and disrupts the negative feedback mechanism. Ectopic Cushing’s syndrome results 
from a non-pituitary ACTH-producing source, which is a rare cause of ACTH-
dependent Cushing’s syndrome and occurs in approximately 5% of cases (36). ACTH-
independent Cushing’s syndrome is caused by an adrenal adenoma or carcinoma, 
which produces cortisol and thereby inhibits ACTH production by the pituitary gland, 
with an incidence of 0.2-0.6 patients per million persons each year (35). Adrenal 
Cushing’s syndrome accounts for approximately 25% of cases of endogenous 
hypercortisolism (36). Other rare causes for Cushing’s syndrome are ectopic CRH 
secretion, bilateral primary pigmented nodular adrenal hyperplasia, the ectopic 
actions of gastric-inhibitory peptide or catecholamines, and other adrenal-dependent 
processes associated with adrenocortical hyperfunction such as McCune-Albright 








Besides Cushing’s syndrome, several other diseases are associated with 
hypercortisolism, formerly known as ‘pseudo-Cushing states’, now called ‘non-
neoplastic hypercortisolism’. These states need to be considered when diagnosing 
Cushing’s syndrome, also because these patients show increased cortisol 
concentrations, as well as varying degrees of symptoms associated with Cushing’s 
syndrome. Non-neoplastic hypercortisolism is related to excessive alcohol intake, 
depression and other psychiatric diseases, obesity, type 2 diabetes mellitus, insulin 
resistance, polycystic ovary syndrome, chronic kidney disease, anorexia nervosa, 
intense chronic exercise, and multiple sclerosis (37). 
 
Treatment of Cushing’s syndrome  
Treatment of Cushing’s syndrome is first aimed at reducing the disease burden of 
symptoms associated with hypercortisolism by normalizing cortisol secretion, or at 
least, reducing circulating cortisol concentrations. Further aims are restoring the 
metabolic changes and reducing the risk of complications, such as hypertension and 
diabetes mellitus, as well as reducing the increased mortality risk associated with 
untreated Cushing’s syndrome. The ideal treatment leads to the highest percentage 
of patients in remission after treatment (effectiveness), with the lowest complication 
rate, and the lowest rate of disease recurrence (safety). 
For Cushing’s disease, the first-choice treatment method is transsphenoidal pituitary 
surgery. In 1907, Hermann Schloffer was the first to perform transsphenoidal 
pituitary surgery (38). Around 1970, this technique was re-discovered and improved 
due to the use of the operating microscope. This microscope allows selective removal 
of the ACTH-producing adenoma instead of complete hypophysectomy, as was 
performed early in the 20th century (39). Starting from 1992, the endoscope became 
available for transsphenoidal pituitary surgery, which can be used either separately 
or in combination with the microscope (40). Potential complications of 
transsphenoidal pituitary surgery are meningitis, cerebrospinal fluid leakage, 
bleeding, syndrome of inappropriate antidiuretic hormone release (SIADH), diabetes 
insipidus, and anterior pituitary deficiencies. Repeat transsphenoidal surgery can be 
performed in case of persistent or recurrent disease after first surgery. Radiotherapy 
is recommended for patients with an invasive pituitary adenoma, and can be used in 
case of persistent or recurrent disease. Although radiotherapy is generally highly 
effective, a potential complication of radiotherapy is hypopituitarism, and it usually 
takes several months before the first beneficial effects of radiotherapy are evident 
(41). 
First-choice treatment for ectopic Cushing’s syndrome is removal of the ACTH-
producing tumor. Adrenalectomy is the first-choice treatment in adrenal Cushing’s 
syndrome if one adrenal gland is involved, removing the adrenal gland with the 
cortisol-producing adenoma, or carcinoma. Bilateral adrenalectomy can also be 































































































































































































































































































































































































































performed in Cushing’s disease or ectopic 
Cushing’s syndrome when a contra-
indication for the first-choice surgical 
procedure exists (e.g. unidentified tumor, 
metastatic ectopic tumor), or in case of 
persistent or recurrent disease after first 
surgery. Bilateral adrenalectomy has the 
disadvantage of causing primary adrenal 
insufficiency, necessitating life-long hydro-
cortisone and fludrocortisone replacement 
therapy. Medical treatment aimed at 
reducing cortisol concentrations (steroido-
genesis inhibitors) is recommended as 
second-line treatment in patients with 
Cushing’s disease when surgery is 
unsuccessful, as primary treatment in 
patients with ectopic Cushing’s syndrome 
with unidentified or metastatic tumor, and 
as adjunctive therapy to reduce cortisol 
concentrations in adrenocortical carci-
noma. Potential side effects vary per 
medical agent (41). A complete summary 
of cortisol-lowering drugs tested in 
Cushing’s disease is provided by Ciato et 
al., including site and mechanism of action 
and development stage (42).  
Criteria for diagnosis and remission of 
Cushing’s syndrome  
Cushing’s syndrome is diagnosed based on 
both clinical grounds as well as bio-
chemical test results. Biochemical criteria 
are dependent on the assay used. 
Therefore, reference values should be 
determined per laboratory for all used 
biochemical parameters. The following 
biochemical tests are considered relevant 
for establishing the diagnosis of Cushing’s 
syndrome: 24 h free urinary cortisol 
excretion, midnight salivary cortisol, and 
the 1 mg overnight dexamethasone 




between ACTH-dependent and ACTH-independent Cushing’s syndrome, ACTH 
concentrations are measured. In case of ACTH-dependent Cushing’s syndrome, 
pituitary imaging by magnetic resonance imaging (MRI) can identify a pituitary 
adenoma in the majority of cases. Computed tomography (CT) can be performed if a 
contraindication for MRI exists, but its discriminatory power to detect intrasellar 
pathology is very limited. If pituitary imaging remains inconclusive, bilateral 
simultaneous sampling of the inferior petrosal sinuses (IPSS) can be performed to 
confirm the pituitary origin of ACTH overproduction. If IPSS is negative, additional 
imaging of the thorax and abdomen are performed to identify a potential ectopic 
source of ACTH secretion. In case of ACTH-independent Cushing’s syndrome, adrenal 
imaging by MRI or CT is used to identify an adrenal adenoma or carcinoma (44).  
 
Remission status is determined based on clinical and biochemical criteria three 
months after surgery. Patients are considered in remission if there is dependence on 
hydrocortisone replacement, or hydrocortisone independence without any 
biochemical signs of hypercortisolism, in combination with regression of clinical signs 
(41). Patients are considered to have persistent Cushing’s syndrome if there is 
absence of remission after the first operation and before a second intervention for 
hypercortisolism is performed. Patients have recurrent disease if, after a period of 
remission, there is re-occurrence of clinical signs as well as biochemical recurrence 





When cortisol is administered as a medical agent, it is called hydrocortisone (1). A 
variety of synthetic corticosteroids, which act similar to hydrocortisone, has been 
developed, which can be administered in various ways, e.g. orally, via inhalation, 
intranasally, topical application (e.g. skin, eye), intravenously, intra-muscularly, and 
intra-articularly. Each has different characteristics, which results in a different 
choice of agent per disease with varying treatment schedules (45). 
 
Hypercortisolism due to the administration of corticosteroids as medication is called 
exogenous hypercortisolism, which can lead to iatrogenic Cushing’s syndrome. 
Corticosteroids are used in the treatment of inflammatory diseases (e.g. asthma, 
rheumatic diseases), malignancies, and after organ transplantation, in order to 
prevent an inflammatory response (2, 46). Both oral and inhalation corticosteroids 
are used by approximately 1% of the adult population at any moment (46, 47). 
Potential side effects of corticosteroid treatment are all symptoms listed for 
endogenous hypercortisolism because corticosteroids bind to the same receptors as 
cortisol. Additionally, use of corticosteroids as medical treatment can suppress the 
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HPA-axis by binding to the glucocorticoid and mineralocorticoid receptors in the 
hypothalamus and the anterior pituitary gland, lowering ACTH concentrations and 
thereby suppressing adrenal function (45). 
 
Iatrogenic Cushing’s syndrome can only be treated by reducing the dose of 
corticosteroids. However, due to the potential suppression of the adrenal function 
during the state of hypercortisolism, corticosteroid dose reductions should be 
executed with caution to prevent adrenal insufficiency. Additionally, patients with 
both exogenous and endogenous hypercortisolism may experience corticosteroid 
withdrawal syndrome to a variable degree when corticosteroid doses are tapered too 
quickly. Patients with corticosteroid withdrawal syndrome may experience a range of 
symptoms that are difficult to interpret, e.g. fatigue, mood changes, diffuse aches, 
and weakness, resulting from a decrease in cortisol concentrations, even though 
adrenal function is sufficient (48). 
 
 
Adrenal insufficiency  
 
The state of hypocortisolism is known as adrenal insufficiency, because the adrenal 
cortex is incapable of producing adequate cortisol concentrations. In primary adrenal 
insufficiency, this is due to a disease of the adrenal gland itself, whereas in 
secondary adrenal insufficiency lack of ACTH production leads to insufficient cortisol 
production. The most common cause of adrenal insufficiency is exogenous 
corticosteroid use. Secondary adrenal insufficiency, resulting from e.g. congenital 
hypopituitarism, a pituitary tumor, or pituitary surgery, is the next most common 
cause of adrenal insufficiency, with a prevalence of 1 in 3,000 persons. The most 
common cause of primary adrenal insufficiency is Addison’s disease, due to 
autoimmune adrenalitis, leading to destruction of the adrenal cortex. Other causes of 
primary adrenal insufficiency are congenital adrenal hyperplasia (of which 21-
hydroxylase deficiency is the most common form), or bilateral adrenalectomy. All-
cause primary adrenal insufficiency is a rare condition with a prevalence of 1 in 8,000 
persons, of which 85% is caused by an autoimmune disease (49, 50). Patients with 
Cushing’s syndrome using cortisol-lowering medication can also experience adrenal 
insufficiency if cortisol concentrations are suppressed excessively by the cortisol-
lowering medication without concurrent hydrocortisone replacement. 
 
Patients with adrenal insufficiency generally present with fatigue, weight loss, 
postural dizziness, anorexia and/or abdominal discomfort. Hyperpigmentation of the 
skin can be present to a variable degree in primary adrenal insufficiency, as well as 
low blood pressure with increased postural drop, and failure to thrive in children. 




uncommonly hypoglycemia and hypercalcemia (51). Adrenal insufficiency is diagnosed 
if cortisol remains under the test-specific cut-off value after a stimulation test using 
ACTH, CRH, insulin-induced hypoglycemia, or metyrapone. As most symptoms are 
nonspecific, diagnosis is often delayed. Mortality is increased in both treated and 
untreated patients with adrenal insufficiency (50). 
 
The most feared complication of adrenal insufficiency is a potentially life-threatening 
situation called adrenal crisis, which represents an acute and severe state of 
glucocorticoid deficiency. An adrenal crisis can occur after any situation with 
increased demand for cortisol, e.g. any illness or psychological stress. There is no 
consensus on the definition of adrenal crisis, and various definitions are used in both 
clinical and research settings. The following definition may be most useful for clinical 
practice: a combination of 1) Major impairment of general health with at least two of 
the following signs and symptoms: hypotension, nausea or vomiting, severe fatigue, 
fever, somnolence, hyponatremia or hyperkalemia, hypoglycemia, and 2) Clinical 
improvement following parenteral glucocorticoid administration (52). Importantly, 
patients with adrenal crisis can have many other nonspecific symptoms, e.g. weight 
loss, dizziness, abdominal pain, fever, back and leg cramps, which can complicate a 
correct and timely diagnosis of adrenal crisis. 
 
Patients with adrenal insufficiency are treated with supraphysiological glucocorticoid 
replacement to control symptoms of adrenal insufficiency and to prevent occurrence 
of an adrenal crisis. On the other hand, overtreatment with glucocorticoids should be 
avoided, to prevent symptoms of hypercortisolism. Typically, patients with adrenal 
insufficiency receive 15-25 mg of hydrocortisone daily, divided into a larger dose in 
the morning and two smaller doses at lunch and dinner time, to represent the normal 
circadian cortisol secretion (49). An adrenal crisis is treated by an immediate bolus 
injection of 100 mg of hydrocortisone intravenously or intramuscularly, followed by 
continuous infusion of 200 mg hydrocortisone per 24 hours intravenously. 
Furthermore, rehydration with a rapid intravenous administration of 1 L of isotonic 
saline should take place within the first hour (53). 
 
To prevent (recurrent) adrenal crisis, an endocrinologist and a specialist endocrine 
nurse should periodically evaluate all patients with adrenal insufficiency, at least 
once every 6-12 months. Patients should be educated about the risk of adrenal crisis, 
including recognition of symptoms of adrenal crisis, and about correct dose 
adjustment of glucocorticoid replacement. As a rule, the glucocorticoid replacement 
dose should be doubled during illness with fever that requires bed rest or antibiotics. 
Furthermore, glucocorticoids should be administered intravenously or intramuscularly 
during longer periods of vomiting or diarrhea, during preparation for colonoscopy, 
and in case of acute trauma or surgery. The patient with adrenal insufficiency and 
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partner or parents should know how to (self-)administer intramuscular 
hydrocortisone, and they should be in possession of a hydrocortisone emergency 
injection kit. Finally, patients with adrenal insufficiency should carry a steroid 
emergency card (Figure 3) (53). 
Patient with adrenal insufficiency
Adrenal crisis
Prevention of (recurrent) 
adrenal crisis
Hydrocortisone replacement therapy
15-25 mg/day in 3 doses
1: Frequent review by endocrinologist
2: Patient education about adrenal crisis
3: Double dose of glucocorticoids during 
illness with fever
4: Intravenous or intramuscular 
glucocorticoid replacement during 
vomiting or diarrhea, preparation for 
colonoscopy, and in case of acute trauma 
or surgery
5: Patient and partner/parents can 
(self-)administer hydrocortisone
6: Patient is in possession of hydrocortisone 
emergency kit
1: Bolus injection of 100 mg hydrocortisone
2: Continuous infusion of 200 mg 
hydrocortisone per 24 hours
3: Rehydration with isotonic saline
 
Figure 3: Management of patients with adrenal insufficiency. 
 
Outline of the thesis 
 
Endogenous Cushing’s syndrome is rare, but hypercortisolism due to use of exogenous 
corticosteroids is not. Severe complications due to exogenous hypercortisolism are 
underestimated and not well-recognized in clinical practice, including mortality and 
adrenal insufficiency. Endogenous Cushing’s syndrome on the other hand causes high 
morbidity and mortality rates, and therefore treatment of this rare syndrome should 
be optimized. Furthermore, Cushing’s syndrome can serve as a model for long-term 
exposure to stress, which also leads to high concentrations of cortisol. Research on 
the topic of Cushing’s disease before and after treatment will therefore inform us 
about potential consequences of long-term exposure to stress, both during periods of 





Part I: Complications of corticosteroid use 
In part I of this thesis, the complications of corticosteroid use will be explored. 
Adrenal insufficiency is a well-known complication of corticosteroids use. However, it 
is unknown in which patients, or under which circumstances, this complication 
occurs. In Chapter 2 and in Appendix I, the literature is systematically reviewed and, 
by use of meta-analysis, the proportion of patients with adrenal insufficiency after 
use of corticosteroids is estimated per route of administration, underlying disease, 
treatment dose, and treatment duration, to identify patients with high risk of adrenal 
insufficiency. Mortality may be increased in patients using corticosteroids as 
medication. However, both corticosteroid use, and mortality, depend on underlying 
disease. Therefore, in Chapter 3, we examined all patients with incident perforated 
diverticular disease in Denmark, and compared mortality rates between patients that 
used corticosteroids and patients that did not use corticosteroids to find if use of 
corticosteroids causes excessive mortality in patients with perforated diverticular 
disease. 
 
Part II: Treatment outcome in Cushing’s syndrome 
For the first-choice treatment in Cushing’s disease, selective transsphenoidal 
adenomectomy, two surgical techniques are in use: microscopy and endoscopy. Until 
now, only few small cohort studies have compared both techniques, so insufficient 
evidence exists to recommend use of one technique over the other. In Chapter 4, we 
compare both techniques in the large Leiden cohort of patients treated at our 
referral center, aiming to find differences in surgical outcome, e.g. remission rate 
and recurrence rate, and in complication rates, e.g. cerebrospinal fluid leakage and 
anterior pituitary deficiencies. This subject is further investigated in Chapter 5, 
where we perform a systematic review of the literature regarding microscopic and 
endoscopic transsphenoidal surgery. We use meta-analysis to find differences 
between both techniques that indicate a preference for either technique based on 
surgical outcome or complication rates. Medical treatment aimed at reducing cortisol 
concentrations is used regularly in patients with contraindications to surgery or in 
case of persistent or recurrent disease. To explore effectiveness and potential side 
effects of this treatment method, we systematically reviewed the literature and 
performed meta-analyses per cortisol-lowering drug in Chapter 6. 
 
Part III: Clinical outcome in Cushing’s syndrome 
Cushing’s disease occurs more often in females than in males, and males are thought 
to be at higher risk for ectopic Cushing’s syndrome than females. In Chapter 7, we 
study a cohort of patients from Leiden and Berlin to determine whether there are 
differences between both sexes regarding clinical presentation, diagnostic strategy, 
and treatment outcome in ACTH-dependent Cushing’s syndrome. A potential serious 
complication of treatment of Cushing’s syndrome is adrenal crisis due to inadequately 
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treated adrenal insufficiency. However, it is unknown how often this complication 
occurs, and which patients may be at increased risk of developing adrenal crisis after 
treatment for Cushing’s syndrome. We determine the incidence of adrenal crisis in a 
population of successfully treated patients with Cushing’s syndrome from Leiden and 
Berlin and explore patient characteristics for potential risk factors for adrenal crisis 
in Chapter 8. Hypercortisolism also negatively affects cognition and quality of life, 
which may even be present in the long-term. In Chapter 9, we perform a systematic 
review of the literature and we determine by meta-analysis if patients improve in 
quality of life and cognitive functioning after treatment. We also determine if 
patients normalize regarding quality of life and cognitive functioning by comparing 





1. Nobel F. Physiology or medicine 1942-1962. Amsterdam: Elsevier, 1964. 
2. Rodger RS, Watson MJ, Sellars L, Wilkinson R, Ward MK, Kerr DN. Hypothalamic-pituitary-
adrenocortical suppression and recovery in renal transplant patients returning to maintenance 
dialysis. Q J Med. 1986;61:1039-1046. 
3. Schleimer RP. Interactions between the hypothalamic-pituitary-adrenal axis and allergic 
inflammation. J Allergy Clin Immunol. 2000;106:S270-274. 
4. Fernandez-Rodriguez E, Stewart PM, Cooper MS. The pituitary-adrenal axis and body composition. 
Pituitary. 2009;12:105-115. 
5. Portaluppi F, Vergnani L, Manfredini R, Fersini C. Endocrine mechanisms of blood pressure 
rhythms. Ann N Y Acad Sci. 1996;783:113-131. 
6. Rome HP, Braceland FJ. The psychological response to ACTH, cortisone, hydrocortisone, and 
related steroid substances. Am J Psychiatry. 1952;108:641-651. 
7. Gonzalez-Cabrera J, Fernandez-Prada M, Iribar-Ibabe C, Peinado JM. Acute and chronic stress 
increase salivary cortisol: a study in the real-life setting of a national examination undertaken by 
medical graduates. Stress. 2014;17:149-156. 
8. Prete A, Yan Q, Al-Tarrah K, Akturk HK, Prokop LJ, Alahdab F, Foster MA, Lord JM, Karavitaki N, 
Wass JA, Murad MH, Arlt W, Bancos I. The cortisol stress response induced by surgery: A 
systematic review and meta-analysis. Clin Endocrinol (Oxf). 2018;89(5):554-567. 
9. Liyanarachchi K, Ross R, Debono M. Human studies on hypothalamo-pituitary-adrenal (HPA) axis. 
Best Pract Res Clin Endocrinol Metab. 2017;31:459-473. 
10. Gjerstad JK, Lightman SL, Spiga F. Role of glucocorticoid negative feedback in the regulation of 
HPA axis pulsatility. Stress. 2018;21(5):403-416. 
11. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ. Agomelatine, the 
first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug 
Discov. 2010;9:628-642. 
12. Hyman SE. How adversity gets under the skin. Nat Neurosci. 2009;12:241-243. 
13. Roelfsema F, van Heemst D, Iranmanesh A, Takahashi P, Yang R, Veldhuis JD. Impact of age, sex 
and body mass index on cortisol secretion in 143 healthy adults. Endocr Connect. 2017;6:500-509. 
14. Van Cauter E, Leproult R, Kupfer DJ. Effects of gender and age on the levels and circadian 
rhythmicity of plasma cortisol. J Clin Endocrinol Metab. 1996;81:2468-2473. 
15. Follenius M, Brandenberger G, Hietter B. Diurnal cortisol peaks and their relationships to meals. J 
Clin Endocrinol Metab. 1982;55:757-761. 
16. Zhao ZY, Xie Y, Fu YR, Li YY, Bogdan A, Touitou Y. Circadian rhythm characteristics of serum 
cortisol and dehydroepiandrosterone sulfate in healthy Chinese men aged 30 to 60 years. A cross-
sectional study. Steroids. 2003;68:133-138. 
17. Elder GJ, Wetherell MA, Barclay NL, Ellis JG. The cortisol awakening response--applications and 




18. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences 
of circadian misalignment. Proc Natl Acad Sci U S A. 2009;106:4453-4458. 
19. Morris CJ, Purvis TE, Mistretta J, Scheer FA. Effects of the Internal Circadian System and 
Circadian Misalignment on Glucose Tolerance in Chronic Shift Workers. J Clin Endocrinol Metab. 
2016;101:1066-1074. 
20. de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev 
Neurosci. 2005;6:463-475. 
21. Henley D, Lightman S, Carrell R. Cortisol and CBG - Getting cortisol to the right place at the right 
time. Pharmacol Ther. 2016;166:128-135. 
22. Yip CE, Stewart SA, Imran F, Clarke DB, Mokashi A, Kaiser SM, Imran SA. The role of morning basal 
serum cortisol in assessment of hypothalamic pituitary-adrenal axis. Clin Invest Med. 
2013;36:E216-222. 
23. Manetti L, Rossi G, Grasso L, Raffaelli V, Scattina I, Del Sarto S, Cosottini M, Iannelli A, Gasperi M, 
Bogazzi F, Martino E. Usefulness of salivary cortisol in the diagnosis of hypercortisolism: 
comparison with serum and urinary cortisol. Eur J Endocrinol. 2013;168:315-321. 
24. Aranda G, Careaga M, Hanzu FA, Patrascioiu I, Rios P, Mora M, Morales-Romero B, Jimenez W, 
Halperin I, Casals G. Accuracy of immunoassay and mass spectrometry urinary free cortisol in the 
diagnosis of Cushing's syndrome. Pituitary. 2016;19:496-502. 
25. Wester VL, van Rossum EF. Clinical applications of cortisol measurements in hair. Eur J 
Endocrinol. 2015;173:M1-10. 
26. Christensen M, Madsen RF, Moller LR, Knudsen CS, Samson MH. Whole blood samples for 
adrenocorticotrophic hormone measurement can be stored at room temperature for 4 hours. 
Scand J Clin Lab Invest. 2016;76:653-656. 
27. Chrousos GP, Kino T, Charmandari E. Evaluation of the hypothalamic-pituitary-adrenal axis 
function in childhood and adolescence. Neuroimmunomodulation. 2009;16:272-283. 
28. Abdu TA, Elhadd TA, Neary R, Clayton RN. Comparison of the low dose short synacthen test (1 
microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test 
for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. J Clin 
Endocrinol Metab. 1999;84:838-843. 
29. Cegla J, Jones B, Seyani L, Papadoulou D, Wynne K, Martin NM, Meeran K, Chapman R, Donaldson 
M, Goldstone AP, Tan T. Comparison of the overnight metyrapone and glucagon stimulation tests 
in the assessment of secondary hypoadrenalism. Clin Endocrinol (Oxf). 2013;78:738-742. 
30. Cushing H. The pituitary body and its disorders: clinical states produced by disorders of the 
hypophysis cerebri. Philadelphia: Lippincott, 1912. 
31. Pereira AM, Tiemensma J, Romijn JA. Neuropsychiatric disorders in Cushing's syndrome. 
Neuroendocrinology. 2010;92 Suppl 1:65-70. 
32. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of 
Cushing's syndrome and pseudo-Cushing's states. Endocr Rev. 1998;19:647-672. 
33. Plotz CM, Knowlton AI, Ragan C. The natural history of Cushing's syndrome. Am J Med. 
1952;13:597-614. 
34. Pluta RM, Burke AE, Golub RM. JAMA patient page. Cushing syndrome and Cushing disease. JAMA. 
2011;306:2742. 
35. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, 
Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J. Incidence and late prognosis of 
cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86:117-123. 
36. Valassi E, Franz H, Brue T, Feelders RA, Netea-Maier R, Tsagarakis S, Webb SM, Yaneva M, 
Reincke M, Droste M, Komerdus I, Maiter D, Kastelan D, Chanson P, Pfeifer M, Strasburger CJ, 
Toth M, Chabre O, Tabarin A, Krsek M, Fajardo C, Bolanowski M, Santos A, Wass JA, Trainer PJ. 
Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. Eur 
J Endocrinol. 2017;176:613-624. 
37. Chabre O. The difficulties of pseudo-Cushing's syndrome (or "non-neoplastic hypercortisolism"). 
Ann Endocrinol (Paris). 2018;79:138-145. 
38. Schmidt RF, Choudhry OJ, Takkellapati R, Eloy JA, Couldwell WT, Liu JK. Hermann Schloffer and 
the origin of transsphenoidal pituitary surgery. Neurosurg Focus. 2012;33:E5. 
39. Hardy J. Transsphenoidal hypophysectomy. J Neurosurg. 1971;34:582-594. 
40. Jankowski R, Auque J, Simon C, Marchal JC, Hepner H, Wayoff M. Endoscopic pituitary tumor 
surgery. Laryngoscope. 1992;102:198-202. 
41. Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A. Treatment 
of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 
2015;100:2807-2831. 
General introduction and outline of the thesis 
23 
 
42. Ciato D, Mumbach AG, Paez-Pereda M, Stalla GK. Currently used and investigational drugs for 
Cushing s disease. Expert Opin Investig Drugs. 2017;26:75-84. 
43. Guignat L, Bertherat J. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical 
Practice Guideline: commentary from a European perspective. Eur J Endocrinol. 2010;163:9-13. 
44. Bista B, Beck N. Cushing syndrome. Indian J Pediatr. 2014;81:158-164. 
45. Williams DM. Clinical Pharmacology of Corticosteroids. Respir Care. 2018;63:655-670. 
46. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids 
in the United Kingdom. QJM. 2000;93:105-111. 
47. van Staa TP, Cooper C, Leufkens HG, Lammers JW, Suissa S. The use of inhaled corticosteroids in 
the United Kingdom and the Netherlands. Respir Med. 2003;97:578-585. 
48. Dixon RB, Christy NP. On the various forms of corticosteroid withdrawal syndrome. Am J Med. 
1980;68:224-230. 
49. Pazderska A, Pearce SH. Adrenal insufficiency - recognition and management. Clin Med (Lond). 
2017;17:258-262. 
50. Quinkler M, Ekman B, Zhang P, Isidori AM, Murray RD. Mortality data from the European Adrenal 
Insufficiency Registry-Patient characterization and associations. Clin Endocrinol (Oxf). 
2018;89:30-35. 
51. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, 
Murad MH, Stratakis CA, Torpy DJ. Diagnosis and Treatment of Primary Adrenal Insufficiency: An 
Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:364-389. 
52. Allolio B. Extensive expertise in endocrinology. Adrenal crisis. Eur J Endocrinol. 2015;172:R115-
124. 
53. Arlt W. SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Emergency 










































Chapter 2  
Adrenal insufficiency in corticosteroids use: 
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We aimed to estimate pooled percentages of patients with adrenal insufficiency after 
treatment with corticosteroids for various conditions in a meta-analysis. Secondly, we 




We searched seven electronic databases (PubMed, MEDLINE, EMBASE, COCHRANE, 
CENTRAL, Web of Science, and CINAHL/Academic Search Premier) in February 2014 
to identify potentially relevant studies. Original articles testing adult corticosteroid 
users for adrenal insufficiency were eligible. 
 
Results 
We included 74 articles with a total of 3,753 participants. Stratified by administration 
form, percentages of patients with adrenal insufficiency ranged from 4.2% for nasal 
administration (95% confidence interval [CI]: 0.5%-28.9%) to 52.2% for intra-articular 
administration (95% CI, 40.5%-63.6%). Stratified by disease, percentages ranged from 
6.8% for asthma with inhalation corticosteroids only (95% CI: 3.8%-12.0%) to 60.0% for 
hematological malignancies (95% CI: 38.0%-78.6%). The risk also varied according to 
dose from 2.4% (95% CI: 0.6%-9.3%) (low dose) to 21.5% (95% CI: 12.0%-35.5%) (high 
dose), and according to treatment duration from 1.4% (95% CI: 0.3%-7.4%) (<28 days) 
to 27.4% (95% CI: 17.7%-39.8%) (>1 year) in asthma patients. 
 
Conclusions 
1) Adrenal insufficiency after discontinuation of glucocorticoid occurs frequently; 2) 
There is no administration form, dosing, treatment duration, or underlying disease 
for which adrenal insufficiency can be excluded with certainty, although higher dose 
and longer use give the highest risk; 3) The threshold to test corticosteroid users for 
adrenal insufficiency should be low in clinical practice, especially for those patients 
with nonspecific symptoms after cessation.  
 
  





Corticosteroids are widely used for the treatment of various inflammatory conditions 
and malignancies and after organ transplantation. Therapy with corticosteroids is 
targeted toward inhibition of an inflammatory response (1–3). However, the use of 
corticosteroids is associated with numerous side effects and is considered to be the 
most common cause of adrenal insufficiency (4, 5). Chronic use of corticosteroids 
inhibits the function of the hypothalamic-pituitary-adrenal axis by negative feedback, 
which may cause adrenal insufficiency also after the cessation of corticosteroid 
treatment (4, 6). Adrenal insufficiency is a serious, potentially life-threatening side 
effect of corticosteroid use. Therefore, patients may require glucocorticoid 
replacement therapy after chronic use of corticosteroids in periods of stress, such as 
trauma, surgery, or acute illness, until full recovery of adrenal function. In some 
cases, chronic replacement with physiological doses of glucocorticoid therapy is 
indicated (7–9). 
 
Neither treatment dose and duration, nor administration form, nor random serum 
cortisol measurements seem to accurately predict the development of adrenal 
insufficiency after the use of corticosteroids (10, 11). The magnitude of the risk of 
developing this side effect is unclear. Given the high prevalence of corticosteroid 
users, it is of great clinical relevance to try to obtain knowledge about the risk of 
developing adrenal insufficiency. 
 
Objective of the study 
The aim of this study is to perform a systematic review and meta-analysis of the 
percentage of patients that develops adrenal insufficiency after the use of 
corticosteroids. Secondary aims are to stratify the results by route of administration, 
underlying disease, treatment dose, and duration, and to perform a separate analysis 






Original studies assessing adrenal insufficiency in adult human corticosteroid users 
were eligible for inclusion. The diagnosis of adrenal insufficiency had to be 
established by one of the following tests: the insulin tolerance test, ACTH stimulation 
tests (0.5, 1, or 250 µg), CRH test, or metyrapone test. There were no restrictions in 




corticosteroids were oral, inhalation, topical, nasal, intra-articular injection, and 
intra-muscular injection. 
 
Articles were excluded if the examined population was not at risk of adrenal 
insufficiency secondary to the use of corticosteroids (e.g., corticosteroid replacement 
therapy for primary or secondary adrenocortical failure, if not all patients used 
corticosteroids, or if patients included in the study were selected on the basis of 
having adrenal insufficiency). Articles were also excluded if no data or insufficient 
data were presented to analyze adrenal insufficiency after corticosteroid use. 
 
Inclusion of articles was restricted to those in English and to articles that included at 
least 10 subjects to minimize the risk of selection bias. Articles containing the 
following populations were excluded: pregnant women, intensive care patients, and 
patients receiving corticosteroids perioperatively. Because we aimed to include 
studies in individuals aged 12 years or older, no dose corrections for body surface 
area were deemed necessary. If an article presented data for multiple study groups, 
of which some were eligible for inclusion, eligible study groups were included if the 
pertinent data could be extracted. Articles were also excluded if they were 
duplicates from already included articles or if they examined the same population as 
an already included article. Articles that were not retrievable online were requested 
by contacting the authors. 
 
Definition of adrenal insufficiency 
The cutoff value for serum cortisol used to define adrenal insufficiency was ≤500 
nmol/L or higher (such as ≤550 nmol/L) to include as many articles as possible that 
have a low false-negative rate for adrenal insufficiency (12–14). Two articles were 
included that used a cutoff of 2 standard deviation (SD) values below the cortisol 
value from a reference group within the study population, and one article was 
included that had a different cutoff value due to assay technique (≤370 nmol/L). 
After using the metyrapone test, cortisol had to be at least 200 nmol/L (12). If no 
cutoff had been provided or if the cutoff used was not 500 nmol/L but individual data 
were presented, a cutoff of 500 nmol/L was employed to identify patients with 
adrenal insufficiency. A separate sensitivity analysis was performed for articles 




In February 2014, PubMed, MEDLINE, EMBASE, COCHRANE, CENTRAL, Web of Science, 
and CINAHL/Academic Search Premier were searched in cooperation with a 
specialized librarian to identify potentially relevant articles (see Supplemental Data 1 
for complete search string). References of key articles were also assessed to identify 
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potentially eligible articles. Only articles published from 1975 to the present were 
searched because radioimmunoassay (RIA) for cortisol became available shortly 
before the start of that year (15). Randomized controlled trials, cohort studies, and 
cross-sectional studies were considered, whereas case-control studies and case series 
are not suitable to estimate absolute risks (16). 
 
Data extraction 
All identified articles were entered in Reference Manager version 12 (Thomson 
Reuters) and were first screened on title and abstract. Potentially relevant articles 
were then reviewed in detail before inclusion into this meta-analysis. Two different 
reviewers performed both the screening of the title and abstract and the review in 
detail for potentially relevant articles. Articles containing more than one study group 
had multiple entries in this meta-analysis. The Meta-analysis Of Observational Studies 
in Epidemiology (MOOSE) guidelines were used for reporting (17). 
 
Risk of bias assessment 
Study elements that could potentially bias an association between corticosteroid use 
(exposure) and the development of adrenal insufficiency (outcome) were assessed for 
all included articles. Risk of selection bias was considered low if consecutive exposed 
patients or a random sample of exposed patients was included (thereby preventing 
selection bias) and if eligibility criteria were reported. Ascertainment of exposure to 
corticosteroids was considered adequate if this was done by protocol or medical 
record. Measurement of adrenal insufficiency was considered adequate if RIA was 
used for measuring cortisol concentrations (15). Loss to follow-up <5% was considered 
a low risk of bias for randomized controlled trials and cohort studies. Studies not 
following these criteria harbor a higher risk of bias. We did not exclude these articles 
from analyses because this would result in a very low number of studies available for 
systematic review and meta-analyses. 
 
Statistical analysis 
The main outcomes of this meta-analysis were the pooled percentages of patients 
with adrenal insufficiency after corticosteroid use, stratified by administration form, 
disease, treatment dose, and treatment duration. Percentages were pooled in a 
random-effects logistic regression model. A fixed logistic regression model was used 
when the number of studies in a particular subgroup was less than five. Analyses were 
performed with Stata version 12.1 (StataCorp). 
 
Analysis stratified by administration form was based on administration forms used at 
the time of adrenal testing. If studies included patients using multiple types of 
corticosteroids (for example, use of inhalation corticosteroid next to oral 




are: asthma (including chronic obstructive pulmonary disease) with only inhalation 
corticosteroids, asthma (including chronic obstructive pulmonary disease) with other 
administration forms (including multiple administration forms) of corticosteroids, 
allergic rhinitis and rhinosinusitis, dermatological disorders (psoriasis, atopic 
dermatitis, and lichen planus), rheumatic diseases (including osteoarthritis and 
rheumatoid arthritis), renal transplant, hematological cancers (including myeloma, 
lymphoma, acute lymphoblastic leukemia, and Hodgkin’s disease), nasal polyposis, 
cystic fibrosis, and Crohn’s disease. Diseases that were studied in one study only 
were not included in the analysis of adrenal insufficiency after the use of 
corticosteroids stratified by condition. 
 
Treatment duration was categorized as follows: <1 month use, short term; 1 month to 
1 year, medium term; and >1 year, long-term use. Treatment dose was categorized 
according to recommended doses, with the doses between the lower and upper 
bounds of the recommendation coded as medium dose, doses below the lower bound 
as low dose, and doses above the upper bound as high dose. Because the most used 
doses were supraphysiological, doses were not grouped according to physiological and 
supraphysiological dose. Limits used for the aim of categorization of dose groups and 
references can be found in Supplemental Data 2. For categorization, the average 
dose and duration were used. Studies not reporting treatment dose or duration could 
not be included in the respective stratified analysis. Not included in the treatment 
duration analysis were articles with multiple short courses of corticosteroids spread 
out over a period of time longer than 1 month. Analysis of the percentage of patients 
with adrenal insufficiency by treatment dose and by treatment duration was 
performed in asthma patients only, as opposed to the entire population of 
corticosteroids users, to provide a homogeneous patient population. 
 
Separate analysis of study groups that performed repeated tests after discontinuation 
of corticosteroids was performed. Retesting 4 weeks after cessation of corticosteroid 
therapy was predominantly performed after a short-term, high-dose corticosteroid 
treatment regimen, whereas retesting 6 months after cessation of corticosteroid 
therapy predominantly occurred after long-term corticosteroid use in a medium-dose 
regimen. These two groups were therefore separated in the analysis. The percentage 
of patients with adrenal insufficiency at the retest was calculated as the number of 
patients with adrenal insufficiency at the retest divided by the total number of 
patients that were measured at time of the first test. 
 
Sensitivity analyses were performed for studies using the ACTH 250-µg test only to 
exclude test heterogeneity and for studies using the RIA only because this is the 
preferred assay to detect cortisol. All sensitivity analyses were performed in asthma 
patients only, to minimize patient heterogeneity. No sensitivity analysis for insulin 
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tolerance test use only was performed because there were only three studies using 





Study selection  
The initial search provided 3,600 unique articles. By assessment of references of key 
articles, another 16 articles were found, yielding a total of 3,616 articles. After 
screening titles and abstracts, 365 articles remained for detailed review. Reasons for 
exclusion are shown in Supplemental Data 3. Finally, 74 articles were included in this 
meta-analysis, containing a total of 136 study groups. Although in principle articles 
containing patients below the age of 12 years were excluded, two articles including 
patients from 9 to 11 years old were included because most of the patients in these 
articles were above the age of 12. One article could not be retrieved even after 
contacting the first author (18). 
 
Study characteristics 
Study characteristics are shown in Supplemental Data 4. Included studies were 
published from 1975 to 2014. Of the 74 articles, 36 were clinical trials (19–54), 23 
were cohort studies (1, 2, 8, 11, 55–73), and 15 were cross-sectional studies (10, 74–
87). The 136 study groups contained a total of 3,753 participants, of which 124 were 
healthy volunteers. There were 68 studies on asthma patients, eight studies on 
rhinitis or rhinosinusitis patients, 12 studies on patients with dermatological 
conditions (psoriasis, atopic dermatitis, and lichen planus), eight studies on patients 
with rheumatological disorders (including rheumatoid arthritis and osteoarthritis), 
eight studies on renal transplant patients, four studies on patients with hematological 
malignancies, two studies on patients with nasal polyposis, three studies on patients 
with cystic fibrosis, two studies on patients with Crohn’s disease, and one study each 
on patients with glaucoma, kidney and pancreas transplantation, bronchiectasis, 
various carcinomas, and giant cell arteritis, respectively. There were eight studies on 
patients with various conditions. 
 
Risk of bias assessment 
Inclusion of consecutive exposed patients or use of a random sample of exposed 
patients was explicitly stated in 17 articles (23%). Eligibility criteria were reported in 
48 articles (65%). In 38 articles (51%), it was unclear how exposure to corticosteroids 
was ascertained. The remaining 36 articles did this by the use of a protocol or by 
retrieving data from medical records. In 14 articles (24%), loss to follow-up was 




up exceeded 5% in one cohort study and two clinical trials. Details of risk of bias 
analysis at the level of individual studies are shown in Supplemental Data 5. 
 
Study outcomes 
Of the 3,753 participants, 1,190 were diagnosed with adrenal insufficiency. The ACTH 
250-µg test was used by 103 study groups, and the time between the last dose of 
corticosteroids and the test for adrenal insufficiency was reported to be 24 hours or 
longer in 79 study groups. In seven study groups including 199 patients, use of other 
corticosteroids was allowed as co-medication. Details of study outcomes and tests 
used at the level of individual studies are shown in Supplemental Data 6. 
 
Adrenal insufficiency and symptoms of adrenal insufficiency 
In only 10 study groups, symptoms of adrenal insufficiency were reported. In total, 10 
of 521 patients reported symptoms of adrenal insufficiency. Symptoms were not 
scored systematically in either of the articles. After testing, 98 patients appeared to 
have adrenal insufficiency within these study groups. Consequently, 88 patients 
would have been missed when only patients with symptoms of adrenal insufficiency 
had been tested. 
 
Pooled analysis: adrenal insufficiency by administration form (Figure 1) 
The percentage of adrenal insufficiency was 48.7% (95% confidence interval [CI]: 
36.9%–60.6%) after oral administration of corticosteroids. The results for other 
administration forms were: 7.8% (95% CI: 4.2%–13.9%) for inhalation, 4.7% (95% CI: 
1.1%–18.5%) for topical administration, 4.2% (95% CI: 0.5%–28.9%) when administered 
intranasally, and 52.2% (95% CI: 40.5%–63.6%) in patients that used intra-articular 
corticosteroids. The use of multiple administration forms of corticosteroids resulted 
in a pooled percentage of adrenal insufficiency of 42.7% (95% CI: 28.6%–58.0%). 
 
Pooled analysis: adrenal insufficiency per condition (Figure 2) 
Pooled percentages of adrenal insufficiency per condition are presented in Figure 2 
for conditions with at least two studies. Pooled percentages ranged from 6.8% to 
60.0%. Asthma patients had an overall percentage adrenal insufficiency of 11.1% (95% 
CI: 6.8%–17.7%). This was lower for patients with asthma using inhaled corticosteroids 
(6.8%; 95% CI: 3.8%–12.0%), than for asthma patients using other administration forms 
including oral (43.7%; 95% CI: 27.3%–61.6%). 
 




Figure 1: Meta-analysis, adrenal insufficiency after corticosteroids use by administration form. 
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Adrenal insufficiency by treatment dose and treatment duration (Figure 3) 
Analysis per treatment dose and treatment duration was performed in asthmatic 
patients only for reasons of population homogeneity. Use of corticosteroids in low, 
medium, or high doses resulted in a percentage of adrenal insufficiency of 2.4% (95% 
CI: 0.6%–9.3%), 8.5% (95% CI: 4.2%–16.8%), and 21.5% (95% CI: 12.0%–35.5%), 
respectively. Use of corticosteroids for a short, medium, or long term resulted in a 
percentage of adrenal insufficiency of 1.4% (95% CI: 0.3%–7.4%), 11.9% (95% CI: 5.8%–
23.1%), and 27.4% (95% CI: 17.7%–39.8%), respectively. 
 
If performed in asthma patients using inhaled corticosteroids only, the percentages of 
adrenal insufficiency in low, medium, and high doses were 1.5% (95% CI: 0.2%–9.4%), 
5.4% (95% CI: 2.7%–10.4%), and 18.5% (95% CI: 8.7%–35.2%), respectively. In short-, 
medium-, and long-term treatment duration groups, percentages of adrenal 
insufficiency were 1.3% (95% CI: 0.2%–7.2%), 9.0% (95% CI: 4.3%–17.9%), and 20.3% 
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Adrenal insufficiency after retesting (Figure 4) 
Analysis of retests was split into studies that retested after 4 weeks, using mainly 
short-term, high-dose corticosteroids, and studies that retested after 6 months, using 
mainly long-term, medium-dose corticosteroids. Studies retesting after 4 weeks had a 
percentage of adrenal insufficiency after their first test of 38.7% (95% CI: 21.7%–
58.8%). After 4 weeks, retesting showed a percentage of adrenal insufficiency of 
14.9% (95% CI: 6.8%–29.5%). Studies retesting after 6 months had a percentage of 
adrenal insufficiency after their first test of 56.4% (95% CI: 38.2%–72.9%). After 6 




Figure 4: Meta-analysis, adrenal insufficiency after corticosteroids use by time of test. 
 
Sensitivity analysis 
For the sensitivity analysis, we combined all studies with asthma patients, which 
resulted in a percentage of adrenal insufficiency of 11.1% (95% CI: 6.8%–17.7%) as a 
reference group. When only studies were included that explicitly tested for adrenal 
insufficiency at least 24 hours after the last corticosteroid dose, the percentage of 
adrenal insufficiency was slightly lower (6.6%; 95% CI: 2.2%–18.3%). When performed 
on studies using the ACTH 250-µg test only, a percentage of 8.5% (95% CI: 4.7%–14.8%) 
was found. When performed on studies using RIA only, a percentage of 14.7% (95% CI: 
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We performed a systematic review and meta-analysis to estimate the percentage of 
patients that develop adrenal insufficiency after the use of corticosteroids. 
Depending on administration form, the percentage of patients with adrenal 
insufficiency varied from 4.2% for nasal corticosteroids to 52.2% for intra-articular 
corticosteroids. Stratified by disease, percentages ranged from 6.8% for asthma 
patients with inhalation corticosteroids only to 60.0% for patients with hematological 
malignancies. According to dose, the percentage of adrenal insufficiency varied from 
2.4% (low dose) to 21.5% (high dose), and according to treatment duration from 1.4% 
(<28 days) to 27.4% (>1 year) in asthma patients. This means that there is no 
administration form, disease, dose group, or treatment duration for which the risk of 
adrenal insufficiency can be safely excluded. Although the percentage of patients 
with adrenal insufficiency after corticosteroids use declines over time, a substantial 
number of patients remained adrenal insufficient after 6 months. 
 
This is the first meta-analysis providing a broad view on the risk of adrenal 
insufficiency after use of various types of corticosteroids for several diseases. To the 
best of our knowledge, only one meta-analysis (88) has been published on 
appropriately tested adrenal insufficiency in asthma, reporting percentages of 
adrenal insufficiency ranging from 5.5% to 13.3%. In the current meta-analysis, we 
found a percentage of 6.8% of adrenal insufficiency in asthmatic patients using 
inhaled corticosteroids, which is in line with results from the meta-analysis 
mentioned. 
 
Included studies displayed heterogeneity in the type of corticosteroid used, 
underlying condition, treatment dose, treatment duration, and route of 
administration. It is important to consider that this heterogeneity reflects clinical 
practice. It should also be kept in mind that condition, treatment dose, treatment 
duration, and route of administration are clearly related. In our stratified analysis, 
we did not adjust for all mutually dependent factors, mainly because these factors 
are related in clinical practice as well, but also because meta-regression techniques 
would fall short in the absence of individual patient level data to disentangle these 
clearly related factors. Differences in the percentage of patients with adrenal 
insufficiency per condition may partly be explained by treatment dose and duration, 
partly by administration form, and partly by the nature of the disease. Higher 
treatment dose and longer treatment duration give higher systemic levels of 
corticosteroids, and therefore higher percentages of adrenal insufficiency (89). This 
might explain the low risk of adrenal insufficiency in nasal corticosteroids use and the 
high risk of adrenal insufficiency in rheumatic diseases, after renal transplant, in 
hematological malignancies, and when multiple administration forms are used. The 
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use of oral corticosteroids results in higher systemic levels of corticosteroids than in 
cases of inhalation, topical, and nasal corticosteroids use, and consequently leads to 
higher percentages of adrenal insufficiency (32). The use of nasal as well as oral and 
inhalation corticosteroids in rhinitis and rhinosinusitis patients might have 
contributed to the higher percentage of adrenal insufficiency than in patients using 
nasal corticosteroids only. The use of only topical corticosteroids in patients with 
psoriasis, atopic dermatitis, or lichen planus may explain the low percentage of 
patients with adrenal insufficiency. The different administration forms in asthma 
patients may largely explain the low percentage of adrenal insufficiency in patients 
with asthma using only inhalation corticosteroids and the high percentage of adrenal 
insufficiency in asthma patients using other administration forms of corticosteroids. 
Intra-articular corticosteroids are administered at high doses and are known to 
suppress serum cortisol levels within 24–48 hours, recovering only after 1–4 weeks 
(90). This might explain the high percentage of adrenal insufficiency after the use of 
intra-articular corticosteroids. The high rate of adrenal insufficiency is probably also 
a reflection of the fact that these injections are depot formulations. The presence of 
adrenal insufficiency in such situations may in part be due to the continued presence 
of corticosteroids in the body, whereas reduction of steroid levels will be gradual 
rather than abrupt. Most studies did not provide data on treatment adherence, and 
assessing the impact of (non-)adherence on risk of adrenal insufficiency was 
therefore not possible. Because all included studies were observational, the results of 
our meta-analyses are likely to reflect clinical practice. 
 
Included studies also showed heterogeneity in cortisol assay and in the type of 
cortisol tests performed. The sensitivity analysis did not reveal any material 
difference in overall percentage of adrenal insufficiency if only articles using a RIA 
were included, or if only articles using the ACTH 250-µg test were included. Although 
the diagnostic performance of RIA in the routine evaluation of adrenocortical 
function is considered superior to other competitive protein-binding analytical 
methods, like fluorimetry (91, 92), the chemiluminescence immunoassay seems to 
have comparable diagnostic performance and accuracy to RIA (93). It should be kept 
in mind that test criteria for adrenal insufficiency available in clinical practice have a 
high sensitivity rather than a high specificity, and therefore the number of false-
positive test results is not negligible. None of the studies retrieved by our literature 
search used the more modern tandem mass spectrometry (94). 
 
Several pathophysiological pathways may be involved in the development of adrenal 
insufficiency after the use of corticosteroids. It is certainly relevant to disentangle 
these different pathways and address the question of whether differences in dosage, 
treatment duration, and type of corticosteroid differentially affect the activity of the 




the effect of corticosteroids on adrenal function in clinical practice instead of 
disentangling the exact mechanisms of adrenal insufficiency. 
 
There was no sensitivity analysis performed for low risk of bias articles only, because 
there was only one article with low risk of bias (based on the inclusion of patients 
and loss to follow-up) within the group of studies with asthma patients only. If only 
studies with a time gap of at least 24 hours between the last dose of corticosteroids 
and the test for adrenal insufficiency were included, the percentage of adrenal 
insufficiency decreased only slightly. In our main analyses, we included articles 
irrespective of the time between last corticosteroid use and time of test. It is 
important to keep in mind that the percentage of patients with adrenal insufficiency 
would have been slightly higher than estimated in this meta-analysis had all articles 
used a time gap of at least 24 hours between the last dose of corticosteroids and the 
time of the test. 
 
Corticosteroids are used by at least 1% of the population (3). The risk of developing 
adrenal insufficiency in these patients is 1.4% to 60.0%, and symptoms of mild to 
moderate adrenal insufficiency, like fatigue and abdominal discomfort, are 
nonspecific and therefore difficult to ascribe to adrenal insufficiency. In addition, 
accurate predictors are not available to distinguish between the patients that will 
become adrenal insufficient and those that will not. Also there is insufficient 
evidence to prove any withdrawal scheme after steroid use to be efficient or safe 
(95). Therefore, we recommend that all patients with unexplained symptoms after 
steroid withdrawal be tested for possible adrenal insufficiency. In case of insufficient 
response, treatment should be initiated with physiological doses of hydrocortisone. 
 
In conclusion, this study demonstrates that all patients using corticosteroid therapy 
are at risk for adrenal insufficiency. This implies that clinicians should: 1) Inform 
patients about the risk and symptoms of adrenal insufficiency; 2) Consider testing 
patients after cessation of high-dose or long-term treatment with corticosteroids; and 
3) Display a low threshold for testing, especially in those patients with nonspecific 
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Corticosteroid use and mortality risk in patients 
with perforated colonic diverticular disease:  
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Corticosteroids are a potential risk factor for mortality in patients with perforated 
diverticular disease, due to blinding of disease severity, hampered wound healing or 
adrenal insufficiency. We examined mortality in corticosteroid users and non-users 
among patients with perforated diverticular disease. 
 
Methods 
A cohort study based on medical databases including all patients ≥18 years in 
Denmark (source population 5,289,261 inhabitants) admitted to a hospital with 
incident perforated diverticular disease between 2005 and 2013. 7-day, 1-month, 3-
month and 1-year mortality risks in corticosteroid users and non-users were 
calculated using the Kaplan–Meier method, and compared with Cox proportional 
hazard regression adjusted for age, sex and comorbidities. 
 
Results 
The study included 4,640 patients with perforated diverticular disease. Of these, 
3,743 (80.7%) had not used corticosteroids in the year before admission and 725 
(15.6%) had been exposed to systemic corticosteroid treatment. The remaining 172 
patients had been exposed to either inhaled or intestinal acting corticosteroid 
therapy. Mortality risk in non-users was 4.4% after 7 days and 15.6% after 1 year. This 
risk was doubled for corticosteroid users who filled their last prescription during the 
90 days before admission, with mortality risks ranging from 14.2% after 7 days to 
47.6% after 1 year. 1-year mortality risk was even higher for corticosteroid users with 
a first filled prescription ≤90 days before admission: 52.5%. 
 
Conclusions 
Corticosteroid use was associated with clearly increased mortality risk after 
perforated diverticular disease. Thus, use of corticosteroids should be regarded as an 
important clinical prognostic factor for mortality in patients with this condition. 
  





In Western countries, the prevalence of colonic diverticular disease reaches 50% 
among persons aged 60 and older (1, 2). Although most patients remain 
asymptomatic, the lifetime risk for developing diverticulitis is ∼10%–25% (3), which is 
known to present with perforation (4, 5). The incidence of perforated diverticular 
disease is ∼4 per 100,000 persons each year, reported in hospital records in the UK of 
Great Britain and Northern Ireland and the USA (6). Mortality after perforated 
diverticular disease requiring operative intervention has been reported to be as high 
as 12%–36% in small cohort studies (78–121 cases) (7, 8). Given this high mortality 
risk, a better understanding of prognostic factors associated with mortality is clearly 
needed. 
 
Use of corticosteroids is a potential prognostic factor affecting mortality in patients 
with perforated diverticular disease. Corticosteroids are widely prescribed for 
inflammatory diseases, malignancies and after organ transplantation, in order to 
inhibit an inflammatory response (9–11). At the same time, corticosteroids have been 
associated with bowel perforation in patients with diverticular disease. Three case–
control studies reported increased odds ratios of 1.7 to 28.3 and one cohort study 
reported a relative risk of 2.2 (12–15). A recent meta-analysis showed odds ratios for 
perforation of diverticular disease after use of corticosteroids of 2.17 to 31.90 (16). 
 
There are several reasons why mortality may be increased in patients with perforated 
diverticular disease who use corticosteroids. Disease severity might be masked by use 
of corticosteroids (17), leading to incorrect staging of disease severity and, 
consequently, inadequate treatment (6). Corticosteroid use might hamper wound 
healing as well through its anti-inflammatory effects, by suppressing cellular wound 
responses and by inducing diabetes, and thus increasing the risk of wound infection 
(18). A systematic review also showed that corticosteroid use may increase the risk of 
anastomotic leakage after colorectal surgery (19). Use of corticosteroids is associated 
with an increased risk of venous thromboembolism (20). In perforated diverticulitis, 
undiagnosed and untreated adrenal insufficiency may lead to an Addisonian crisis, 
which increases mortality risk in affected patients (21). 
 
Study aims 
The primary aim of this study was to examine absolute mortality risks and compare 7-
day, 1-month, 3-month and 1-year mortality rates in patients with perforated 
diverticular disease who were corticosteroid users versus non-users. The secondary 
aim was to examine mortality rates in patients with perforated diverticular disease 








The source population for this study was the entire population of Denmark (5,289,261 
inhabitants) between 2005 and 2013. The study period began in 2005 because a full 
record of medications sold at community pharmacies and hospital-based outpatient 
pharmacies became available starting in 2004 in the National Health Service 
Prescription Database (22). The study was based on data from the Danish National 
Patient Registry, which has recorded all acute care hospital discharges since 1977 
and all outpatient specialist clinic and emergency room visits since 1995 (23). Data 
from the Danish Civil Registration System were used to determine vital status (24). 
 
Study population and follow-up  
The study included all adult patients (≥18 years), with and without use of 
corticosteroids, hospitalized with incident perforated diverticular disease between 
2005 and 2013. Identification of perforated and non-perforated diverticular disease 
was based on International Classification of Diseases (ICD) codes (see Supplemental 
Data 1 for specification of the codes). The codes used for perforated diverticular 
disease have a positive predictive value ranging from 0.73 to 0.75 (25). There were 
no restrictions in corticosteroid dose or treatment duration. Patients diagnosed 
during an emergency room visit were excluded because of the low predictive value of 
emergency room diagnoses; diagnostic accuracy improves with more extensive 
diagnostic procedures (26). The year 2005 as start of follow-up was chosen in order to 
provide a 1-year prediagnosis period in which exposure to corticosteroids could be 
assessed similarly in all patients. Patient follow-up began on the hospital admission 
date for perforated diverticular disease and ended on death, emigration or end of 
follow-up on 30 November 2013, whichever came first. 
 
Classification of corticosteroid use and surgical procedures  
Corticosteroid use was categorized as follows, based on the National Health Service 
Prescription Database (22): 
I. Non-users: patients not prescribed corticosteroids during the year prior to hospital 
admission. 
II. Current users: patients using corticosteroids at time of admission, that is, the last 
prescription for corticosteroids was filled during the 90 days before admission. The 
group of current users was subdivided into new users, defined as patients who filled 
their first prescription ≤90 days before admission, and chronic users, which included 
all other current users. 
III. Recent users: patients who used corticosteroids until shortly before admission, 
that is, their last corticosteroid prescription was filled between 91 and 365 days 
before admission. 
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Analyses were performed separately for patients using systemic corticosteroids 
regardless of use of other forms of corticosteroids, for patients using systemic 
corticosteroids only, for patients using inhaled corticosteroids only, and for patients 
using intestinal acting corticosteroids only. There was one patient using both inhaled 
and intestinal acting corticosteroids. 
 
The analysis of cumulative dose was based on categorizing the 1-year cumulative 
dose of systemic corticosteroids among current users, calculated using prednisone 
dose equivalents. The cumulative dose cut-offs were ≤625 mg, >625 mg to 2000 mg, 
>2000 mg to 3500 mg and >3500 mg, to provide four groups of approximately equal 
size. 
 
Surgical procedures related to diverticular perforation (including a 30-day period 
around date of admission for diverticular disease) were categorized as explorative 
surgery including lavage; stoma with or without resection; and resections with 
primary anastomosis (see Supplemental Data 2 for surgical codes). 
 
Statistical analysis 
Descriptive contingency tables were prepared, showing demographic characteristics 
and medical history (age, sex, calendar year of perforated diverticular disease 
diagnosis, comorbidities) of corticosteroid users and non-users. 
 
For time-to-event analyses, the Kaplan-Meier method and Cox regression were used. 
Absolute mortality risks in corticosteroid users and non-users were calculated using 
the Kaplan-Meier method. Cox proportional hazard regression was used to compare 
mortality rates among the predefined categories of corticosteroid users, providing 
hazard ratios (HRs) for 7-day, 1-month, 3-month and 1-year mortality. Stratified 
analyses were performed according to type of surgery within 30 days before or after 
diagnosis of perforated diverticular disease. 
 
Subgroup analyses were performed to compare mortality risks among patients taking 
different forms of corticosteroids (inhaled only, intestinal only and systemic only) and 
with different 1-year cumulative doses of systemic corticosteroid use. Also, 
sensitivity analyses were performed after excluding patients with malignancies, 
patients with inflammatory bowel disease, patients with a previous code for 
diverticular disease and patients with rheumatic diseases including mixed connective 
tissue disease. 
 
In addition to crude analyses, we performed adjusted analyses including the following 
potential confounders: age, sex, use of cardiovascular medications (anticoagulants, 




β blockers, calcium channel blockers, diuretics, selective serotonin reuptake 
inhibitors, and nitrates) (16) during the 90 days before admission, hypertension, 
chronic obstructive pulmonary disease (COPD; as a proxy for smoking), liver disease 
or chronic pancreatitis, alcoholism-related diseases other than those affecting the 
liver or pancreas, inflammatory bowel disease, rheumatoid arthritis, connective 
tissue disease, malignancies and modified Charlson Comorbidity Index score (see 
Supplemental Data 1 for specification of the codes). The modified Charlson 
Comorbidity Index score was calculated after exclusion of COPD, liver diseases, 
connective tissue disease and malignancies. These characteristics and conditions are 
associated with corticosteroid use and constitute potential risk factors for mortality. 
 
We used SAS V.9.2 (SAS Institute, Cary, North Carolina, USA) for our statistical 






A total of 4,640 patients with perforated diverticular disease were included in the 
study. Of these, 3,743 (80.7%) had not used corticosteroids in the year before 
hospital admission (Table 1). Of the 897 patients using corticosteroids in the prior 
year, 725 (80.8%) were exposed to systemic corticosteroid treatment (current and 
recent users combined). Of systemic corticosteroid users, 88.8% used prednisone or 
prednisolone, 6.9% methylprednisolone, 13.4% β-methasone, 1.5% triamcinolone and 
1.0% hydrocortisone. Since the number of patients using only intestinal acting 
corticosteroids was small (n=28), this patient group was not analyzed further. 
Corticosteroid users were on average older than non-users and more often female 
than non-users (64.8% vs 54.2%). Patients using systemic corticosteroids were more 
often hypertensive, more often had COPD, chronic bronchitis, emphysema or asthma, 
and more often had malignancies, rheumatoid arthritis, connective tissue disease or 
inflammatory bowel disease. Almost all patients using only inhaled corticosteroids 
had a diagnosis of COPD, chronic bronchitis, emphysema or asthma, but were 
otherwise comparable to non-users. Charlson Comorbidity Index scores were higher 
for all groups of corticosteroid users compared with non-users. 
 
Mortality risk in patients with perforated colonic diverticular disease  
A total of 889 patients (19.2%) with perforated diverticulitis died within 1 year 
following their diagnosis (Table 2). Mortality risk in non-users of corticosteroids was 
4.4% after 7 days, 8.8% after 30 days, 11.9% after 90 days and 15.6% after 1 year. This 
risk was doubled for current users of corticosteroids (adjusted HRs ranging from 1.96 
(30-day mortality) to 2.10 (7-day mortality)), with mortality risks reaching 14.2% 
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after 7 days and 47.6% after 1 year (Figure 1). Mortality risk was even higher for new 
corticosteroid users, increasing from 15.7% 7 days post diagnosis to 52.5% after 1 
year. Among chronic corticosteroid users, mortality risks also were almost doubled, 
with adjusted HRs of 1.89 after 7 days and 1.74 after 1 year, and absolute mortality 
risks reaching 13.7% after 7 days and 45.9% after 1 year. 
 
 
Figure 1: Cumulative mortality in patients with systemic corticosteroid use, regardless of other use. 
 
Mortality risk according to 1-year cumulative dose  
In our study population, 124 patients had a 1-year cumulative dose ≤625 mg, 144 
patients had a 1-year cumulative dose >625–2000 mg, 140 patients had a 1-year 
cumulative dose >2000–3500 mg and 86 patients had a 1-year cumulative dose >3500 
mg (Table 3). A higher 1-year cumulative dose was not clearly associated with higher 
mortality risk in patients with perforated diverticular disease. 
 
Abdominal surgical procedures  
In total, 2,497 (53.8%) of 4,640 patients had a diverticulitis-related surgical 
procedure (Table 1). The percentage of patients with surgery within 30 days before 
or after incident perforated diverticular disease was higher among systemic 
corticosteroid users (62.9%) compared with users of inhalation corticosteroids only 




procedure resulting in a stoma (33.8%) more often than patients not using 
corticosteroids (22.6%). 
 
Within categories of surgery (explorative surgery including lavage, stoma, resection 
with primary anastomosis), mortality risk was increased when comparing current 
users to non-users. After explorative surgery, mortality risk after 1 year was 14.8% for 
non-users and 43.5% for current users (adjusted HR 1.12 [95% CI 0.69 to 1.83]). For 
patients who received a stoma, mortality risk after 1 year was 26.5% for non-users 
and 48.8% for current users (adjusted HR 1.37 [95% CI 1.03 to 1.82]). After a resection 
with primary anastomosis, mortality risk after 1 year was 15.2% for non-users and 
54.1% for current users (adjusted HR 2.88 [95% CI 1.57 to 5.28]). 
 
Subgroup and sensitivity analyses  
The mortality risk among patients currently using systemic corticosteroids only (13.9% 
after 7 days and 48.0% after 1 year) was comparable to that among patients using 
systemic corticosteroids regardless of other corticosteroid use (Figure 2). Compared 
with non-users, patients who currently used only inhaled corticosteroids also had an 
increased mortality risk (6.2% after 7 days and 22.3% after 1 year), with an adjusted 
HR ranging from 1.44 to 1.85 (Table 4). 
 
Figure 2: Cumulative mortality in patients with systemic use of corticosteroids only.  
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Table 1: Baseline characteristics of corticosteroid users and non-users among patients with perforated 
diverticular disease. 
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Sex (male) 1713 45.8 256 35.3 232 35.4 56 38.6 
Calendar year of perforated 




































Diverticular disease of the colon 
without perforation 
Hypertension 
COPD, chronic bronchitis, 
emphysema and asthma 
Liver disease and/or chronic 
pancreatitis 
Alcoholism-related diseases 
other than those affecting the 
liver or pancreas 
Cancer 
Rheumatoid arthritis / 
connective tissue disease 






































































































































































Surgery within 30 days before 
or after diagnosis of 
diverticulitis (total) 
Explorative surgery including 
lavage 
Stoma 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































When we excluded patients with malignancies, inflammatory bowel disease, a 
previous code for diverticular disease, or rheumatic diseases including mixed 
connective tissue disease, the results of the analysis of current users of systemic 
corticosteroids regardless of use of other corticosteroids did not materially change 





We examined mortality risks between corticosteroid users and non-users among 
patients with perforated diverticular disease. One-year mortality risk for current 
users of corticosteroids was 47.6%, double that of non-users after adjustment for 
confounders. One-year mortality risk was even higher for new corticosteroid users: 
52.5%. Thus, corticosteroid use was clearly associated with an increased mortality 
risk for patients with perforated diverticular disease, continuing until at least 1 year 
after diagnosis, regardless of corticosteroid dose. 
 
This is the first large cohort study comparing mortality risks between corticosteroid 
users and non-users among patients with perforated diverticular disease. The 
advantage of the cohort approach is the ability to calculate absolute mortality risks, 
which can inform clinical practice. Our study showed that corticosteroid use is a 
strong indicator for 1-year mortality. An earlier study of patients with perforated 
peptic ulcer disease reported a 30-day mortality ratio of 2.1 after corticosteroid use 
(27). This is in line with the increased mortality risk (adjusted HR of 1.96 for 30-day 
mortality) that we found among current users of systemic corticosteroids in the 
present study. 
 
The following study limitations need to be taken into account in interpreting our 
results. Determination of exposure was based on redeemed prescriptions, which may 
not always coincide completely with medication taken by patients (28). We also did 
not consider use of corticosteroids for longer than a year before hospital admission. 
Also, since prednisolone and prednisone were the most frequently used systemic 
steroids (89%), the results in first line apply to this patient category; whether our 
results also apply to patients using steroids with high first pass metabolism needs 
further study. Finally, perforated diverticular disease may be misclassified (6, 17), as 
the sensitivity of relevant ICD codes is not 100% accurate. Since misclassification is 
probably more likely in corticosteroid users (due to blinding of symptoms and severity 
of the condition), mortality risk is potentially overestimated if less severe cases in 
corticosteroid users go undetected (25). However, in analyses stratified by type of 
surgery, which most likely harmonizes the diagnostic category, a similar increased 
risk was found. 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The central causal question is whether increased mortality risk in corticosteroid users 
is actually caused by corticosteroid use prior to diagnosis. Clinical arguments 
underlying the rationale for a causal association are masked disease severity (17), 
impaired wound healing and increased infection risk (18), increased risk of venous 
thromboembolism (20) and unrecognized adrenal insufficiency (29). The risk was 
doubled for corticosteroid users in our fully adjusted statistical model, but residual 
confounding (no perfectly valid data on actual disease severity status) might still be 
an issue. For instance, high mortality among patients using corticosteroids may be 
explained partially by the underlying diseases for which corticosteroids were 
prescribed. However, our subgroup analyses showed no clear differences when high-
risk subgroups were excluded. Regardless of the causal question, our study indicated 
that corticosteroid use was an important prognostic factor for mortality. 
 
Two explanations are possible for the lack of an association observed between 
mortality risk and dose. First, the risk may be associated with corticosteroid use per 
se, so that the maximum increase in risk is already reached at a low (but still 
supraphysiological) dose. Second, our classification did not distinguish between short-
term, high-dose corticosteroid use and long-term, low-dose use, because the 
prescription database used does not provide certainty whether a drug is prescribed in 
high doses for short-term use, or in lower doses for longer duration. Although 
clinically short-term, high-dose corticosteroid use and long-term, low-dose 
corticosteroid use are very heterogeneous groups of patients, in our analysis 
according to dose, both translate into the same 1-year cumulative dose. 
 
In conclusion, this study demonstrated that corticosteroid use was associated with 
increased mortality risk after diagnosis of perforated diverticular disease. Clinically, 
use of systemic corticosteroids should be regarded as an important risk marker for 





1. Tănase I, Păun S, Stoica B, Negoi I, Gaspar B, Beuran M. Epidemiology of diverticular disease—
systematic review of the literature. Chirurgia (Bucur). 2015;110:9–14. 
2. Warner E, Crighton EJ, Moineddin R, Mamdani M, Upshur R. Fourteen-year study of hospital 
admissions for diverticular disease in Ontario. Can J Gastroenterol. 2007;21:97–99. 
3. Stollman N, Raskin JB. Diverticular disease of the colon. Lancet. 2004;363:631–639. 
4. Morris CR, Harvey IM, Stebbings WS, Hart AR. Incidence of perforated diverticulitis and risk 
factors for death in a UK population. Br J Surg. 2008;95:876–881. 
5. Hart AR, Kennedy HJ, Stebbings WS, Day NE. How frequently do large bowel diverticula perforate? 
An incidence and cross-sectional study. Eur J Gastroenterol Hepatol. 2000;12:661–665. 
6. Moore FA, Catena F, Moore EE, Leppaniemi A, Peitzmann AB. Position paper: management of 
perforated sigmoid diverticulitis. World J Emerg Surg. 2013;8:55. 
7. Nagorney DM, Adson MA, Pemberton JH. Sigmoid diverticulitis with perforation and generalized 
peritonitis. Dis Colon Rectum. 1985;28:71–75. 
Corticosteroid use and mortality risk in perforated colonic diverticular disease 
61 
 
8. Finlay IG, Carter DC. A comparison of emergency resection and staged management in perforated 
diverticular disease. Dis Colon Rectum. 1987;30:929–933. 
9. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids 
in the United Kingdom. QJM. 2000;93:105–111. 
10. Rodger RS, Watson MJ, Sellars L, Wilkinson R, Ward MK, Kerr DN. Hypothalamic-pituitary-
adrenocortical suppression and recovery in renal transplant patients returning to maintenance 
dialysis. QJM. 1986;61:1039–1046. 
11. Spiegel RJ, Vigersky RA, Oliff AI, Echelberger CK, Bruton J, Poplack DG. Adrenal suppression after 
short-term corticosteroid therapy. Lancet. 1979;1:630–633. 
12. Morris CR, Harvey IM, Stebbings WS, Speakman CT, Kennedy HJ, Hart AR. Anti-inflammatory 
drugs, analgesics and the risk of perforated colonic diverticular disease. Br J Surg. 2003;90:1267–
1272. 
13. Piekarek K, Israelsson LA. Perforated colonic diverticular disease: the importance of NSAIDs, 
opioids, corticosteroids, and calcium channel blockers. Int J Colorectal Dis. 2008;23:1193–1197. 
14. Humes DJ, Fleming KM, Spiller RC, West J. Concurrent drug use and the risk of perforated colonic 
diverticular disease: a population-based case-control study. Gut. 2011;60:219–224. 
15. Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Willett WC. Use of acetaminophen and 
nonsteroidal anti-inflammatory drugs: a prospective study and the risk of symptomatic 
diverticular disease in men. Arch Fam Med. 1998;7:255–260. 
16. Kvasnovsky CL, Papagrigoriadis S, Bjarnason I. Increased diverticular complications with 
nonsteriodal anti-inflammatory drugs and other medications: a systematic review and meta-
analysis. Colorectal Dis. 2014;16:O189–196. 
17. Symmonds RE Jr. Surgical management of complicated diverticulitis. Clin Geriatr Med. 
1985;1:471–483. 
18. Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res. 2010;89:219–229. 
19. Eriksen TF, Lassen CB, Gögenur I. Treatment with corticosteroids and the risk of anastomotic 
leakage following lower gastrointestinal surgery: a literature survey. Colorectal Dis. 
2014;16:O154–160. 
20. Johannesdottir SA, Horváth-Puhó E, Dekkers OM, Cannegieter SC, Jørgensen JO, Ehrenstein V, 
Vandenbroucke JP, Pedersen L, Sørensen HT. Use of glucocorticoids and risk of venous 
thromboembolism: a nationwide population-based case-control study. JAMA Intern Med. 
2013;173:743–752. 
21. de Herder WW, van der Lely AJ. Addisonian crisis and relative adrenal failure. Rev Endocr Metab 
Disord. 2003;4:143–147. 
22. Johannesdottir SA, Horváth-Puhó E, Ehrenstein V, Schmidt M, Pedersen L, Sørensen HT. Existing 
data sources for clinical epidemiology: the Danish National Database of Reimbursed Prescriptions. 
Clin Epidemiol. 2012;4:303–313. 
23. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 
2011;39(7 Suppl):30–33. 
24. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in 
epidemiology. Eur J Epidemiol. 2014;29:541–549. 
25. Erichsen R, Strate L, Sørensen HT, Baron JA. Positive predictive values of the International 
Classification of Disease, 10th edition diagnoses codes for diverticular disease in the Danish 
National Registry of Patients. Clin Exp Gastroenterol. 2010;3:139–142. 
26. Barksdale AN, Hackman JL, Gaddis M, Gratton MC. Diagnosis and disposition are changed when 
board-certified emergency physicians use CT for non-traumatic abdominal pain. Am J Emerg Med. 
2015;33:1646–1650. 
27. Christensen S, Riis A, Nørgaard M, Thomsen RW, Tønnesen EM, Larsson A, Sørensen HT. Perforated 
peptic ulcer: use of pre-admission oral glucocorticoids and 30-day mortality. Aliment Pharmacol 
Ther. 2006;23:45–52. 
28. Iudici M, Russo B, Mitidieri M, Cuomo G, Valentini G. Glucocorticoids in systemic sclerosis: 
patients’ beliefs and treatment adherence. Scand J Rheumatol. 2015;44:229–237. 
29. Broersen LH, Pereira AM, Jørgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroids use: 
systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100:2171–180. 
 
Part II 








































Chapter 4  
Microscopic versus endoscopic  
transsphenoidal surgery in the Leiden cohort 
treated for Cushing’s disease:  










Leonie H. A. Broersen, Femke M. van Haalen, Nienke R. Biermasz, Daniel J. Lobatto, 
Marco J.T. Verstegen, Wouter R. van Furth, Olaf M. Dekkers, and Alberto M. Pereira 
 







First-choice treatment for Cushing’s disease is transsphenoidal adenomectomy. Since 
its introduction in the 1970s, many centers have now switched from microscopic to 
endoscopic surgery. We compared both techniques for the treatment of Cushing’s 




Cohort study with inclusion and follow-up of consecutive patients with Cushing’s 
disease primarily treated by transsphenoidal surgery at the Leiden University Medical 
Center between 1978 and 2016. We compared remission rates (primary endpoint), 
mortality, and complications between microscopic (performed up to 2005) and 
endoscopic (performed from 2003 onwards) surgery. Subgroup analyses were 
performed by tumor size, surgical experience, and preoperative imaging techniques. 
Additionally, surgeons’ intraoperative findings regarding presence and removal of the 
adenoma were related to surgical outcome. 
 
Results 
Of 137 included patients, 87 were treated microscopically and 50 endoscopically. 
Three months after microscopic surgery, 74 patients (86%) were in remission. Five-
year recurrence-free survival was 89% (95% confidence interval [CI]: 82%-96%), and 
ten-year recurrence free survival was 84% (95% CI: 75%-93%). After endoscopic 
surgery, 39 patients (83%) were in remission. Both five-year and ten-year recurrence-
free survival were 71% (95% CI: 55%-87%). Hazard ratio for recurrence was 0.47 (95% 
CI: 0.19-1.14), and for mortality 2.79 (95% CI: 0.35-22.51), for microscopic versus 
endoscopic surgery. No learning curve was found for endoscopy, nor an influence of 
preoperative imaging technique for microscopy. In addition, we did not find a clear 
relation between the surgeons’ intraoperative findings and surgical outcomes. 
 
Conclusions 
This study did not identify a clear advantage of microscopic or endoscopic 
transsphenoidal surgery for the treatment of Cushing’s disease based on clinical 
outcome. The transition to endoscopic surgery at our center was not accompanied by 
transient worsening of outcomes, which may be reassuring for those considering 
transitioning. 
  





Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting 
pituitary adenoma, resulting in endogenous glucocorticoid excess. The incidence is 
estimated to be 1.2-1.7 per million each year (1). Glucocorticoid excess causes 
osteoporosis, central obesity, insulin resistance, dyslipidemia, hypertension, 
hypercoagulability, and neuropsychiatric disorders (2, 3). First-choice treatment 
remains transsphenoidal pituitary surgery, selectively removing the corticotroph 
adenoma (4, 5). Despite biochemical cure, mortality risk remains increased in 
patients with Cushing’s disease (6). 
 
Two main techniques have been used for transsphenoidal pituitary surgery: 
microscopic and endoscopic surgery. The endoscope has also been used to confirm 
findings during microscopic surgery, which is called endoscopy assisted surgery. 
Microscopic surgery used to be the established method for transsphenoidal surgery. 
However, since 1992, when the endoscope was first used as a tool to assist in 
microscopic surgery for a pituitary adenoma (7), many centers have switched to a full 
endoscopic technique, which was first described in 1997 for treatment of Cushing’s 
disease (8). However, proper evaluation of outcomes in a single center has yet to be 
performed. A limited number of small cohort studies (13-25 patients per study group) 
have compared both the microscopic and endoscopic techniques for treatment of 
Cushing’s disease performed in the same center (9-12). None showed a significant 
difference in remission rate or surgical morbidity between microscopic and (transition 
to) endoscopic surgery. Additionally, significant differences in remission rates based 
on tumor size could not be determined (9). Several systematic reviews concerning 
transsphenoidal microscopic versus endoscopic surgery have evaluated outcomes for 
all pituitary adenomas and found comparable results for remission and recurrence 
rates, and inconclusive results regarding complication rates (13-15). Theoretically, 
endoscopic surgery has the advantage of achieving better tumor visualization, mainly 
in laterally invasive or large tumors. This increased visibility enables improved 
resectability, leading to potentially higher remission rates. However, these 
advantages have also led to a higher risk of cerebrospinal fluid (CSF) leakage, most 
likely due to a more aggressive surgical approach in an attempt to obtain complete 
adenoma removal (16). Several studies have reported on a learning curve for the 
endoscopic technique (17-20), showing that outcomes improve with increased surgical 
experience, which possibly leads to biased results in series when comparing between 
years of experience in the microscopic surgical technique and the newer endoscopic 
technique. 
 
Due to the lack of comparability of available studies, we present our long-term data 




with as primary endpoint remission rate, as well as complication rates for both 
techniques. To date, there are unresolved questions regarding long-term remission 
rates and surgical morbidity after both treatments, overall as well as in relation to 
tumor size. Furthermore, differences in long-term mortality, endocrinological 
complications, and morbidity between the two surgical techniques need to be 
explored to be able to properly evaluate both treatment options. Finally, in order to 
establish the predictive value of intraoperative findings, it is important to relate the 




The primary study aim was to compare microscopic and endoscopic transsphenoidal 
surgery for Cushing’s disease regarding: 1) Surgical outcome (remission rate = primary 
endpoint, recurrence, and hydrocortisone dependency), 2) Long-term mortality risk, 
and 3) Short- and long-term surgical and endocrinological complications. Secondary 
study aims were to stratify these results based on 1) Tumor size and 2) Surgical 
experience for endoscopy, and 3) To relate surgeons’ intraoperative findings 






Consecutive patients with Cushing’s disease primarily treated with transsphenoidal 
surgery at the tertiary referral center Leiden University Medical Center, the 
coordinating center of the newly established European Reference Network for rare 
Endocrine conditions, and a European reference center for pituitary diseases, were 
included in this cohort study. Inclusion started in 1978, when the first transsphenoidal 
operation in the Netherlands was performed in Leiden. Microscopic surgery was 
performed from 1978 to 2005, whereas endoscopic surgery has been performed since 
2003. Patients were included if surgery was performed before January 1
st
 2017. 
Patients were excluded if they had undergone a unilateral adrenalectomy and/or 
pituitary irradiation prior to transsphenoidal surgery. There were no restrictions in 
presurgical medical treatment with cortisol lowering agents or in adjuvant therapy in 
case of persistent disease or for recurrence of disease. 
 
The diagnosis of Cushing’s disease was made based both on clinical grounds and 
biochemical tests: increased morning serum cortisol (>500 nmol/L), increased 24-h 
urinary free cortisol (UFC) excretion (>220 nmol until 2010, after which the cut-off 
level was >150 nmol), increased midnight salivary cortisol excretion (>5.7 nmol/L, 
measured since 2004), insufficient suppression of morning serum cortisol after low-
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dose dexamethasone (1 mg in the evening), as well as a non-suppressed ACTH. Until 
1988, urinary 17-KgS was measured in some patients instead of UFC (increased if >16 
mg/24h for women and >22 mg/24h for men). All patients underwent pituitary 
imaging either by computed tomography (CT, until 1994, and one patient in 2009 due 
to a contraindication for magnetic resonance imaging [MRI]), or MRI. Three patients 
who were operated before 1980 underwent imaging by sellar planigraphy, with or 
without basal cisternography (X-ray). If pituitary imaging yielded inconclusive results, 
bilateral simultaneous sampling of the inferior petrosal sinuses (IPSS) was performed. 
Subsequently, pituitary surgery with exploration of the sella was performed when the 
results of IPSS were consistent with a pituitary source of ACTH overproduction. 
Otherwise, imaging studies (CT of the thorax and octreotide or gallium DOTATATE 
PET scan) were performed to identify an ectopic source of ACTH overproduction. In 
case no ectopic ACTH-producing tumor was found, diagnostic tests were repeated 
after a period of watchful waiting, and surgical treatment was performed only after 
imaging or IPSS indicated a pituitary adenoma. 
 
Interventions and postoperative evaluation  
The primary treatment was either microscopic or endoscopic transsphenoidal 
pituitary adenomectomy for all included patients. A direct transnasal transsphenoidal 
microscopic approach was performed solely until 2002. From 2003 onwards, the 
endoscopic procedure was introduced in our center for the surgical treatment of 
pituitary tumors, including Cushing’s disease. At first, an endoscopic assisted 
approach was used to confirm findings of the microscope. In this study, endoscopic 
assisted surgery was analysed in the study group of microscopic surgery, because the 
surgery was primarily performed using the microscope, which was therefore the main 
technique to be considered for treatment success and complication rates. From 2006 
onwards, purely endoscopic transnasal transsphenoidal approaches were the only 
surgical treatment modality. All surgical procedures were performed by three 
dedicated pituitary neurosurgeons. Postoperative biochemical evaluation was always 
performed within two weeks. Three to six months postoperatively, remission was 
defined based on both clinical criteria (dependency on hydrocortisone replacement, 
or hydrocortisone independency without any biochemical signs of hypercortisolism 
and regression of clinical signs) and biochemical criteria (morning cortisol suppression 
after 1 mg dexamethasone to below 50 nmol/L and normal 24-h UFC excretion or 
midnight salivary cortisol excretion in two consecutive samples, if not on 
hydrocortisone replacement) (21). Persistent Cushing’s disease was defined as the 
absence of remission after first surgery. Disease recurrence was defined as 
biochemical recurrence according to the aforementioned criteria, and re-occurrence 






Endpoints and follow-up  
Study endpoints were surgical outcomes, mortality, and short- and long-term 
morbidity. Surgical outcomes considered were the following: 1) Remission rate 
(primary endpoint), 2) Persistent disease, 3) Recurrent disease, and 4) 
Hydrocortisone dependency three months after surgery (divided in three categories: 
a) Absolute deficiency [insufficient cortisol response to corticotropin-releasing 
hormone (CRH)-test or equivalent], b) Hydrocortisone to treat withdrawal symptoms 
despite normal cortisol response to CRH stimulation, and c) Pragmatic hydrocortisone 
replacement without stimulation test).  
 
Short-term morbidity (≤3 month after first surgery): 1) Postoperative CSF-leakage, 2) 
Bacterial meningitis (or start of antibiotic treatment due to suspicion of meningitis), 
3) All intra- and postoperative bleedings (considered were internal carotid artery 
injury, epistaxis, severe venous blood loss), 4) Severe bleeding (requiring surgical 
intervention or described as severe in patient file), 5) Syndrome of inappropriate 
antidiuretic hormone secretion (Na <135 mmol/L), 6) Diabetes insipidus (transient, 
requiring medication at least once), 7) Anterior pituitary deficiency other than ACTH 
requiring medication, 8) Corticosteroid withdrawal syndrome (complaints and/or 
requirement of increase in hydrocortisone replacement dose) (22), and 9) 
Cardiovascular morbidity (thrombosis, pulmonary embolism, cerebrovascular 
accident, transient ischemic attack, and myocardial ischemia). 
 
Long-term morbidity (>3 months after first surgery): 1) Anterior pituitary deficiency 
other than ACTH requiring medication (measured one year after surgery), 2) 
Hydrocortisone dependency for >3 years (for patients with >3 years follow-up), 3) 
Diabetes insipidus (permanent: >3 months), 4) Cardiovascular morbidity, 5) 
Hypertension (de novo as well as persisting after surgery), 6) Diabetes mellitus (de 
novo as well as persisting after surgery), and 7) Neuropsychiatric morbidity 
(complaints/symptoms as well as consultation of psychologist or psychiatrist). 
 
Follow-up was defined as time between date of surgery and death, loss to follow-up, 
or December 31
st
 2016, whichever came first. For time-to-event analyses, follow-up 
was defined as time between date of surgery and outcome event (mortality or 
recurrence), death, loss to follow-up, or December 31
st
 2016, whichever came first. 
Presurgical information was collected regarding diagnosis (including Cushing’s 
syndrome severity index score [CSI score] (23)), comorbidities (hypertension, 
diabetes mellitus, dyslipidemia), and medical treatment prior to surgery. In case of 
loss to follow-up, data collection was completed to our best ability by contacting 
both patient and current health care provider.  
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Tumor characteristics: tumor size on preoperative imaging divided tumors into 
microadenomas (≤10 mm) and macroadenomas (>10 mm). Giant adenomas (>3 cm) 
were not analysed separately. Intraoperative findings were classified into three 
categories: complete adenomectomy (surgeon reported complete removal of the 
adenoma), (at least) partial adenomectomy (surgeon reported partial removal of the 
adenoma, but is uncertain whether there is residual tumor), and residual tumor 
(surgeon is certain there is residual tumor). 
 
Risk of bias  
Consecutive patients were included in this study to minimize selection bias, although 
selection could still be a cause of bias in our data. Patients were assigned to a 
treatment method based on the availability of the treatment method in our center at 
time of inclusion, although this does not guarantee comparability of both study 
groups, e.g. due to time trends. To assess potential differences through time, we 
plotted percentage macroadenomas per period of five calendar years. Selective loss 
to follow-up could have led to selection bias (24), although this was minimized by our 
attempts at complete data collection, reducing the number of patients lost to follow-
up by 21. Selective referral of patients from other centers, mainly patients with 
(difficult and/or invasive) macroadenomas, could potentially have led to selection 
bias if referral was different for microscopy and endoscopy. Interventions were 
unlikely to be misclassified. Confounding is a potential source of bias and was 
assessed by comparing baseline patient characteristics between the study groups. 
Furthermore, follow-up time was assessed as a potential source of bias. 
 
Statistical analysis 
To describe homogeneity between the surgical groups as well as between 
microadenomas and macroadenomas, various parameters were analysed by bivariate 
test. Contingency tables were presented, comparing characteristics of microscopic 
and endoscopic surgery. A table was prepared with short- and long-term morbidity 
according to tumor size, comparing microscopic to endoscopic surgery. All variables 
in Tables 1 and 2 were compared between the two surgical techniques for the entire 
cohort as well as for microadenomas and macroadenomas separately as this is 
considered an effect modifier. We used the unpaired T-test for continuous outcomes, 
and the two-sample test of proportions for categorical variables (in case of >2 
categories, we performed this test separately per category to calculate the 
difference between the groups). Additionally, the Chi-squared test was used to 
calculate one p-value for categorical variables with >2 categories. If data were 
missing for ≥5% of patients per parameter, this was marked in the tables. An “as 
treated” analysis was performed, excluding patients with missing data for 




























(95% CI; p-value) 
(Macroadenoma 
only) 
 N % N %    




Age at diagnosis, 
years* 
38.9 15.4 44.4 15.1 5.5  
(0.1 to 10.9; 
p=0.045) 
3.4  
(-2.6 to 9.3; 
p=0.263) 
9.0  
(-3.5 to 21.4; 
p=0.152) 
Sex (female) 69 79.3 34 68.0 11.3  
(-4.2 to 26.8; 
p=0.140) 
7.7  
(-10.4 to 25.8; 
p=0.391) 
20.8  
(-8.5 to 50.1; 
p=0.170) 








(17.1 to 21.2; 
p=0.000) 
20.4  
(18.1 to 22.6; 
p=0.000) 
14.7  







4.7 2.0-7.4 13.4  
(11.0 to 15.8; 
p=0.000) 
14.0  
(11.2 to 17.7; 
p=0.000) 
11.3  


















































(-12.6 to 17.4; 
p=0.756) 
13.9  
(-1.0 to 28.8; 
p=0.055) 
6.9  





(-15.2 to 21.8; 
p=0.723) 
13.5  
(-4.1 to 31.1; 
p=0.110) 
3.0  





(-11.0 to 41.6; 
p=0.271) 
14.5  
(-14.0 to 43.0; 
p=0.320) 
9.0  






































(-0.98 to 0.79; 
p=0.832) 
0.09  
(-1.00 to 1.17; 
p=0.877) 
-0.72  
(-2.31 to 0.86; 
p=0.357) 






















(-4.2 to 26.8; 
p=0.140) 
- - 




4 4.6 6 12.0 7.4  
(-2.6 to 17.4; 
p=0.109) 
3.0  
(-5.9 to 11.9; 
p=0.459) 
13.9  

































(16.5 to 40.5; 
p=0.000) 
34.8  
(23.6 to 46.0; 
p=0.000) 
14.6  
(-14.4 to 43.6; 
p=0.335) 
*mean + standard deviation, °mean + range, $median + interquartile range; CI=confidence interval 
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30 34.5 13 26.0 8.5  
(-7.2 to 24.2; 
p=0.302) 
2.4  






CT or X-ray 
 
MRI 1.5 Tesla 
 
































(18.5 to 39.5) 
33.0  
(16.5 to 49.5) 
62.0  




(19.3 to 44.5) 
38.7  
(20.1 to 57.3) 
70.6  




(-0.5 to 33.9) 
27.0  
(-2.8 to 56.8) 
43.8  

































(0.6 to 30.6) 
13.6  
(1.6 to 27.0) 
2.0  
(-6.7 to 10.7) 
p=0.359 
14.1  
(-5.2 to 33.4) 
12.7  
(-4.9 to 30.3) 
1.3  
(-10.6 to 13.2) 
p=0.339 
5.6  
(-5.0 to 16.2) 
5.6  


































(-9.7 to 17.9) 
4.6  
(-8.1 to 17.3) 
0.5  
(-6.2 to 7.2) 
p=0.940 
0.0  
(-18.2 to 18.2) 
1.5  
(-15.3 to 183) 
1.5  
(-7.8 to 10.8) 
p=0.339 
5.6  
(-5.0 to 16.2) 
5.6  






57 66.3 45 90.0 23.7  
(10.7 to 36.7; 
p=0.002) 
23.5  
(6.9 to 40.1; 
p=0.015) 
16.7  

























































(-9.0 to 26.0) 
17.7  
(2.0 to 33.4) 
0.9  
(-6.3 to 8.1) 
8.3  





(-10.9 to 30.5) 
18.2  
(-0.8 to 37.2) 
1.5  
(-1.5 to 4.5) 
6.8  





(-24.9 to 41.7) 
19.5  
(-7.9 to 46.9) 
5.1  
(-19.2 to 29.4) 
5.9  
(-5.3 to 17.1) 
ACTH=adrenocorticotropic hormone, CI=confidence interval, CT=computed tomography, MRI=magnetic 
resonance imaging 
^Inferior petrosal sinus sampling was considered only for patients with uncertain pituitary tumor, and 
therefore never in macroadenomas, $Data were missing for ≥5% of patients, #No patients with a 





To compare mortality and remission rates time-to-event analyses were performed. 
Kaplan-Meier curves were constructed to visualize overall survival and recurrence-
free survival. Separate curves were constructed for microadenomas and 
macroadenomas, thereby including tumor size as stratification factor, and separate 
curves were constructed stratified by surgeons’ intraoperative findings. As sensitivity 
analyses, time-to-event curves were constructed comparing the early and late years 
of all endoscopic operations to assess a potential learning curve, and separate curves 
were constructed comparing microscopic operations after CT or X-ray imaging versus 
after MRI to check whether preoperative imaging quality influenced surgical success.  
 
Cox proportional hazard regression analyses were performed to provide hazard ratios 
and to adjust for potential confounders (results presented in text and Table 3). To 
take into account different follow-up times, we performed recurrence-free survival 
analyses also separately with inclusion of only the first 5 years of follow-up. We 
considered the following variables as potential confounders based on literature and 
known biological pathways: age at diagnosis, sex, hypertension at diagnosis, diabetes 
mellitus at diagnosis, dyslipidemia at diagnosis, CSI score, tumor size, and prior 
medical treatment. After comparison of these potential confounders, we included 
age at diagnosis and tumor size as confounders in all our Cox analyses, unless 
otherwise specified. 
 
Statistical analyses were performed with IBM SPSS Statistics 23.0 (IBM Corp, Armonk, 
NY, USA) and with Stata 14.2 (Stata Corp., College Station, TX, USA) for the two-
sample test of proportions (command: prtesti) to calculate the difference between 
two proportions with 95% confidence interval (CI), as this was not provided by SPSS. 
All patients gave informed consent to use their data for scientific research and 
permission from the medical ethical committee in the LUMC was granted. The 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 





Study population (Figure 1, and Table 1) 
In total, 137 patients were included, of whom 87 (79.3% female, mean age 38.9 
[range 12-80] years) underwent microscopic and 50 (68% female, mean age 44.4 
[range 10-73] years) endoscopic surgery. Macroadenomas were relatively more 
common in the endoscopic group (32.0% versus 20.7% in the microscopy group), and 
preoperative medical treatment was more common in patients with endoscopic 
surgery (94.0% versus 65.5% in the microscopy group), in line with the changing 
treatment strategies over time. Fifteen patients were lost to follow-up (all in the 
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microscopic surgery group after an average of 101 months, range: 3-261 months). 
Histopathology confirmed a corticotroph adenoma in nineteen patients with negative 
imaging, and was inconclusive in one patient. See Table 2 for a detailed description 
of diagnostic strategy and results. 
 
137 patients included
87 patients microscopic surgery 50 patients endoscopic surgery









- 10 patients microscopic (4 remission)
- 5 patients endoscopic (1 remission)
After failed repeated surgery:
- 3 patients radiotherapy (2 remission)
- 3 patients radiotherapy and adrenalectomy (3 remission)
- 2 patient adrenalectomy (1 remission)
- 1 patient radiotherapy and medical treatment (no disease control)
- 1 patient medical treatment (no disease control)
Recurrence after repeated surgery:
- 1 patient 3rd transsphenoidal surgery (no remission) and 
radiotherapy (remission)
Other adjuvant treatment modalities:
- 9 patients radiotherapy (9 remission)
- 2 patient medical treatment (1 disease control)
- 1 patient radiotherapy and medical treatment (disease control)
- 3 patients no further treatment
Repeated transsphenoidal surgery:
- 13 patients endoscopic (5 remission, 1 too short 
follow-up to determine remission status after 
repeated surgery)
After failed repeated surgery:
- 4 patients radiotherapy (1 remission)
- 2 patients radiotherapy and adrenalectomy 
(2 remission)
- 1 patient 3rd transsphenoidal surgery (remission)
Recurrence after repeated surgery:
- 1 patient 3rd transsphenoidal surgery (remission)
Other adjuvant treatment modalities:
- 2 patients radiotherapy (1 remission)
- 1 patient adrenalectomy (remission)
- 1 patients no further treatment
3 patients too short follow-up 
to determine remission status
 
Figure 1: Flow chart of treatment and remission status. 
 
Surgical outcome and recurrence-free survival  
Three months after microscopic surgery, 74 of 86 patients (86.0%) were in remission, 
of whom 67 patients (77.9%) were hydrocortisone dependent. One patient died three 
days after microscopic surgery (cause not identified). The five-year recurrence-free 
survival rate for the patients in remission after surgery was 89% (95% CI: 82%-96%), 
and the ten-year recurrence free survival rate was 84% (95% CI: 75%-93%).  
 
Three months after endoscopic surgery, 39 of 47 patients (83.0%) were in remission, 
of whom 33 patients (70.2%) were hydrocortisone dependent. Both the five-year and 
ten-year recurrence-free survival rates were 71% (95% CI: 55%-87%) for the patients in 
remission after surgery. All patients with negative pathology were in remission at the 
end of follow-up, except for one patient. Patients with negative pathology achieved 
remission after (repeat) transsphenoidal surgery or pituitary radiotherapy, and in 




Recurrence occurred less often in patients with microscopic surgery (hazard ratio 
0.47, 95% CI: 0.19-1.14), see Figure 2. The hazard ratio was 0.38 (95% CI: 0.15-0.99) 
if only the first 5 years of follow-up were considered. After adjustment, the hazard 
ratio was 0.40 (95% CI: 0.16-1.01). As percentage macroadenomas changed over time 
(Figure 3), separate analyses for microadenomas and macroadenomas were 
performed. For microadenomas the risk of recurrence was similar for the two 
techniques: hazard ratio 0.99 (95% CI: 0.26-3.74), or hazard ratio 0.79 (95% CI: 0.20-
3.16) for the first 5 years of follow-up, which was similar after adjustment for age at 
diagnosis. If only macroadenomas were considered, the hazard ratio was 0.18 (95% CI: 
0.04-0.91, p=0.038), which was exactly the same for the first 5 years of follow-up, 
and 0.14 (95% CI: 0.03-0.77; p=0.023) after adjustment for age at diagnosis, see 
Figure 4. When patients with cavernous sinus invasion were excluded from analysis, 























































Figure 2: Recurrence-free survival after microscopic versus endoscopic transsphenoidal surgery. 
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Surgeons’ intraoperative findings were not clearly related to recurrence-free survival 
(see Figure 5). Hazard ratios compared to the reference group of complete 
adenomectomy were: 1.32 (95% CI: 0.57-3.06) for (at least) partial adenomectomy 
(1.21, 95% CI: 0.43-3.39, for the first 5 years of follow-up), and 3.90 (95% CI: 0.86-
17.63) for residual tumor (4.49, 95% CI: 0.96-21.01, for the first 5 years of follow-up). 
Hazard ratios after adjustment for age at diagnosis, type of adenomectomy 
(microscopy or endoscopy), and tumor size (microadenoma or macroadenoma) were 
similar. To assess a potential learning curve within the endoscopic surgery group, 
patients that underwent endoscopic surgery until December 31
st
 2011 (N=21) were 
compared with patients that underwent endoscopic surgery after January 1
st
 2012 
(N=18). To determine whether preoperative imaging quality influenced surgical 
success in microscopic surgery, patients with CT/X-ray imaging were compared with 
patients with MRI scans. We found no difference between early and late years of 
endoscopic surgery (hazard ratio 1.72, 95% CI: 0.46-6.52, which was exactly the same 
if only the first 5 years of follow-up were included; hazard ratio 1.06, 95% CI: 0.25-
4.53 after adjustment), or between preoperative imaging techniques for microscopic 
surgery (hazard ratio 0.99, 95% CI: 0.36-2.73, which was 0.65, 95% CI: 0.16-2.72, if 























































Figure 5: Recurrence-free survival according to surgeons’ intraoperative findings. 
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Figure 6: Recurrence-free survival according to imaging and time of surgery. 
 
Overall survival  
Within ten years after surgery, ten patients died: nine in the microscopic surgery 
group and one in the endoscopic surgery group (all-cause mortality). One patient died 
three days after microscopic surgery of unidentified cause, although a cardiogenic 
cause was most likely, as left ventricular hypertrophy, coronary artery disease with 
over 50% stenosis, and pulmonary edema were found at autopsy. Ten-year overall 
survival rate was 89% (95% CI: 82%-96%) for microscopic surgery and 94% (95% CI: 83%-
100%) for endoscopic surgery. The hazard ratio for mortality was 2.79 (95% CI: 0.35-
22.51, similar after adjustment) for microscopic versus endoscopic surgery, see 
Figure 7. 
 
Short- and long-term morbidity  
In the microscopic group, less patients experienced a corticosteroid withdrawal 
syndrome compared to the endoscopic group (hazard ratio after adjustment: 0.38, 
95% CI 0.20 to 0.72). Patients with microscopic surgery also had less long-term 




Table 3, a detailed overview is presented of hazard ratios for short- and long-term 
morbidity for endoscopic versus microscopic surgery. 
 
Four patients were treated with antibiotics for meningitis, all after microscopic 
surgery (two of whom had positive CSF cultures, with pseudomonas and klebsiella 
species, respectively). Three patients had a severe bleeding (two in the microscopy 
group and one in the endoscopy group), which was discovered directly after surgery 
based on clinical findings/deterioration and confirmed on postoperative imaging: of 
these patients one patient had a subdural hematoma (microscopy), one patient had a 
intracerebral hematoma (microscopy) and a subarachnoid bleeding (both patients 
were treated surgically), and one patient had severe epistaxis and hematemesis 
(treated conservatively, but described as severe in the patient file, with at least 800 
ml of blood loss; endoscopy). The other, non-severe bleedings were intraoperative 
venous bleedings (predominantly from the cavernous sinus), that were excessive 
compared to the expected amount of blood loss during surgery, and another episode 























































Figure 7: Overall survival after microscopic versus endoscopic transsphenoidal surgery. 
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Repeated transsphenoidal surgery  
Fifteen patients with initial microscopic surgery underwent a second transsphenoidal 
surgery after a mean of 111 months (range: 7-242), of which ten were microscopic 
and five endoscopic. Remission was obtained in five of these patients (33.3%) (all 
hydrocortisone dependent [absolute deficiency], as evaluated three months after 
repeated surgery), one of whom had undergone endoscopic and four repeated 
microscopic surgery. In the endoscopic group, thirteen patients underwent repeated 
transsphenoidal surgery after a mean of 21 months (range: 1-43), all of which were 
endoscopic. Remission was obtained in five patients (41.7%) (four hydrocortisone 
dependent [absolute deficiency] three months after repeated surgery), and duration 
of follow-up was insufficient in one patient to determine remission status after 
repeated surgery. A third transsphenoidal surgical procedure was performed in three 
patients, resulting in remission in two patients (one hydrocortisone dependent 
[absolute deficiency]). For more detailed information on adjuvant treatment and 





In this study, we compared remission rates, mortality risk, and short- and long-term 
complications between patients treated at a European reference center for Cushing’s 
disease with microscopic versus endoscopic transsphenoidal pituitary surgery. Both 
techniques yielded similar results regarding remission rate and percentage of patients 
with hydrocortisone dependency. Patients with microscopic surgery had longer 
recurrence-free survival, but a higher mortality rate, than patients with endoscopic 
surgery. When analysed separately, patients with a macroadenoma had a longer 
recurrence-free survival after microscopic surgery than after endoscopic surgery. Our 
results could not prove indications of the presence of a learning curve for endoscopic 
surgery, nor did we find that the type of imaging technique influenced our results for 
microscopic surgery. No clear relation was found between the surgeons’ 
intraoperative findings and recurrence-free survival, although patients with a certain 
residual tumor after surgery seemed to perform worse than patients with complete 
adenomectomy. After endoscopic surgery, more patients had symptoms consistent 
with corticosteroid withdrawal, and patients showed a higher hazard ratio for long-
term neuropsychiatric morbidity.  
 
While there have been previous cohort studies, a major strength of this study is that 
this study includes the largest cohort to date, thereby increasing reliability of results 
stratified by tumor size. This is also the first cohort study investigating long-term 
mortality in Cushing’s disease after endoscopic surgery and comparing this to long-




obtained from this study are in line with previously published small cohort studies in 
Cushing’s disease directly comparing both techniques (9-12). Our recently published 
systematic review comparing both surgical techniques in Cushing’s disease showed an 
advantage of performing endoscopic surgery for macroadenomas based on remission 
and recurrence rates (26). This could not be confirmed in the current cohort study.  
 
Table 3: Short- and long-term morbidity. 
 Hazard ratio (95% CI;  
p-value)#, unadjusted 
Hazard ratio (95% CI; p-value)#, 
adjusted for age at diagnosis and 






- Absolute deficiency  
- Normal cortisol response* 
- Pragmatic replacement$  
Repeat surgery 
Remission after first repeat surgery 
 
0.82 (0.34 to 2.01; p=0.663) 
0.47 (0.19 to 1.14; p=0.093) 
1.11 (0.73 to 1.68; p=0.625) 
1.06 (0.69 to 1.62; p=0.793) 
° 
° 
0.30 (0.13 to 0.70; p=0.005) 
0.21 (0.04 to 1.13; p=0.069) 
 
0.88 (0.35 to 2.21; p=0.789) 
0.40 (0.16 to 1.01; p=0.052) 
1.04 (0.68 to 1.60; p=0.845) 
0.97 (0.63 to 1.50; p=0.888) 
° 
° 
0.27 (0.11 to 0.64; p=0.003) 
0.17 (0.02 to 1.16; p=0.070) 
Short term morbidity: ≤3 month 
after first surgery 




Syndrome of inappropriate 
antidiuretic hormone release 
Diabetes insipidus 
Anterior pituitary deficiency 
- One axis 
- Two axes 
- Three axes 






0.56 (0.22 to 1.41; p=0.221) 
° 
0.32 (0.09 to 1.09; p=0.069) 
 
1.04 (0.54 to 1.99; p=0.904) 
0.76 (0.37 to 1.54; p=0.444) 
0.85 (0.37 to 1.96; p=0.704) 
0.41 (0.09 to 1.83; p=0.243) 
° 






0.56 (0.22 to 1.44; p=0.227) 
° 
0.29 (0.08 to 1.02; p=0.054)a 
 
0.96 (0.49 to 1.86; p=0.901) 
1.06 (0.51 to 2.22; p=0.870) 
1.18 (0.50 to 2.79; p=0.708) 
0.52 (0.11 to 2.45; p=0.409) 
° 
0.38 (0.20 to 0.72; p=0.003) 
° 
Long term morbidity: >3 months 
after first surgery 
Anterior pituitary deficiency after 1 
year 
- One axis 
- Two axes 
- Three axes 
Hydrocortisone dependency >3 years 
Diabetes insipidus >3 months 
Cardiovascular morbidity 
Hypertension 




0.79 (0.42 to 1.52; p=0.488) 
 
0.83 (0.38 to 1.83; p=0.642) 
0.65 (0.17 to 2.41; p=0.517) 
° 
1.05 (0.56 to 1.96; p=0.878) 
1.71 (0.68 to 4.29; p=0.251) 
0.37 (0.12 to 1.16; p=0.088) 
0.85 (0.51 to 1.41; p=0.529) 
0.53 (0.22 to 1.29; p=0.160) 
0.14 (0.03 to 0.68; p=0.015) 
 
 
1.03 (0.52 to 2.01; p=0.056) 
 
1.10 (0.48 to 2.48; p=0.827) 
0.74 (0.19 to 2.89; p=0.663) 
° 
1.11 (0.59 to 2.10; p=0.742) 
1.84 (0.72 to 4.69; p=0.204) 
0.43 (0.13 to 1.38; p=0.155) 
0.92 (0.53 to 1.58; p=0.749) 
0.56 (0.23 to 1.36; p=0.198) 
0.15 (0.03 to 0.76; p=0.022) 
CI=confidence interval 
#Reference group for hazard ratios was endoscopic surgery. 
aAdjusted for age at diagnosis only. 
*Hydrocortisone for symptoms despite normal cortisol response to CRH stimulation. °Insufficient data for 
analysis. 
$Pragmatic hydrocortisone replacement (without stimulation test). 
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There are several study limitations that need to be taken into account when 
interpreting the study results. Patients treated microscopically were included in a 
different time period than patients treated by endoscopic surgery, which might have 
resulted in substantial differences between both study groups. The prevalence of 
certain comorbidities has changed over time, as well as the available treatment 
modalities for these comorbidities. However, patient characteristics were compared 
between the study groups, and only follow-up duration and the use of medical 
treatment prior to surgery differed largely. It is impossible to say in which direction 
mortality might have changed due to the differences in prevalence and treatment of 
comorbidities over time, as one might expect a worse survival with a higher 
prevalence of comorbidities, but a better survival due to improved treatment 
modalities. It is unlikely that recurrence-free survival is influenced by prevalence or 
treatment of comorbidities. Although we adjusted for confounders, residual 
confounding due to unmeasured or incorrectly measured confounders remains a 
potential issue. To exclude a potential chronological bias completely, a new study 
should be performed comparing both surgical techniques in the same study center 
and in the same time period. 
 
Selective loss to follow-up could have led to selection bias, as all patients lost to 
follow-up were in the microscopic surgery group. As patients could have become lost 
to follow-up due to various reasons (including both excellent health as well as very 
poor health status), the direction in which the results may have been biased cannot 
be determined. This effect was minimized as our analyses were confined to the first 
ten years after surgery and loss to follow-up was on average 8.3 years after surgery. 
Selection due to selective referral for endoscopic surgery to our center of mainly 
complex cases (i.e. macroadenomas and/or those with inconclusive imaging features 
suggesting lateral invasion of the cavernous sinus), may have led to worse surgical 
outcomes and higher complication rates after endoscopic surgery than expected. This 
is exemplified by the higher percentage of adenomas with cavernous sinus invasion in 
the endoscopically treated group. 
 
Over time, diagnostic strategies and treatment for Cushing’s disease have changed. 
Diagnostic imaging has changed from CT to MRI resulting in better visualization of 
suspect lesions, increasing the certainty of which target to address during surgery. 
There have been several treatment changes at our center, e.g. the surgical technique 
has changed from microscopic surgery to endoscopic surgery, and after 1990, 
preoperative medical treatment to control cortisol secretion became common 
practice at our center. Patients were not randomized to a certain treatment but 
were treated by the method available at that time. Therefore, effects of time, 
imaging technique, and use of medical therapy prior to surgery, cannot be separated 




medical treatment on outcome per se, a randomized trial is needed which compares 
patients with the same surgical technique with and without medical pretreatment, 
which has not yet been performed to our knowledge. 
 
According to the STROBE statement, generalizability of the study needs to be 
discussed (25). Theoretically, this study is generalizable to all patients with Cushing’s 
disease with a primary surgical treatment of transsphenoidal adenomectomy. 
However, generalizability is reduced due to specific effects produced by the setting 
(hospital, neurosurgeons) and time period of inclusion of patients per study group. 
 
In the endoscopic group, a higher rate of corticosteroid withdrawal syndrome was 
seen. This is especially remarkable, as many patients received preoperative medical 
treatment to lower cortisol concentrations before endoscopic surgery. However, this 
result is in agreement with our clinical experience, and might be explained by 
increased awareness for the corticosteroid withdrawal syndrome during recent years, 
leading to better recognition and improved hydrocortisone adjustments, when 
needed. Patients treated endoscopically showed a higher hazard ratio for long-term 
neuropsychiatric morbidity. This is, at least in part, due to the increased awareness 
of persistent neuropsychiatric comorbidity in patients with (previous) Cushing’s 
disease in recent years. 
 
Better results were anticipated for endoscopic surgery compared to microscopic 
surgery regarding recurrence-free survival and complication rates, based on the 
better visualization of tumors, certainly for the laterally invasive or large tumors. 
Regarding recurrence-free survival, we found an advantage of microscopic surgery for 
macroadenomas only. Microadenomas are most likely completely within the field of 
vision regardless of the surgical technique, explaining the lack of difference between 
both surgical techniques. As our recently published review showed an advantage of 
endoscopic surgery for macroadenomas (26), the advantage of microscopic surgery 
for macroadenomas shown in this study regarding recurrence-free survival might be 
explained by the surgeons’ attempt to perform a complete tumor resection with 
limited visibility of the entire tumor, although extent of anterior pituitary deficiency 
after surgery was similar for both techniques. Another explanation is that more 
difficult and invasive macroadenomas were referred to our center for endoscopic 
surgery (six endoscopic versus four microscopic treated patients were referred by 
other neurosurgeons or university medical centers), resulting in eight endoscopic 
(50.0%) versus five microscopic (27.8%) macroadenomas with cavernous sinus 
invasion. However, excluding patients with macroadenomas and cavernous sinus 
invasion did not change the hazard ratio for recurrence. Differences between both 
surgical techniques may also have occurred due to the small number of patients per 
study group after stratification by tumor size. Differences in outcomes between the 
Transsphenoidal surgery for Cushing's disease, a cohort study 
85 
 
current cohort study and our recently published systematic review and meta-analysis 
on the same subject (26) may have resulted from differences in included patients in 
both studies, e.g. as a result of selective referral of more difficult and invasive 
macroadenomas to our center, or as a result of differences in experience in and use 
of both techniques for Cushing’s disease or also other pituitary adenomas between 
our center and other centers included in the systematic review. Differences may also 
have resulted from variations in used definitions for remission, recurrence, and 
complications between study centers. The difference in outcome between the 
current cohort study and our recently published systematic review emphasizes the 
importance of combining data from multiple centers, as will be done for patient care 






We found no clear advantage for either microscopic or endoscopic transsphenoidal 
surgery in Cushing’s disease, based on surgical outcome or complications. In addition, 
no learning curve was found for endoscopic surgery. The transition from microscopic 
surgery to endoscopic surgery for Cushing’s disease in our center was made without 
temporarily deterioration of outcomes, which may be reassuring for surgeons who 
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Systematic review and meta-analysis comparing endoscopic and microscopic 
transsphenoidal surgery for Cushing’s disease regarding surgical outcomes (remission, 




Nine electronic databases were searched in February 2017 to identify potentially 
relevant articles. Cohort studies assessing surgical outcomes or complication rates 
after endoscopic or microscopic transsphenoidal surgery for Cushing’s disease were 
eligible. Pooled proportions were reported including 95% confidence intervals. 
 
Results 
We included 97 articles with 6,695 patients in total (5,711 microscopically and 984 
endoscopically operated). Overall, remission was achieved in 5,177 patients (80%), 
with no clear difference between both techniques. Recurrence was around 10% and 
short-term mortality <0.5% for both techniques. Cerebrospinal fluid leak occurred 
more often in endoscopic surgery (12.9% versus 4.0%), whereas transient diabetes 
insipidus occurred less often (11.3% versus 21.7%). For microadenomas, results were 
comparable between both techniques. For macroadenomas, the percentage of 
patients in remission was higher after endoscopic surgery (76.3% versus 59.9%), and 
the percentage recurrence lower after endoscopic surgery (1.5% versus 17.0%). 
 
Conclusions 
Endoscopic surgery for patients with Cushing’s disease reaches comparable results for 
microadenomas, and probably better results for macroadenomas than microscopic 
surgery. This is present despite the presumed learning curve of the newer endoscopic 
technique, although confounding cannot be excluded. Based on this study, 
endoscopic surgery may thus be considered the current standard of care. Microscopic 
surgery can be used based on neurosurgeon’s preference. Endocrinologists and 
neurosurgeons in pituitary centers performing the microscopic technique should at 
least consider referring patients with Cushing’s disease with a macroadenoma.   





Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting 
pituitary adenoma, with an estimated incidence of 1.2–1.7 per million each year (1). 
The resulting excess of glucocorticoids induces insulin resistance, dyslipidemia, 
central obesity, hypercoagulability, and increases the risk of osteoporosis, 
hypertension, and neuropsychiatric disorders (2, 3). First-choice treatment for 
Cushing’s disease is transsphenoidal pituitary surgery, with selective adenoma 
removal (4). Despite biochemical cure, mortality risk in patients with Cushing’s 
disease remains increased (5). 
 
Two main techniques have been used for transsphenoidal pituitary surgery: 
microscopic and endoscopic surgery. Furthermore, the microscopic and endoscopic 
techniques have been used in combination, in which the endoscope was used to 
visually confirm findings of the microscope. The microscopic technique was the 
established method to perform transsphenoidal surgery, until the first reports on 
endoscopic pituitary surgery were published, starting in 1992 (6). With the operating 
microscope, intraoperative differentiation of pathologic tissue from normal tissue is 
achieved by providing three-dimensional vision in a direct line to the pituitary (7, 8). 
Endoscopic pituitary surgery provides a broader field of vision using endoscopes with 
various angles in close proximity to the pituitary, however losing the three-
dimensional vision and thus depth perception (6, 8). From the introduction of the 
endoscope in transsphenoidal surgery, most surgical centers have chosen for 
microscopy or endoscopy. Only few small cohort studies have compared the 
microscopic and endoscopic surgical techniques in Cushing’s disease performed in the 
same center (9–12). No clear differences in remission rate or surgical morbidity 
between microscopic and endoscopic surgery could be shown. However, the studies 
had only limited statistical power (9). 
 
Several systematic reviews have compared endoscopic and microscopic surgical 
techniques in a heterogeneous population of patients with various pituitary 
adenomas. These studies have found a reduced rate of some complications 
(postoperative diabetes insipidus, rhinological complications), but an increased rate 
of other complications (vascular complications, cerebrospinal fluid leak, anterior 
pituitary hormone deficiency) for the endoscopic technique (8, 13, 14). These 
differences in outcomes may partially be explained by the surgeon’s attempt for a 
more radical tumor excision with the newer endoscopic technique with better vision, 
by the larger proportion of more challenging macroadenomas and re-operations 
reported in literature, and by improved rhinological care by an otolaryngologist after 
endoscopic surgery (8, 13, 14). Until now, no systematic review has been published 




Convincing evidence supporting the choice for one of both techniques in the 
treatment of Cushing’s disease, either based on treatment results or complication 
rate, is thus lacking. 
 
Study aims 
The primary aims of this systematic review were to compare remission and 
recurrence rate, and mortality, after microscopic versus endoscopic transsphenoidal 
pituitary surgery for Cushing’s disease. Secondary study aims were to compare 
complication rates, remission and recurrence rates stratified by tumor size, and 





Eligibility criteria  
Randomized controlled trials and cohort studies in Cushing’s disease assessing 
outcomes after endoscopic or microscopic transsphenoidal surgery were eligible. 
Studies describing endoscope-assisted microscopic surgery were considered 
microscopic surgery. Single-arm studies as well as direct comparisons were 
considered, mainly because we did not expect many direct comparisons in a single 
cohort. Study outcomes of interest were remission rate, recurrence rate, short- and 
long-term mortality risk, and complications of surgery. Studies reporting outcomes 
after primary as well as after repeat transsphenoidal surgery were eligible. Studies 
reporting <10 patients with Cushing’s disease per treatment group were excluded to 
minimize the risk of selection bias. Articles were also excluded if the study included 
children only, if the study did not clearly report which surgery type was performed, 
or if no distinction between surgery types was made in the analysis. Articles including 
patients with selective adenomectomy as well as partial or total hypophysectomy 
were included as long as total hypophysectomy did not exceed 5%. If described 
separately, patients with total hypophysectomy were excluded from analyses. If 
multiple articles described (partially) the same population, the article with the 
largest cohort was included per analysis. Articles irretrievable online were requested 
by contacting the authors. Articles still irretrievable, but with sufficient data 
mentioned in the abstract for reliable eligibility assessment and data extraction, 
were included. Only articles in English were considered. 
 
Search strategy  
To identify potentially relevant articles, PubMed, Embase, Web of Science, 
COCHRANE Library, CENTRAL, Emcare, LWW, ScienceDirect, and Wiley were 
systematically searched in February 2017 in cooperation with a specialized librarian 
(see Supplemental Data 1 for the complete search strategy). References of included 
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articles were searched and the search strategy was manually extended in PubMed 
with the search term ‘pituitary adenoma’ to find more potentially eligible studies. 
 
Data extraction 
All identified articles were imported in endnote 8 (Thomson Reuters, Philadelphia, 
PA, USA). Studies were screened by title and abstract and potentially relevant 
articles were reviewed in detail to assess eligibility. Potentially relevant articles were 
screened and reviewed by two reviewers independently and disagreement was solved 
by consensus. The meta-analysis of observational studies in epidemiology (MOOSE) 
guidelines were used for reporting (15). 
 
Risk of bias assessment 
For risk of bias analysis we used a component approach. Risk of bias was assessed by 
two independent reviewers for all included studies using the following components, 
which could potentially bias a reported association between surgical technique and 
outcome: 
 
1. Inclusion of patients (consecutive inclusion or a random sample is considered 
low risk of bias) 
2. Loss to follow-up (<5% is considered low risk of bias) 
3. Criteria for diagnosis of Cushing’s disease (see below) 
4. Clear reporting of criteria for main study outcome. For most studies the main 
outcome is remission of Cushing’s disease. If remission is not a study 
outcome, studies will be checked for reporting criteria for their primary 
study outcome, most often one or more complications of treatment. 
 
As criteria for diagnosis of Cushing’s disease vary widely over time and per study 
center, and study outcomes also vary per included article, mentioning the criteria for 
diagnosis and study outcome is considered a low risk of bias. Classification of 
interventions was not considered in this risk of bias analysis, because the 
interventions of interest are one-time procedures and therefore unlikely to be 
misclassified. 
 
Risk of bias analysis was used to explore potential heterogeneity. As most studies did 
not compare the two surgical techniques directly, confounding was not judged at the 
study level, but was assessed by comparing baseline characteristics between 
microscopically and endoscopically treated patients. Variables influencing the choice 








The main outcomes of this study were the percentage of patients reaching remission, 
the recurrence rate, and the short-term mortality risk after microscopic and 
endoscopic transsphenoidal pituitary surgery for Cushing’s disease. Secondary 
outcomes were complication rates, rates of remission and recurrence stratified by 
tumor size, and the percentage of patients to reach remission after a repeat 
transsphenoidal surgical procedure. Because of the low number of studies with direct 
comparisons, percentages were reported per surgical technique. 
 
Remission was considered direct postoperatively (until 6 months post-surgery). 
Hydrocortisone dependency was calculated as a percentage of the total patient 
population to maintain comparability with remission rate. Disease recurrence was 
estimated as percentage of the patients with initial remission. Mortality risk was 
analyzed for short-term mortality (<3 months after surgery). Long-term mortality risk 
(≥3 months after surgery) was not analyzed, as time since surgery was often unclear. 
Articles reporting mortality without mentioning time since surgery were excluded 
from mortality analyses. 
 
The following complications were assessed: cerebrospinal fluid leak, meningitis, 
syndrome of inappropriate antidiuretic hormone secretion (SIADH), anterior pituitary 
hormone deficiency, thromboembolism, bleeding, transient diabetes insipidus, 
permanent diabetes insipidus, and psychopathology. If an article described diabetes 




Percentages were pooled in a random-effects logistic regression model if there were 
≥5 articles per analysis. A fixed-effects model was used for analyses with <5 studies. 
The Freeman-Tukey arcsine transformation was used to stabilize variances, in order 
to prevent exclusion of studies with 0% or 100% as outcome. All analyses were 
performed using Stata 11.2 (Stata Corp., College Station, TX, USA). Sensitivity 
analyses were performed to assess the potential effect of high risk of selection bias 
studies by excluding articles in which inclusion of patients was not consecutive or a 
random sample and/or loss to follow-up was ≥5%. Of note, articles not mentioning 
method of inclusion or loss to follow-up were not excluded in these sensitivity 
analyses, as this would not leave sufficient articles for analysis (13 for microscopic 
surgery and one for endoscopic surgery only). Sensitivity analyses were also 
performed for studies with a study period starting from the year 2000 or later, to 
assess the potential cohort effect of calendar year of surgery. Finally, sensitivity 
analyses were performed for studies reporting specific criteria for diagnosis of 
Cushing’s disease (pituitary imaging or petrosal sinus sampling, and at least one of 
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the following laboratory measurements or tests: increased morning serum cortisol, 
increased 24-h urinary free cortisol, increased midnight salivary cortisol, no 
suppression of cortisol after a low dose dexamethasone test combined with a non-
suppressed ACTH) to increase reliability of including only patients with Cushing’s 
disease, as well as for studies using at least a low dose dexamethasone test in the 
determination of remission status to increase test homogeneity, and for studies 
assessing remission status 3–6 months postoperatively, as this is a more reliable 






The initial search identified 932 articles. Searching through references of included 
articles and manually extending the search in PubMed with the search term ‘pituitary 
adenoma’ identified another 16 articles, thereby yielding a total of 948 articles. After 
screening the articles by title and abstract, 685 articles were excluded, leaving 263 
articles for detailed review. Reasons for exclusion are summarized in Figure 1. There 
were 97 articles included in this review, two of which based on abstract only (17, 18). 
 
Potentially relevant published 
articles identified (n=948), 
screened by title and abstract




- No original data: 236
- No Cushing’s disease: 80
- No transsphenoidal surgery: 108
- N<10: 156
- Language other than English: 38
- Children only: 45 
- No human subjects: 10
- Selection on outcome: 12
Articles excluded (n=166)
- Same population: 50
- No relevant outcome: 30
- No separate analysis for Cushing’s 
disease or (type of) transsphenoidal 
surgery: 53
- Selection on outcome: 21 
- No transsphenoidal surgery: 12
 





Study characteristics (Supplemental Data 2) 
No randomized controlled trials were performed comparing microscopic to 
endoscopic surgery. There were 71 studies reporting on microscopic surgery only (4, 
7, 17, 19–86), 22 studies reporting on endoscopic surgery only (18, 87–107), and four 
studies from four different centers reporting on both microscopic and endoscopic 
surgery in the same center (9–12). Studies reporting on both techniques were entered 
twice in the tables and analyses, separately for each of the techniques. Articles were 
published between 1978 and 2017 for microscopic surgery and from 2001 to 2017 for 
endoscopic surgery. Two included articles reported only results for patients after 
repeat transsphenoidal surgery (65, 82). A total of 5,711 patients were included for 
the microscopic technique, and 984 patients for the endoscopic technique. 
 
Risk of bias assessment 
Detailed risk of bias assessment per included article is shown in Supplemental Data 3. 
Reported loss to follow-up (reported in 35 studies [36%]) ranged from 0% to 26.9%. 
Inclusion of consecutive patients or a random sample of patients was explicitly stated 
in 73 articles (75%). There were 80 articles (82%) that reported the criteria for 
Cushing’s disease diagnosis, or that referred to the article in which the exact criteria 
were published. Criteria for main study outcome were reported in 88 articles (91%). 
Remission of Cushing’s disease was the main study outcome in 83 of these 88 articles 
(94%). 
 
Differences in baseline characteristics (confounding) are likely as treatment 
assignment was dependent on calendar year of surgery and center. There were only 
three articles describing both techniques in the same center and in the same 
calendar period (see Supplemental Data 2). Furthermore, there was a slight 
difference in average age at treatment (microscopy 21.5–50 years; endoscopy 31.9–
55.7 years) and in percentage female (microscopy 67%–93%; endoscopy 57%–95%). Co-
interventions that could influence treatment outcome were reported per article in 
Supplemental Data 3. Nine included articles (9%) explicitly reported that no co-
interventions were used, 20 articles (21%) reported use of co-interventions before or 
shortly after treatment in part of their included patients. The remaining 68 articles 
(70%) did not report on co-interventions. 
 
Study outcomes 
For a total of 91 study groups (87 articles), remission was the primary outcome of 
interest. Overall, remission was obtained in 80% (5,177 out of 6,484) of patients. 
There were 48 articles reporting a (short- and/or long-term) mortality rate, and 60 
articles reported the rate of, at least one, complication. For details of study 
outcomes at the individual study level, see Supplemental Data 4. 
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Pooled proportions of surgical outcomes: remission, recurrence, mortality, and 
remission after repeat surgery (Figure 2; Table 1) 
The percentage remission was similar for microscopically and endoscopically treated 
patients, both reaching around 80% remission. Hydrocortisone dependency was seen 
in 39.3% (95% confidence interval [CI]: 23.5%–56.4%) of patients after microscopic 
surgery and in 33.5% (95% CI: 13.3%–57.3%) after endoscopic surgery. Recurrence of 
disease occurred in around 10% of patients after both types of surgery. Average 
follow-up duration for studies reporting on disease recurrence was 1.0–15.4 years for 
microscopy and 1.4–5.9 years for endoscopy. Recurrence occurred after an average of 
6–76 months in studies using the microscopic technique, and after an average of 24–
54 months in studies using the endoscopic technique. Short-term mortality was 0.0% 
(95% CI: 0.0%–0.2%) for microscopic surgery and 0.4% (95% CI: 0.0%–2.2%) for 
endoscopic surgery. The percentage of patients that obtained remission after a 
repeated transsphenoidal surgical procedure was 55.7% (95% CI: 43.3%–67.8%) for 
microscopic surgery, and 42.6% (95% CI: 18.4%–68.4%) for endoscopic surgery. 
Measurements of treatment effect were consistent across individual studies, and 
spread of measurements is reflected by the 95% confidence interval of the outcomes 
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Pooled proportions of complications after transsphenoidal pituitary surgery for 
Cushing’s disease (Figure 3; Table 1) 
Cerebrospinal fluid leak was reported less often in patients after microscopic surgery 
(4.0% [95% CI: 2.3%–6.1%]), than after endoscopic surgery (12.9% [95% CI: 5.8%–
22.1%]). Furthermore, SIADH, bleeding and permanent diabetes insipidus were seen 
slightly less often in patients after microscopic surgery, than in patients after 
endoscopic surgery. Transient diabetes insipidus was reported more often in patients 
after microscopic surgery (21.7% [95% CI: 15.0%–29.3%]), than in patients after 
endoscopic surgery (11.3% [95% CI: 6.6%–17.1%]). Meningitis (around 0.4%), anterior 
pituitary deficiency (around 10.5%), and thromboembolism (little over 1%), were seen 
in about equal percentages of patients, regardless of surgical technique. 
Psychopathology was reported in 0.7% (95% CI: 0.0%–3.1%) of patients after 
microscopic surgery. There were no articles on endoscopic surgery reporting on 
psychopathology. 
 
Table 1: Results of meta-analyses comparing microscopic and endoscopic surgery for Cushing’s disease. 














Short term mortality 





























Meta-analysis of complications 
Cerebrospinal fluid leak 
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Syndrome of inappropriate 
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Remission for macroadenoma 
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Pooled proportions of remission and disease recurrence according to tumor size 
(Figure 4; Table 1) 
For microadenomas, the percentage of patients that achieved remission was 85.5% 
(95% CI: 81.2%–89.3%) after microscopic surgery versus 83.9% (95% CI: 76.8%–90.0%) 
after endoscopic surgery. Recurrence of disease occurred in 9.8% (95% CI: 6.8%–13.2%) 
of patients after microscopic surgery versus 8.1% (95% CI: 4.3%–12.8%) after 
endoscopic surgery. 
 
For macroadenomas, the percentage of patients that achieved remission was 59.9% 
(95% CI: 52.0%–67.6%) after microscopic surgery versus 76.3% (95% CI: 64.3%–86.7%) 
after endoscopic surgery. Disease recurrence occurred in 17.0% (95% CI: 5.6%–31.5%) 
after microscopic surgery versus 1.5% (95% CI: 0.0%–6.4%) after endoscopic surgery. 
 
Sensitivity analysis 
Generally, results from sensitivity analyses were similar to those found in the main 
analyses. Detailed results for sensitivity analyses and the number of studies per 
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Figure 4: Analysis of surgical outcomes of transsphenoidal surgery for Cushing’s disease, stratified by tumor 





We performed a systematic review to compare surgical outcomes after microscopic 
versus endoscopic transsphenoidal pituitary surgery for Cushing’s disease. Regardless 
of surgical technique, remission rates were around 80% and recurrence rates around 
10% after transsphenoidal surgery. There were no clear differences between surgical 
techniques regarding mortality or remission rates after repeat transsphenoidal 
surgery. Complication rates ranged from 0.1% (for meningitis) to 21.7% (for transient 
diabetes insipidus), with minor differences between surgical techniques. Remission 
and recurrence rates for microadenomas were similar for both surgical techniques. 
However, remission rate was higher for macroadenomas (76.3% versus 59.9%), with a 
lower recurrence rate (1.5% versus 17.0%) after endoscopic surgery than after 
microscopic surgery. Thus, for macroadenomas only there seems to be an advantage 
of the endoscopic over the microscopic surgical technique for transsphenoidal 
treatment of Cushing’s disease. 
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This is the first systematic review comparing microscopic and endoscopic 
transsphenoidal pituitary surgery specifically for Cushing’s disease. We found 
comparable remission and mortality rates for both surgical techniques, which is in 
line with results of meta-analyses of heterogeneous populations of various pituitary 
adenomas, and some small cohort studies comparing both techniques directly for 
Cushing’s disease (8–14). Differences in complications rates found in meta-analyses of 
heterogeneous populations of various pituitary adenomas can partially be confirmed 
by our analysis (reduced rate of transient diabetes insipidus, and increased rate of 
vascular complications and cerebrospinal fluid leak for the endoscopic technique) (8, 
13, 14). The increased rate of anterior pituitary hormone deficiency for endoscopic 
transsphenoidal surgery was not found in the present study (14). The difference in 
remission rate between the surgical techniques for macroadenomas, but not 
microadenomas, is in line with the results from a cohort study on multiple pituitary 
adenomas described separately, that reported an advantage of the endoscopic 
technique for macroadenomas, but not for microadenomas. This difference was 
statistically significant for the population as a whole, but was supported by 
differences in the same direction for all included types of pituitary adenoma, 
including Cushing’s disease (11). 
 
In interpreting the results, the following study limitations need to be taken into 
account. Most included studies in this study were single-arm studies, limiting the 
possibilities of directly comparing microscopic to endoscopic transsphenoidal surgery. 
However, as treatment assignment in most studies was based on availability of a 
specific technique in the surgical center, for endoscopy often based on preference of 
the neurosurgeons after a test period, other baseline characteristics, such as age and 
sex distribution, are unlikely to have influenced treatment assignment largely. As 
microscopy was the established surgical technique until the introduction of the 
endoscope for transsphenoidal surgery for Cushing’s disease, year of surgery varied 
widely for included studies (108). For endoscopic surgery, a learning curve has been 
described (97, 98). As most studies did not report patient level data, the effect of a 
potential learning curve per surgical center could not be analyzed in this study. 
However, to avoid measuring an effect of a collective learning curve, the earliest 
studies using endoscopic surgery, with study periods starting before the year 2000, 
were excluded in the previously mentioned sensitivity analysis. 
 
Included studies showed heterogeneity in criteria used for diagnosing Cushing’s 
disease, both in tests used to determine remission status, and in time period after 
surgery for assessment of remission status. Sensitivity analyses showed generally 
comparable results to the main analyses. Differences are likely to have occurred 
because of the small number of studies included in these sensitivity analyses 




many studies did not clearly report loss to follow-up, method of inclusion of patients, 
or both, preventing us from performing a sensitivity analysis excluding both articles 
with unclear risk of selection bias as well as high risk of bias, as this restriction would 
have resulted in one low bias risk article only in endoscopy. Follow-up duration 
differed between publications, which could potentially lead to a bias in the analysis 
of recurrences, as this is the only truly long-term outcome. However, given that most 
recurrences occur early after initial surgery (with only one microscopic study 
reporting average time to recurrence longer than any average follow-up duration of 
an endoscopic study), and given that the average follow-up duration for studies 
reporting on disease recurrence is 1.0–15.4 years for microscopy and 1.4–5.9 years for 
endoscopy, the bias is probably not very large. 
 
From a pathophysiological perspective, the similar results yielded for microscopic and 
endoscopic transsphenoidal surgery may be explained by the large percentage of 
microadenomas in the population of patients with Cushing’s disease (109). For 
microadenomas, there may not be an advantage in increasing field of vision at the 
cost of losing three-dimensional vision and thereby depth perception (6, 8). Most 
likely, due to their small size, microadenomas are completely within the field of 
vision regardless of surgical technique. Our results concerning remission and 
recurrence for microadenomas indeed showed no clear advantage for either 
technique. For macroadenomas, we did show an advantage of the endoscopic surgical 
technique. As macroadenomas are larger and more often invasive, a broader field of 
vision in close proximity to the tumor may aid the neurosurgeon in achieving a 
complete tumor resection, causing higher remission and lower recurrence rates after 
endoscopic surgery. In microscopic surgery, these tumors are more often partially out 
of vision for the neurosurgeon. Unfortunately, due to lack of data, we were unable to 
perform separate analyses for invasive versus non-invasive macroadenomas, as well 
as for small versus larger microadenomas. The increased rate of cerebrospinal fluid 
leak after endoscopic transsphenoidal surgery may partially be explained by the 
neurosurgeon’s attempt to achieve complete tumor resection also in more difficult 
cases with the newer endoscopic technique, whereas the reduced rate of transient 
diabetes insipidus may originate from the more precise tumor excision due to 
improved vision close to the tumor, causing less damage to the posterior lobe of the 
pituitary. Publication bias has been suggested as partial explanation for the increased 
rate of cerebrospinal fluid leak after endoscopic surgery, as more often challenging 
macroadenomas have been described (14). 
 
For most patients with Cushing’s disease, this study shows no clear advantage of 
either microscopic or endoscopic transsphenoidal surgery regarding surgical outcomes 
and complication rates. For macroadenomas, the endoscopic technique yields better 
results regarding remission and recurrence rate. These results are present despite the 
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presumed learning curve of the newer endoscopic technique within the study period, 
although confounding by indication and improved radiological investigations with 
time cannot be excluded. As most patients with Cushing’s disease have 
microadenomas (109), there is no reason that all neurosurgical centers treating 
patients with Cushing’s disease should change to the endoscopic technique. However, 
there is also no particular reason to keep using the microscopic technique for 
patients with Cushing’s disease, other than neurosurgeon’s preference. Based on this 
study, centers that choose to use the microscopic technique should consider referral 
of patients with Cushing’s disease and a macroadenoma to another surgical center 
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To systematically review the effectiveness of medical treatment for Cushing’s 
syndrome in clinical practice, regarding cortisol secretion, clinical symptom 




Eight electronic databases were searched in March 2017 to identify potentially 
relevant articles. Randomized controlled trials and cohort studies assessing the 
effectiveness of medical treatment in patients with Cushing’s syndrome, were 
eligible. Pooled proportions were reported including 95% confidence intervals. 
 
Results 
We included 35 articles with in total 1,520 patients in this meta-analysis. Most 
included patients had Cushing’s disease. Pooled reported percentage of patients with 
normalization of cortisol ranged from 35.7% for cabergoline to 81.8% for mitotane in 
Cushing’s disease. Patients using medication monotherapy showed a lower 
percentage of cortisol normalization compared to use of multiple medical agents 
(49.4% versus 65.7%); this was even higher for patients with concurrent or previous 
radiotherapy (83.6%). Mild side effects were reported in 39.9%, and severe side 
effects were seen in 15.2% of patients after medical treatment. No meta-analyses 




This meta-analysis shows that medication induces cortisol normalization effectively in 
a large percentage of patients. Medical treatment for patients with Cushing’s disease 
is thus a reasonable option in case of a contraindication for surgery, a recurrence, or 
in patients choosing not to have surgery. When experiencing side effects or no 
treatment effect, an alternate medical therapy or combination therapy can be 
considered.   





Cushing’s syndrome due to endogenous glucocorticoid excess is either 
adrenocorticotropic hormone (ACTH)-dependent or ACTH-independent, both with a 
variety of underlying causes (1). Cushing’s disease results from an ACTH-secreting 
pituitary adenoma and has a reported incidence of approximately 1.2–1.7 patients per 
million each year (2). Ectopic Cushing’s syndrome is a rare condition resulting from a 
non-pituitary ACTH-producing source. ACTH-independent Cushing’s syndrome is 
caused by a cortisol-producing adrenal adenoma or carcinoma (1). Excess of 
glucocorticoids alters body composition and metabolic profile, inducing fat 
maldistribution, muscle wasting, insulin resistance, dyslipidemia, hypercoagulability, 
and increasing the risk of osteoporosis, hypertension, and neuropsychiatric disorders 
(3, 4). 
 
Transsphenoidal pituitary adenomectomy is a well-established and effective 
treatment for Cushing’s disease (5). Cushing’s syndrome is generally approached by 
removing the ACTH-producing tumor in ectopic Cushing’s syndrome and by 
adrenalectomy in ACTH-independent Cushing’s syndrome (6). However, there is 
increasing experience with first line medical treatment, both for patients with 
contraindications for surgery and for patients with recurrent disease (7). 
Furthermore, drugs can be used to control cortisol secretion preoperatively and to 
bridge the time period until control of hypercortisolism is achieved by radiotherapy 
(7). Drugs used in medical practice vary per country and underlying cause of 
Cushing’s syndrome and include ketoconazole, metyrapone, mitotane, cabergoline, 
pasireotide, and mifepristone (7, 8). A recent review described the percentage of 
patients achieving cortisol normalization after monotherapy with the steroidogenesis 
inhibitors ketoconazole and metyrapone (9). However, until now no systematic 
review and meta-analysis has been performed to summarize the effectiveness of all 
medical agents used in clinical practice (ketoconazole, metyrapone, mitotane, 
cabergoline, pasireotide, and mifepristone). 
 
Study aims 
The primary aim of the present systematic review and meta-analysis was to evaluate 
the effectiveness of medical treatment for Cushing’s syndrome in clinical practice. 
Effectiveness of medical treatment was evaluated regarding cortisol secretion, 
clinical symptom improvement, and quality of life. The secondary study aim was to 









Eligibility criteria  
Randomized controlled trials and cohort studies assessing the effectiveness of 
FDA/EMA approved medical treatment for treatment of Cushing’s syndrome, either 
de novo or with persistent or recurrent disease, were eligible for inclusion, as well as 
cabergoline, which has been used for Cushing’s syndrome in multiple investigator 
initiated clinical trials. Medical agents considered were ketoconazole, metyrapone, 
mitotane, cabergoline, pasireotide, and mifepristone. Articles were excluded if 
reporting broad inclusion categories without separating the subgroup of Cushing’s 
patients, or if the study included children (age <18 years) only. For eligibility, at 
least ten patients had to be included per treatment group to minimize risk of 
selection bias. For multiple articles describing (partially) overlapping populations, the 
article with the largest study population was included in the analysis. Articles 
irretrievable online were requested by contacting the authors. Only articles in the 
English language were considered. 
 
Search strategy  
To identify potentially relevant articles, PubMed, Embase, Web of Science, 
COCHRANE Library, CENTRAL, Emcare, LWW, and ScienceDirect were systematically 
searched in March 2017 in cooperation with a specialized librarian (see Supplemental 
Data 1 for the complete search strategy). The search was repeated in PubMed in May 
2017. Furthermore, references of included articles were searched to increase the 
number of potentially eligible articles. 
 
Data extraction 
All identified articles were imported in EndNote 8 (Thomson Reuters, Philadelphia, 
PA, USA). Studies were screened by title and abstract and two independent reviewers 
reviewed potentially relevant articles in detail. The Meta-analysis Of Observational 
Studies in Epidemiology (MOOSE) guidelines were used for reporting (10). 
 
From included articles we extracted the following data: number and type of patients 
with Cushing’s syndrome included, type of medical agent used, treatment dose, 
treatment duration, duration of follow-up, number of patients pre-treated with 
medication before surgery, number of patients with normalization of cortisol, clinical 
improvement, well-being, quality of life, and side effects. Where available, separate 
outcomes were extracted for patients with primary treatment (before any other 
treatment for Cushing’s syndrome) and patients with secondary treatment (after 
recurrence or failure of surgery and/or radiotherapy). For clinical improvement, all 
reported symptoms as well as general statements (e.g. “Clinical signs regressed in 
full responders”, without specifying which clinical signs) were extracted. However, 
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only hypertension and diabetes mellitus were considered for analysis, because these 
symptoms were expected to be reported homogeneously by multiple articles. For 
quality of life, all general and Cushing’s disease specific questionnaires were 
considered. All reported side effects were extracted. 
 
Risk of bias assessment 
We used a component approach to assess risk of bias for all included studies. The 
following components were included, which could potentially bias a reported 
association between medical treatment for Cushing’s syndrome and outcome: 
 
1. Inclusion of patients (consecutive inclusion from all patients eligible or a 
random sample is considered low risk of bias) 
2. Loss to follow-up (<5% is considered low risk of bias) 
3. Criteria for diagnosis of Cushing’s syndrome adequately reported (see below) 
4. Outcome measurement for cortisol normalization: urinary free cortisol, 
midnight salivary cortisol or a low dose dexamethasone test is considered low 
risk of bias 
5. Reporting of outcome definition (see below)  
6. Description of protocol for laboratory measurements (see below) 
7. Description of dose and duration of intervention (see below) 
 
As criteria for diagnosis of Cushing’s syndrome vary widely over time and even by 
study center, and per underlying etiology, adequately reporting the criteria used for 
diagnosis is considered a low risk of bias. Reporting of outcome definition is 
considered adequate if the article at least mentioned which outcome was studied, 
which test was used to determine the outcome, and if applicable, which cortisol level 
had to be measured. Description of protocol for laboratory measurements is 
considered adequate if the assay used for measuring cortisol is reported, or the assay 
for the main outcome if this was not cortisol. Description of dose and duration of 
intervention is considered adequate if dose (per day or per week) and duration of 
medical treatment are reported (average and range, or exact dose and duration if 
this is equal for all patients). Also considered adequate is reporting of exact 
treatment protocol for trials with dose increase based on cortisol levels. Referring to 
another published article in which the information is reported is also considered 
adequate. 
 
Risk of bias assessment was conducted to explore potential heterogeneity. As there 
were no studies that compared two different medical agents directly, confounding 
was not judged at the study level, but was assessed by comparing baseline 






Primary outcome of this study was the effectiveness of medical treatment for 
Cushing’s syndrome, represented by the pooled percentage of patients reaching 
normalization of cortisol secretion (definition according to the authors) after medical 
treatment, patients showing symptom improvement, improved well-being and 
improved quality of life. Main analyses were performed in studies reporting on 
pituitary Cushing patients. Separate analyses were performed for publications 
reporting on (1) mixed etiologies other than adrenocortical carcinomas, (2) mixed 
etiologies including adrenocortical carcinomas, and (3) ectopic Cushing only, if 
sufficient data were available. Studies were categorized according to type of medical 
agent (ketoconazole, metyrapone, mitotane, cabergoline, pasireotide, and 
mifepristone). Studies using more than one of the above mentioned medical agents at 
the same time or consecutively were assessed separately. 
 
For normalization of cortisol, all measurements of cortisol were considered. 
However, measurement of urinary free cortisol, midnight salivary cortisol or morning 
cortisol after a low dose dexamethasone test was considered low risk of bias (see 
above). Data on reduction of cortisol as a percentage of baseline were not considered 
for analysis. 
 
Secondary outcomes were the pooled percentages of patients with mild or severe 
side effects stratified by medical agent. Severe side effects were considered those 
that required therapy adjustment or withdrawal, as well as all side effects 
categorized as severe by the authors. Mild side effects were all not categorized as 
severe. For articles reporting only specific side effects, the side effect that affected 
the most patients was included in the analysis. 
 
Subgroup analyses were performed according to indication (primary therapy, 
including pre-treatment before surgery, and therapy for recurrence) if described 
separately. As few studies provided separate data for primary/secondary analysis, a 
separate subgroup analysis was performed, in which studies were categorized as low 
(≤20%) or high (≥80%) percentage of patients using medical agents as pre-treatment 
before surgery. A separate analysis was performed for normalization of cortisol 




A random-effects logistic regression model was used to pool percentages for analyses 
including ≥5 articles, whereas a fixed-effects logistic regression model was used for 
analyses including <5 articles. All pooled percentages are accompanied by 95% 
confidence intervals (CI). The Freeman-Tukey arcsine transformation was used to 
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stabilize variances, in order to prevent exclusion of studies with 0% or 100% as 
outcome. All analyses were performed using Stata 11.2 (Stata Corp., College Station, 
TX, USA). 
 
Sensitivity analyses were performed for normalization of cortisol for low risk of bias 
studies, and for the combination of low and intermediate risk of bias studies. Articles 
were considered low risk of bias if they adhered to at least six (out of seven) of the 
above-mentioned criteria for risk of bias. Only one article adhered to all seven 
criteria (11). Articles were considered intermediate risk of bias if they adhered to 






The initial search identified 960 potentially relevant articles. Searching through 
references of included articles identified one additional article, thereby yielding a 
total of 961 articles. By screening these articles by title and abstract, 874 articles 
were excluded. The remaining 87 articles were reviewed in detail. Reasons for 
exclusion are summarized in Figure 1. In total, 35 articles were included, reporting 
on six different drugs. 
 
Potentially relevant published 
articles identified (n=961), 
screened by title and abstract




- No original data: 276
- No Cushing’s syndrome: 64
- No medical treatment: 88
- Wrong medical agent: 7
- N<10: 254
- Language other than English: 148
- No human subjects: 35
- Children only: 2
Articles excluded (n=52)
- Same population: 13
- No relevant outcome: 19
- No separate analysis for Cushing’s 
syndrome: 1
- N<10: 12
- Selection on outcome: 3
- Wrong medical agent: 1
- No medical treatment: 2
- Only abstract available: 1
 




Study characteristics (Supplemental Data 2) 
We included five studies on mitotane (12–16), two on pasireotide (17, 18), three on 
cabergoline (19–21), eight on ketoconazole (22–29), five on metyrapone (30–34), two 
on mifepristone (35, 36), and ten on multiple medical agents (11, 37–45). Studies 
were published between 1971 and 2017. There were eleven single-arm trials, two 
randomized trials with two treatment arms (pasireotide 600 μg versus pasireotide 900 
μg; first cabergoline, then add ketoconazole versus first ketoconazole, then add 
cabergoline), and 22 cohort studies. We included eighteen studies on Cushing’s 
disease only, two on ectopic Cushing’s syndrome only, and fifteen on patients with 
Cushing’s syndrome due to various underlying etiologies. In total, 1,520 patients were 
included. There were 28 articles measuring normalization of cortisol by at least 
urinary free cortisol, midnight salivary cortisol or a low dose dexamethasone test 
(88% of 32 articles reporting normalization of cortisol as an outcome). There were 25 
studies reporting on clinical improvement, and three studies reporting on quality of 
life. 
 
Baseline characteristics of included studies show clear differences between studies. 
Reported average age varied between 32.2 and 60.0 years. Percentage female varied 
between 21.7% and 95.0%. Average duration of follow-up was 2 weeks to 11.5 years. 
Seven articles reported that at least part of their study population received 
radiotherapy in addition to medical treatment (two with mitotane, one with 
ketoconazole, and four with metyrapone). Pasireotide and cabergoline were used 
only for Cushing’s disease, whereas all other medical agents were used for various 
etiologies of Cushing’s syndrome. 
 
Risk of bias assessment (Supplemental Data 3) 
Loss to follow-up (reported in twelve studies [34%]) ranged from 0% to 60%. Inclusion 
of consecutive patients or a random sample was explicitly stated in seventeen 
articles (49%). Criteria for diagnosis of Cushing’s syndrome were adequately reported 
in 31 articles (89%). Reporting of outcome definition was adequate in 25 articles 
(71%). Description of protocol for laboratory measurements was adequate in 23 
articles (66%). Description of dose and duration of intervention was adequate in 23 
articles (66%). A total of nine articles were with low risk of bias (adherent to at least 
six out of seven criteria) and another nine articles with intermediate risk of bias 
(adherent to five out of seven criteria). 
 
Study outcomes 
For 26 articles (1,000 patients) normalization of cortisol was reported as outcome 
measure. There were 25 articles reporting on clinical improvement. One article 
reported no improvement in any of the measured clinical symptoms (weight, blood 
pressure, glucose, and HbA1c) (19). All other articles reported improvement in one or 
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more clinical symptoms. Well-being was not reported by any of the included articles. 
Three articles (228 patients) reported on quality of life. These reported an 
improvement in CushingQoL score, SF-36 score, and emotional reaction on the 
Nottingham Health Profile (NHP), and on the other hand more pain measured by the 
RAND-36 (18, 36, 44). There were 30 articles (86%) reporting at least one side effect. 
Two of these articles, using mifepristone, described an increase in cortisol levels 
during the study period in a total of 47 out of 70 included patients (67%) (35, 36). No 
meta-analysis was performed for clinical improvement, as results were considered 
too heterogeneous. Hypertension and diabetes mellitus were described by 
heterogeneous articles (type of medical agent, etiology of Cushing’s syndrome) and 
the type of outcome was heterogeneous (difference in blood pressure and glucose 
versus number of patients with improved values, only patients with disturbed values 
at start of the study versus all patients analyzed). Detailed study outcomes at the 
individual study level are reported in Supplemental Data 4. 
 
Meta‑analyses of normalization of cortisol (Table 1; Figure 2: normalization of 
cortisol per medical agent in pituitary Cushing) 
For Cushing’s disease, pooled reported treatment effect ranged from 32.3% if a large 
percentage of patients used medication as pre-treatment before surgery, to 83.6% if 
medication was combined with radiotherapy. When comparing medical agents, a 
relatively high percentage of patients using mitotane showed normalization of 
cortisol (81.8%), whereas treatment with cabergoline and pasireotide less often 
normalized cortisol secretion (35.7% and 41.1%). For detailed results, including data 
on different etiologies (mixed etiologies other than adrenocortical carcinomas, mixed 
etiologies including adrenocortical carcinomas, and ectopic Cushing), see Table 1. 
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Seven studies reported data separately for medication as primary (n=4) and/or 
secondary therapy (n=5). For patients with Cushing’s disease, medication as primary 
therapy normalized cortisol in 58.1% (95% CI: 49.7%–66.2%), similar to the effect of 
medication as secondary therapy, 57.8% (95% CI: 41.3%–73.6%). Articles in which ≤20% 
of patients were medically pre-treated before surgery showed normalization of 
cortisol in 59.7% of patients (95% CI: 49.4%–69.6%). Articles in which ≥80% of patients 
were pre-treated with medication before surgery showed a preoperative 
normalization of cortisol in 32.3% (95% CI: 20.0%–45.8%) for patients with Cushing’s 
disease. Patients with medical monotherapy showed a relatively low percentage of 
cortisol normalization. This percentage was higher for patients using multiple agents, 
and highest for patients with concurrent or previous radiotherapy. 
 
The sensitivity analyses, both excluding articles with high risk of bias (n=18 included), 
as well as excluding articles with high and intermediate risk of bias (n=9 included), 
showed similar results as the main analysis. The most remarkable difference is that 
lower percentages of patients with normalization of cortisol were seen for multiple 
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Meta‑analyses of side effects (Table 1; Figure 3: side effects per medical agent in 
pituitary Cushing) 
For Cushing’s disease, mild side effects were reported in 39.3% (95% CI: 25.0%–55.8%) 
of patients after medical treatment. Patients using mitotane and pasireotide more 
often showed mild side effects compared to the total population (68.5% and 58.3%). 
 
For Cushing’s disease, severe side effects were seen in 15.2% (95% CI: 9.1%–22.4%). In 
the group of mixed etiologies including adrenocortical carcinoma, patients using 
mifepristone showed severe side effects relatively often (42.0%; 95% CI: 30.4%–
54.0%). Due to the severe side effects, 23.9% (95% CI: 15.9%–32.8%) of patients 
adjusted their medical therapy, and 8.5% (95% CI: 2.8%–16.3%) of patients stopped 





We performed a systematic review and meta-analysis to evaluate effectiveness of 
medical treatment in routine clinical practice in Cushing’s syndrome. Medical 
treatment was effective in normalizing cortisol levels in Cushing’s syndrome in 35.7% 
(cabergoline) to 81.8% (mitotane) of patients. Furthermore, the combined use of 
medical agents at the same time or consecutively increased the percentage of 
patients with normalized cortisol secretion (65.7%). Importantly, medical agents for 
hypercortisolism can cause severe side effects, leading to therapy adjustment or 
withdrawal in 4.8% (cabergoline) to 28.4% (mitotane) of patients. These results 
suggest that medical therapy can be considered a reasonable treatment alternative 
to the first-choice surgical treatment when regarding treatment effectiveness and 
side effects. 
 
This study is the first systematic review and meta-analysis of all medical agents 
currently used in clinical practice for Cushing’s syndrome. Only one previous study 
performed a systematic review and meta-analysis of two medical agents in Cushing’s 
syndrome. Daniel et al. studied normalization of cortisol after monotherapy with 
ketoconazole or metyrapone, and found that urinary free cortisol normalized in 60% 
(ketoconazole) and that normalization of hypercortisolism as defined by the authors 
occurred in 75% of patients using metyrapone (9). This is in line with the results 
obtained in the current study (49.0%–71.1% for ketoconazole and 60.0%–75.9% for 
metyrapone depending on patient categories). Since our last search in May 2017, one 
more research article on medical treatment in Cushing’s syndrome was published. 
Lacroix et al. described a 12-month clinical trial using pasireotide in various dosages 
in 150 patients. Urinary free cortisol normalized in 41.3% of patients. This is in line 




pasireotide (41.1%). Adverse events grade 1–2 were described in up to 48% of 
patients, and adverse events grade 3–4 in up to 16% of patients. This is in line with 
our own results for mild side effects (58.3%) and severe side effects (15.7%) for 
patients using pasireotide (46). 
 
In interpreting the results, the following study limitations need to be taken into 
account. There was a large amount of heterogeneity in included studies, regarding 
medical agent, etiology of Cushing’s syndrome, indication for use of medical therapy 
for Cushing (presurgical cortisol control, contra-indication for surgery, post-surgical 
therapy failure or recurrence), outcome measurement (definition of cortisol 
normalization), and concurrent or previous use of radiotherapy. Heterogeneity 
concerning medical agent and etiology was handled by performing separate analyses 
per medical agent and per etiology, although this substantially reduced the number 
of articles in some categories. Due to heterogeneity regarding outcome measurement 
for clinical symptoms (difference in blood pressure and glucose versus number of 
patients with improved values, only patients with disturbed values at start of the 
study versus all patients analyzed), we were unable to perform a quantified analysis 
of clinical improvement after medical therapy. Included articles showed various 
levels of risk of bias. However, sensitivity analyses excluding articles with high risk of 
bias or with high and intermediate risk of bias showed similar results to the main 
analysis. 
 
For patients with Cushing’s disease, first line transsphenoidal surgery yields better 
results than medical therapy (80% remission). However, remission after a repeat 
surgery was shown to be only 42.6%–55.7% in a recent meta-analysis. Various 
complications occurred in up to 18.5% of patients (47). This underlines that medical 
treatment is a reasonable alternative to repeat surgical procedure. 
 
Differences in effectiveness and side effects between the various etiological groups 
were small. In ectopic Cushing’s syndrome only, a higher percentage of patients 
reached normalization of cortisol levels than in the other etiological categories. As 
there were only three articles with separate data on patients with ectopic Cushing’s 
syndrome (of which one article only reported on one patient with ectopic Cushing’s 
syndrome, besides reporting on Cushing patients with other etiologies), no further 
subanalyses were possible, and reliability of this result is uncertain. However, we 
found no explanation for this high percentage of cortisol normalization in ectopic 
Cushing’s syndrome when considering risk of bias, type of medical agent, or 
additional treatment. 
 
When comparing different medical agents, it seems that a high percentage of 
patients with cortisol normalization corresponds to a high percentage of patients with 
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side effects and vice versa. However, all dosages used and studied were within the 
boundaries advised by the European Medicines Agency (EMA) and the Food and Drug 
Administration (FDA). It might mean that advised and commonly used dosages are in 
fact not the optimal dosages for treatment of Cushing’s syndrome considering the 
balance between treatment effect and side effects. Furthermore, medical agents 
with a high percentage of patients with normalized cortisol secretion (mitotane and 
metyrapone) are relatively often combined with radiotherapy, which may lead to 
overestimating the effect and side effects of the drug per se. The use of combined 
medical therapy, in combination or consecutively, increases the likelihood of 
successful treatment, i.e. in normalizing cortisol levels. This suggests that sensitivity 
for different medical agents may vary per patient. 
 
No difference was shown in normalization of cortisol between patients using medical 
agents as primary treatment versus secondary treatment, suggesting that 
effectiveness of medical agents is independent of other treatment modalities. A 
higher percentage of patients reached normalization of cortisol in studies where a 
small part of included patients received medication preoperatively (including 
patients with contraindications to surgery and patients after previous surgery) than in 
studies where a large part of included patients received medication before elective 
surgery. The most likely explanation is that in patients with planned surgery, 
medication is given to control cortisol excess, and surgery is performed before 
complete normalization of cortisol occurs. Unfortunately, we do not know the 
average time until cortisol normalization, as this was not reported by most articles. 
Total follow-up time was not different for studies with a high percentage of medical 
pre-treatment before surgery (average 0.1–11.5 years) than for all included studies. It 
would be interesting to know if the effectiveness of surgery is dependent upon the 
normalization of cortisol with medical treatment before surgery compared to 
presurgical medical treatment without cortisol normalization and compared to no 
presurgical medical treatment at all. Especially in Cushing’s disease, the percentage 
of patients with preoperative medical treatment that reaches cortisol normalization 
is low. This might be due to the higher expectations of surgery in Cushing’s disease 
compared to other etiologies, which may be why surgery is performed before patients 
reach normalization of cortisol levels. However, these results should be interpreted 
with caution, as a small number of articles were included in these analyses, and in 
the articles with a mixed etiologies population, a large proportion of included 
patients had Cushing’s disease (23, 43). 
 
Based on the current study, medication can be regarded a valuable alternative to 
pituitary surgery for patients with Cushing’s disease with contraindications to 
surgery, patients with a recurrence considering repeat surgery, and patients that 




surgery remains the first-choice treatment. For other etiologies of Cushing’s 
syndrome, at present, there is insufficient evidence to recommend when to use 
medical treatment to lower cortisol levels. However, from the total group of 
patients, it suggests that medical agents have similar effectiveness in normalizing 
cortisol levels for all etiologies of Cushing’s syndrome. For a higher chance of 
treatment success, a different medical agent could be tried if there is no treatment 
effect or if the patient experiences side effects. There is no evidence for which drug 
should be used first. Based on the current study, mitotane or metyrapone seem to be 
most effective in normalizing cortisol levels, but also cause the highest percentage of 
patients with side effects. 
 
In conclusion, we consider medical treatment for Cushing’s disease a reasonable 
option in patients with contraindication to surgery, with a recurrence, or that choose 
not to have surgery. Patients that experience side effects or no treatment effect 
should be advised to start treatment with a different medical agent to increase the 
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Chapter 7  
Sex differences in presentation but not in outcome 
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Sex differences in the clinical picture of adrenocorticotropic hormone (ACTH)-
dependent Cushing’s syndrome are controversial, except for the known higher 
prevalence in females. We compared a broad range of potential differences to enable 




Cohort study including consecutive patients with ACTH-dependent Cushing’s 
syndrome from Leiden and Berlin diagnosed between 2000-2016, comparing clinical 
presentation, biochemical parameters, diagnostic tests, surgical outcome, and 
comorbidities between men and women. 
 
Results 
We included 130 patients: 37 males and 93 females. With similar cortisol 
concentrations, ACTH concentrations were higher in males than females at time of 
diagnosis (median: 116 ng/L versus 57 ng/L). The prevalence of osteoporosis was 
higher in males than in females (48.6% versus 25.0%), persisting after surgery, with 
more vertebral fractures (16.2% versus 5.4%) before surgery. Males showed more 
anemia (75.9% versus 36.8%) after surgery. There were no differences in etiology, 




Based on this study, males and females with ACTH-dependent Cushing’s syndrome 
present different clinical patterns. However, these differences do not justify 
different diagnostic strategies or treatment based on sex, considering the similar 
surgical outcome. Clinicians should be alert to diagnose accompanying osteoporosis 
(with fractures) in male patients with ACTH-dependent Cushing’s syndrome. 
  





Cushing’s syndrome is characterized by endogenous glucocorticoid excess, either 
adrenocorticotropic hormone (ACTH)-dependent or ACTH-independent, both with a 
variety of underlying causes (1). The vast majority of patients has Cushing’s disease 
caused by an ACTH-secreting pituitary adenoma, with an estimated incidence of 1.2-
1.7 per million each year (2). First-choice treatment for Cushing’s disease is 
transsphenoidal pituitary surgery, selectively removing the corticotroph adenoma (3). 
Ectopic Cushing’s syndrome is a rare condition resulting from a non-pituitary ACTH-
producing source, and is generally approached by removing the ACTH-producing 
tumor, if identified and resectable. Excess of glucocorticoids causes osteoporosis, 
central obesity, insulin resistance, dyslipidemia, hypertension, hypercoagulability and 
neuropsychiatric disorders (4, 5). Despite biochemical cure, mortality risk remains 
increased in patients with Cushing’s disease (6). 
 
Sex distribution differs markedly between different etiologies. There is consensus 
that Cushing’s disease occurs up to five times more often in females, and that male 
patients with ACTH-dependent Cushing’s syndrome have a relatively higher risk of an 
ectopic ACTH-secreting tumor. However, exact figures are lacking and a 
pathophysiological explanation for the sex distribution is absent (7, 8). Interestingly, 
the female preponderance is not yet present in prepubertal cases, suggesting that 
males are diagnosed with Cushing’s syndrome at a younger age (9, 10). This is 
confirmed by some studies in adults with Cushing’s syndrome (11, 12), but rejected 
by others (13, 14). Some cohort studies have reported males to have more severe 
clinical presentation (higher body mass index and waist circumference, reduced 
libido and sexual dysfunction, more striae, myopathy, and hypokalemia), biochemical 
parameters (higher ACTH, serum cortisol, and urinary free cortisol [UFC] 
concentrations), complications at diagnosis (higher HbA1c concentrations, more often 
hypertension, anemia, spine osteoporosis with vertebral fractures, rib fractures, and 
hypercoagulable state), and worse outcome after surgery (more often anemia, lower 
cortisol normalization rate, and higher recurrence rate), than females (8, 9, 11-16). 
Pituitary tumors were less easily visualized by pituitary magnetic resonance imaging 
(MRI) in males (12, 13). One study reported more macroadenomas, with higher 
invasion and apoplexy rate (11), whereas another study reported equal percentages 
of macroadenomas in males and females (12). No differences were found in quality of 
life between males and females on multiple validated questionnaires (CushingQoL, 
EQ-VAS, and SCL-90-R) (8, 11, 17). Table 1 summarizes the reported literature 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Potential differences between males and females could for example be based on: 1) 
Different concentrations of corticosteroid binding globulin (CBG) (19), 2) Different 
interaction between corticosteroids and the gonadotroph axis, and 3) Different 
disease entity of Cushing’s syndrome. A large cohort study focusing on a broad range 
of potential differences between both sexes is needed to confirm the sometimes 
conflicting results from previous small studies focusing on a limited number of 
aspects, to enable a more accurate understanding of the clinical picture of sex-
specific ACTH-dependent Cushing’s syndrome. 
 
Study aims 
To compare the phenotype of male and female patients with ACTH-dependent 
Cushing’s syndrome regarding: 1) Clinical presentation, 2) Biochemical parameters 
and diagnostic test results, 3) Surgical outcome (i.e. percentage remission, 
hydrocortisone dependency, recurrence, and mortality), and comorbidities. Based on 
previous literature, we hypothesized that males show more symptoms related to 
hypercortisolism at diagnosis, with higher concentrations of ACTH and cortisol, and 
more comorbidity at diagnosis, specifically hypertension, anemia, and osteoporosis. 
We also hypothesized that males show worse outcome after surgery regarding 





Study population  
Consecutive patients with ACTH-dependent Cushing’s syndrome from the Leiden 
University Medical Center and the Charité Universitätsmedizin Berlin were included. 
Only patients with a diagnosis from January 1
st
 2000 onwards were included, as this 
guaranteed data collection from equal time periods for both centers. There were no 
restrictions regarding treatment (transsphenoidal surgery, adrenalectomy, 
radiotherapy, medical treatment, and ectopic tumor resection).  
 
The process to diagnose ACTH-dependent Cushing’s syndrome was published 
previously (20). Cut-off levels for the used diagnostic tests varied between study 
center and time period, due to use of different assays. All patients had pituitary 
imaging by MRI, except for three patients who had computed tomography (CT) only: 
one Cushing’s disease patient due to a contraindication for MRI, and two ectopic 
Cushing patients who already had CT for other reasons, revealing tumors with a high 
suspicion of ectopic ACTH secretion.  
 
First choice treatment for Cushing’s disease was transsphenoidal adenomectomy 
(TSA). One patient underwent bilateral adrenalectomy (ACTH-dependent Cushing’s 
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syndrome without clear pituitary adenoma, but also no ectopic source), two did not 
have surgery yet within the study period, and two were being treated long-term 
medically (one with cabergoline and one with levoketoconazole in a controlled trial 
setting). For ectopic Cushing’s syndrome, first choice treatment was removal of the 
ectopic ACTH-producing tumor. In 2001, one patient had TSA first, as a pituitary 
adenoma was identified on MRI, before the diagnosis of ectopic Cushing’s syndrome 
was established. Two patients underwent adrenalectomy (one unilateral because the 
ectopic tumor was located in the adrenal, and one bilateral because this could be 
combined with a nephrectomy for a renal cell carcinoma), and two patients died 
before treatment was instituted. The method of postoperative evaluation and 
definitions of surgical outcomes (remission, recurrence, and persistent disease) were 
presented previously (20). 
 
Outcomes and follow-up  
Outcomes of interest were clinical presentation of ACTH-dependent Cushing’s 
syndrome, surgical outcome, and short- and long-term morbidity. Surgical outcome 
included percentage remission, hydrocortisone dependency, recurrence, and 
mortality. Hydrocortisone dependency was measured three months after surgery and 
was divided in three categories: a) Absolute deficiency if insufficient cortisol 
response to a stimulation test [corticotropin-releasing hormone (CRH)-test, ACTH-test 
or insulin tolerance test], b) Hydrocortisone for symptoms despite normal cortisol 
response to stimulation, and c) Pragmatic hydrocortisone replacement (without 
stimulation test). 
 
Short-term morbidity (≤3 months after first surgery) included 1) Anemia (defined as 
hemoglobin concentrations of <8.5 mmol/L for males and <7.5 mmol/L for females, 
measured within two weeks after surgery), 2) Anterior pituitary deficiency other than 
ACTH requiring medication (number of deficient axes, with gonadal axis deficiency 
also described separately), 3) Severe bleeding (requiring surgical intervention or 
bleeding described as severe in patient file), and 4) Cardiovascular event 
(thrombosis, pulmonary embolism, cerebrovascular accident, transient ischemic 
attack, and myocardial ischemia).  
 
Long-term morbidity (>3 months after first surgery) included 1) Anterior pituitary 
deficiency (one year after surgery), 2) Hypertension (de novo as well as persisting 
after surgery), 3) Diabetes mellitus (de novo as well as persisting after surgery), 4) 
Neuropsychiatric morbidity (complaints as well as consultation of psychologist or 
psychiatrist), 5) Osteoporosis (defined as a bone mineral density of -2.5 standard 
deviation [SD]), and 6) Fractures (symptomatic as well as radiologically diagnosed 




described separately). Anterior pituitary deficiency was described only for patients 
after a transsphenoidal adenomectomy. 
 
We followed patients from date of diagnosis until death, loss to follow-up, or 31 
December 2016, whichever came first. The following patient information was 
collected at time of diagnosis: age, comorbidities (cardiovascular event, 
hypertension, diabetes mellitus, dyslipidemia, neuropsychiatric morbidity, anemia, 
osteoporosis, fractures in patient history), and all eight items of the Cushing’s 
syndrome Severity Index score (CSI score) (21). 
 
Ectopic Cushing’s syndrome was classified according to the following underlying 
disorders: neuroendocrine tumor of the gastrointestinal tract, lung tumor, and other 
source of ACTH production. Pituitary tumor size was divided into microadenomas (≤10 
mm) and macroadenomas (>10 mm). 
 
Risk of bias  
This study included all eligible patients to prevent selection bias. However, selective 
loss to follow-up could have led to selection bias, if more patients from one sex were 
lost to follow-up than from the other sex caused by e.g. presence of comorbidities. 
This could alter the percentages of patients with long-term comorbidity after 
treatment in our study, leading to biased results. Confounding was not assessed as a 
potential source of bias, as study groups were formed based on sex, and no factor of 
interest was thought to influence sex. Factors associated with sex could have 
influenced our results due to selection bias, e.g. by differences in age, and these 
factors were compared between both sexes, as described in the next paragraph. 
 
Statistical analysis 
The following contingency tables were prepared, comparing male to female patients 
with ACTH-dependent Cushing’s syndrome: 1) Demographic characteristics, 
phenotype of Cushing’s syndrome, and medical history (above mentioned patient 
information collected at time of diagnosis, as well as duration of follow-up), and 2) 
Surgical outcome, and short- and long-term morbidity. Furthermore, diagnostic 
strategy and results (biochemical parameters at diagnosis, type and result of 
radiologic imaging, simultaneous bilateral inferior petrosal sinus sampling, etiology of 
Cushing’s syndrome, tumor size for pituitary adenomas, medical treatment prior to 
surgery, histology results, and immunohistochemistry results) were compared 
between male and female patients. The unpaired T-test was used to compare 
outcomes for continuous variables, and for categorical variables the two-sample test 
of proportions was used. To correct for multiple testing, the Bonferroni method was 
used and tests were considered significant if p<0.001, although this was probably too 
conservative for this study due to correlations between the analyses (e.g. 
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osteoporosis and fractures). All performed analyses were reported in this article. In 
the tables, percentages were reported according to the total number of patients with 
a valid value for the specific parameter. If per parameter, data were missing for ≥5% 
of patients, this was marked in the tables. If variables with ≥5% missing data showed 
a clear difference between sexes, we also calculated percentages according to total 
number of patients, thereby assuming that patients with a missing value were 
rightfully unmeasured, and reported this in the results section only.  
 
Kaplan-Meier curves were constructed for overall survival since time of diagnosis, and 
for recurrence-free survival since time of surgery between male and female patients. 
For recurrence-free survival, only patients at risk for recurrence were included in the 
analysis. Cox proportional hazard regression analyses were performed to provide 
hazard ratios with 95% confidence intervals. 
 
IBM SPSS Statistics 23.0 (IBM Corp, Armonk, NY, USA) was used to perform all 
statistical analyses, except the two-sample test of proportions (command: prtesti), 
which was performed using Stata 14.2 (Stata Corp., College Station, TX, USA), to 
calculate the difference between two proportions with 95% confidence interval, as 
this was not provided by SPSS. Patients gave informed consent for use of their data 
for scientific research. Permission from the ethical committees in the LUMC and 
Charité Universitätsmedizin was granted. The Strengthening the Reporting of 






Study population (Table 2) 
In total, 130 patients were included (n=85 from Leiden, n=45 from Berlin), of whom 
37 are males (28.5% of total, mean age: 45.3 years, range: 14-74 years) and 93 
females (mean age: 44.8 years, range: 10-80 years). With similar serum cortisol 
concentrations (median: 670 nmol/L versus 680 nmol/L) and UFC (median: 4.5 times 
upper limit of normal versus 3.4 times upper limit of normal), males had higher ACTH 
concentrations at time of diagnosis when compared to females (median: 116 ng/L 
versus 57 ng/L). There were no differences regarding etiology of Cushing’s syndrome 
(males 5.4% ectopic, females 4.3% ectopic), and tumor size of pituitary adenoma 
(males 40.0% macroadenomas, females 32.2% macroadenomas). Radiologic findings 
(pituitary adenoma, ectopic ACTH-secreting tumor, no tumor, or inconclusive), and 
percentage of patients with inferior petrosal sinus sampling were comparable for 
both sexes. Osteoporosis was more prevalent at time of diagnosis in males (48.6% 




patient history (27.0% versus 19.6%), mainly vertebral (16.2% versus 5.4%). None of 
these differences was statistically significant after Bonferroni correction. Males less 
often reported sex-related disturbances than females (positive item on Cushing’s 
syndrome Severity Index score: 22.8% versus 64.0%).  
 
Table 2: Demographic characteristics and phenotype of Cushing’s syndrome. 
 Male Female Tested difference  
(95% CI; p-value*) 
 N % N %  
Total number of patients 37 100.0 93 100.0  
Age at diagnosis, years# 45.3 16.4 44.8 15.1 0.5 (-5.4 to 6.5; p=0.87) 
Duration of follow-up (years)^ 5.9 2.2-9.8 5.6 1.9-12.2 0.6 (-1.2 to 2.5; p=0.50) 







- Hemoglobin (mmol/L)#° 
Osteoporosis 
Fractures in patient history 
- Vertebral fracture 


















































5.3% (-8.2% to 18.8%; p=0.41) 
6.1% (-10.6% to 22.8%; p=0.49) 
2.0% (-15.8% to 19.8%; p=0.82) 
0.7% (-14.3% to 15.7%; p=0.93) 
2.0% (-16.5% to 20.5%; p=0.83) 
0.7% (-10.8% to 12.2%; p=0.90) 
 
23.6% (5.2% to 42.0%; p=0.009) 
7.4% (-9.0% to 23.8%; p=0.36) 


































































































































-0.7 (-1.8 to 0.4; p=0.20) 
 
8.0% (-3.2% to 19.2%; p=0.083) 
 
 
5.2% (-11.6% to 22.0%; p=0.56) 
 
 
2.7% (-16.5% to 21.9%; p=0.78) 
 
 
7.2% (-12.1% to 26.5%; p=0.47) 
 
 
9.2% (-7.1% to 25.5%; p=0.30) 
 
 
4.6% (-13.7% to 22.9%; p=0.63) 
 
 
11.2% (-6.3% to 28.7%; p=0.19) 
 
 
41.2% (24.1% to 58.3%; p=0.000) 
CI=confidence interval  
*Due to the Bonferroni correction, tests were considered significant if p<0.001, #mean + standard deviation, 
^median + IQR, °data were missing for ≥5% of patients 
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Males and females were treated for Cushing’s syndrome similarly: percentage of 
patients with cortisol-lowering medication preoperatively (males 68.6%, females 
65.9%) was comparable. After surgery, histology results (tumor identified, no tumor 
identified, or inconclusive) and immunohistochemistry results (ACTH-positive or 
negative) were also similar for both sexes. 
 
Twenty patients were lost to follow-up (four males [10.8%] and sixteen females 
[17.2%], seventeen patients from Berlin, three patients from Leiden) after an average 
follow-up time of 71 months. For a detailed description of demographic 
characteristics, see Table 2, and Figures 1A-C. As there were only six patients with 
ectopic Cushing’s syndrome, no analyses were performed stratified by etiology. The 
ectopic ACTH-secreting tumors were: pancreatic neuroendocrine tumor (n=1), lung 
tumors (carcinoid [n=1] and carcinoma [n=1]), thymoma (n=1), thymic carcinoma 
(n=1), and pheochromocytoma (n=1). 
 
Surgical outcome  
There were 34 male patients with at least three months follow-up after surgery, of 
whom 28 were in remission (82.4%), and 22 were hydrocortisone dependent (64.7%). 
Of the 28 males in remission after surgery, recurrence occurred in eight patients 
(28.6%), after a mean of 55 months (range: 9-130 months). Five of these eight 
patients were hydrocortisone dependent three months after first surgery (62.5%). 
There were 85 female patients with at least three months follow-up after surgery, of 
whom 68 were in remission (80.0%), and of whom 55 were hydrocortisone dependent 
(64.7%). Of the 68 females in remission after surgery, recurrence occurred in fifteen 
patients (22.1%), after a mean of 30 months (range: 0-109 months). Eight of these 
fifteen patients were hydrocortisone dependent three months after first surgery 
(53.3%). The hazard ratio for recurrence was 1.22 (95% confidence interval: 0.52-
2.89) for males compared to females (Figure 2). Three months after surgery, ACTH 
concentrations were higher in males than in females (mean: 30 ng/L versus 11 ng/L). 
More detailed surgical outcome results can be found in Table 3. 
 
Overall survival  
Within the study period twelve patients died, five males and seven females. The 
hazard ratio for mortality was 2.35 (95% confidence interval: 0.73-7.51) for males 






































































































































































































































































C. Comorbidities after treatment
Male Female
 
Figure 1: Comorbidities and symptoms of ACTH-dependent Cushing’s syndrome by sex. A: Symptoms of 
Cushing’s syndrome at diagnosis. B: Comorbidities at diagnosis. C: Comorbidities after treatment.  
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Table 3: Surgical outcome and short and long-term morbidity. 
 Male Female Tested difference (95% CI; p-value*) 
 N % N %  
Surgical outcome 
Cortisol direct postoperatively 
(nmol/L)^° 
Cortisol 3 to 6 months 
postoperatively (nmol/L)^° 
ACTH 3 to 6 months 
postoperatively (ng/L)^° 
Hydrocortisone dependency 
- Absolute deficiency  
- Normal cortisol response# 







- Ectopic tumor resection 














































































100 (-20 to 220; p=0.096) 
 
30 (-70 to 120; p=0.56) 
 
50 (-13 to 113; p=0.12) 
 




2.4% (-12.6% to 17.4%; p=0.76) 
5.7% (-10.3% to 21.7%; p=0.47) 
5.3% (-13.7% to 24.3%; p=0.58) 
Short term morbidity: ≤3 
month after first surgery 
Anemia° 
- Hemoglobin (mmol/L)~° 
Anterior pituitary deficiency°+ 
- One axis 
- Two axes 
- Three axes 

















































39.1% (19.8% to 58.4%; p=0.000) 
 





4.9% (-3.6% to 13.4%; p=0.13) 
4.3% (-6.5% to 15.1%; p=0.38) 
Long term morbidity: >3 
months after first surgery 
Anterior pituitary deficiency 
after 1 year°+ 
- One axis 
- Two axes 
- Three axes 
- Gonadal axis deficiency 
Hypertension 




- Clinical vertebral fracture 





































































8.7% (-10.2% to 27.6%; p=0.37) 
9.7% (-8.5% to 27.9%; p=0.28) 
9.9% (-2.2% to 22.0%; p=0.17) 
19.0% (0.0% to 38.0%; p=0.047) 
1.8% (-5.2% to 8.8%; p=0.65) 
ACTH=adrenocorticotropic hormone, CI=confidence interval, CSF=cerebrospinal fluid, SIADH=syndrome of 
inappropriate antidiuretic hormone release, TSA=transsphenoidal adenomectomy 
*Due to the Bonferroni correction, tests were considered significant if p<0.001, ~mean + standard deviation, 
^median + IQR, °data were missing for ≥5% of patients, +only for patients with TSA 
#Hydrocortisone for symptoms despite normal cortisol response to CRH stimulation. 




Short- and long-term morbidity  
Postoperatively, anemia was more prevalent in males than in females (75.9% versus 
36.8% for patients with a valid value only). If all patients were included in this 
analysis, assuming that patients without a valid value were rightfully unmeasured, 
this difference was even larger (78.4% versus 26.9%). After surgery, males continued 
to have osteoporosis more often than females (50.0% versus 31.0%). Overall, anterior 
pituitary deficiency was more prevalent in males than females (34.5% versus 22.1) 
three months after surgery. Specifically, gonadal axis deficiency needing replacement 
therapy was more prevalent in males (24.1% versus 6.5%). This difference remained 
one year after surgery. More detailed morbidity results can be found in Table 3, and 
in Figure 1B-C. 
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Figure 2: Recurrence-free survival by sex. 
 
 





In this cohort study, we compared clinical presentation, biochemical parameters, 
diagnostic test results, surgical outcome, and morbidity in male versus female 
patients with ACTH-dependent Cushing’s syndrome. With similar serum cortisol 
concentrations and UFC, males had higher ACTH concentrations at time of diagnosis 
than females, with no difference in etiology of Cushing’s syndrome and pituitary 
tumor size between the sexes. Cushing’s disease was the most common cause of 
ACTH-dependent Cushing’s syndrome in both male and female patients. At diagnosis 
of Cushing’s syndrome, we found a higher prevalence of osteoporosis with (vertebral) 
fractures in males than females. After surgery, the higher prevalence of osteoporosis 
with (vertebral) fractures persisted, and a higher prevalence of anemia in males than 
in females was found. It is important to note that there were no differences in 
surgical outcome, recurrence, or mortality between sexes. Thus, male patients with 
ACTH-dependent Cushing’s syndrome seem to constitute a different clinical pattern 
regarding symptoms and biochemistry, which does, however, not affect the further 
diagnostic strategy, therapy, or surgical outcome in this cohort study, although 
comorbidities did differ between sexes. Therefore, no different diagnostic or 
therapeutic strategy is indicated based on sex. However, based on the differences in 
comorbidities, extra attention should be given to male patients for diagnosing and 
treating osteoporosis (with fractures). 
 
A major strength of this study is that it includes a large cohort from two centers and 
focuses on a broad spectrum of potential differences between sexes, thereby 
allowing a more accurate description and clear understanding of the clinical picture 
of ACTH-dependent Cushing’s syndrome based on sex, than previous cohort studies. 
The differences in biochemistry and morbidity found in this study are largely in line 
with previous studies: higher plasma ACTH (9, 12-14), more often anemia (16) and 
osteoporosis (with fractures) (8, 11-13). The lack of difference in etiology and 
pituitary tumor size was in agreement with some studies (9, 12), but not with others 
(8, 11). Similarly, the lack of difference in surgical outcome was in agreement with 
one study (9), but not with two others (11, 12). Thus, this study adds evidence to the 
existence of a sex difference with respect to ACTH, anemia, and osteoporosis (with 
fractures), and to the lack of a sex difference in etiology and pituitary tumor size. 
The existence of a sex difference regarding surgical outcome is doubtful, as now two 
studies show a difference, whereas two others do not, indicating that more research 
is needed into the existence of a sex difference in surgical outcome. 
 
When interpreting the results, the following study limitations should be taken into 
account. As this study compared a broad spectrum of potential differences between 




tests considered significant only if p<0.001. Consequently, the cohort size was 
insufficient to detect any differences that were smaller than 40% between the study 
groups. In order to find a 20% difference between the study groups with a significance 
level of p<0.001, we would have needed at least 450 patients in total, given the sex 
distribution in this study, which would have taken many more study centers or 
multiple extra decades to assemble. However, none of the previously published 
studies on potential sex differences controlled for multiple testing, without exception 
using a significance level of p<0.05 despite using many statistical tests per study. This 
should be taken into account when comparing our study results to the literature. 
Furthermore, as there were only six patients with ectopic Cushing’s syndrome, no 




























4 3 3 2
14 8 2


























Figure 3: Overall survival by sex. 
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Loss to follow-up could have led to selection bias, since more female than male 
patients were lost to follow-up. However, as no patient was lost to follow-up within 
six months postoperatively, and most study endpoints were measured within six 
months postoperatively, selective loss to follow-up is unlikely to have influenced 
study results.  
 
As this study was performed retrospectively, using information from patient files, 
information could not always be collected from similar time points for each patient, 
leading to missing data in some patients (e.g. anemia at diagnosis), and information 
bias is likely to have occurred due to selective questioning of patients (e.g. sex-
related disturbances in the Cushing’s syndrome Severity Index score). This 
presumably led to the improbable low percentage of males reporting sex-related 
disturbances, whereas other studies found males to have sex-related disturbances 
more often than females (8, 11). Thus, it is important to inquire patients at disease 
presentation thoroughly about this subject and ideally also interview the patient’s 
partner in this regard. 
 
As should be discussed according to the STROBE guideline (22), this study is 
theoretically generalizable to all patients with ACTH-dependent Cushing’s syndrome. 
However, the small number of patients with ectopic Cushing’s syndrome precludes 
generalizability for this etiological ultrarare subgroup.  
 
ACTH has been reported to be higher in males than in females with ACTH-dependent 
Cushing’s syndrome consistently across multiple studies (9, 12-14). Some studies, that 
also reported higher concentrations of UFC in males than in females, suggested that 
ACTH-dependent Cushing’s syndrome is a more aggressive disease in males (12, 13). 
The increased ACTH concentrations could not be related to larger tumor size of the 
pituitary adenoma (14). Likewise, as the percentage of patients with ectopic 
Cushing’s syndrome was similar for both sexes, etiological differences are no 
satisfying explanation for the observed variation in ACTH concentrations. Until now, 
no study has found a convincing pathophysiological explanation why ACTH is higher in 
males than in females. Interestingly, higher concentrations of ACTH in males do not 
consistently seem to increase concentrations of cortisol (serum cortisol as well as 
UFC), reducing the probability that ACTH-dependent Cushing’s syndrome in males 
actually is a more aggressive disease than in females. Future research with the aim to 
discover why ACTH is higher in males than in females could focus first on which 
factors other than pituitary tumor size or etiology might be related to a higher ACTH 
per sex. 
 
Osteoporosis (with fractures) and anemia were more prevalent in males than in 




diagnostic process, as males may have less pronounced symptoms than females in the 
earlier stages of the disease (i.e. menstrual disturbances), leading to a greater delay 
in diagnosis and therefore more, and more severe complications at time of diagnosis 
in males. Furthermore, it has been suggested that interaction between 
corticosteroids and the gonadotropic axis leads to hypogonadism in males more often 
than in females, which may markedly influence bone damage in Cushing’s syndrome 
(8, 13). This is in accordance with our study results, which showed postoperative 
hypogonadism more often in males than females. This hypogonadism may also cause 
an endocrine anemia due to the insufficient drive of testosterone on erythropoiesis 
(23). However, a meta-analysis of prior corticosteroid use and (osteoporotic) fracture 
risk found no difference between men and women (24). 
 
In conclusion, male patients with ACTH-dependent Cushing’s syndrome seem to show 
a different clinical picture than females. However, no different diagnostic strategy or 
treatment is indicated based on sex, in view of the similar surgical outcome. 
Clinicians should pay more attention to male patients with ACTH-dependent Cushing’s 
syndrome in particular regarding diagnosis and treatment of accompanying 
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Adrenal crisis, the most feared complication of adrenal insufficiency, is a potentially 
life-threatening state of acute glucocorticoid deficiency. After successful surgery for 
Cushing’s syndrome, many patients develop (transient) adrenal insufficiency. The 
incidence of adrenal crisis in patients treated for hypercortisolism is unknown. 
 
Methods 
Cohort study including consecutive patients with Cushing’s syndrome with adrenal 
insufficiency after surgery from Leiden and Berlin from 2000-2015. We summarized 
incidence of adrenal crisis, compared patients with and without adrenal crisis 
regarding potential risk factors for its occurrence, and assessed the effect of better 
education in time on incidence of adrenal crisis. 
 
Results 
We included 106 patients, of whom 19 patients had a total of 41 adrenal crises. There 
were 9.0 crises per 100 patient-years at risk (95% confidence interval [CI]: 6.7-12.0). 
All crises occurred while on hydrocortisone replacement. The risk ratio for a 
recurrent crisis was 2.3 (95% CI: 1.2-4.6). No clear change in incidence of adrenal 
crisis due to better education in time was observed. There was no difference in 
recurrence rate between patients with, and without any crisis, but patients with 
adrenal crisis had more often pituitary deficiencies. 
 
Conclusions 
The incidence of adrenal crises after treatment for Cushing’s syndrome is substantial, 
and patients who suffered from an adrenal crisis have higher risk for recurrent crisis. 
However, further risk factor analysis is needed to identify risks for a first crisis. 
Effective education methods to prevent adrenal crises should be identified and 
implemented, including stress instructions by trained nursing staff before hospital 
discharge. 
  





An adrenal crisis is a potentially life-threatening situation of an acute state of 
glucocorticoid deficiency, which can develop after any situation of increased demand 
for stress hormones, such as intercurrent illness or psychological stress, and is the 
most feared complication of adrenal insufficiency (1). The incidence of adrenal crisis 
in the heterogeneous population of patients with adrenal insufficiency is estimated to 
be 4.1 to 9.3 per 100 patient-years (2-9). There is no consensus on the definition of 
(imminent) adrenal insufficiency. However, the proposed definition by Allolio et al. is 
useful for clinical practice: a combination of 1) Major impairment of general health 
with at least two of the following signs/symptoms: hypotension, nausea or vomiting, 
severe fatigue, fever, somnolence, hyponatremia or hyperkalemia, hypoglycemia, 
and 2) Parenteral glucocorticoid administration followed by clinical improvement 
(10). A recent Dutch guideline developed by a multi-disciplinary group, that also 
included patient representatives, provides clear guidance on when to act to prevent 
adrenal crisis in daily life, e.g. in case of elective surgical procedures or acute illness 
with intensive care admission, and how to treat acute adrenal crisis (11). 
 
Cushing’s syndrome is the result of a prolonged state of endogenous hypercortisolism. 
This can be adrenocorticotropic hormone (ACTH)-dependent (e.g. Cushing’s disease) 
or ACTH-independent (e.g. an adrenal cortisol-producing adenoma) (12). Excess of 
glucocorticoids causes osteoporosis, central obesity, insulin resistance, dyslipidemia, 
hypertension, hypercoagulability, cognitive dysfunction, and neuropsychiatric 
disorders (13, 14). First-choice treatment is transsphenoidal selective adenomectomy 
for Cushing’s disease (15), surgical removal of the tumor in case of ectopic ACTH-
producing tumors, and adrenalectomy for an adrenal adenoma (16). 
 
After successful surgery, patients with Cushing’s disease develop (transient) severe 
adrenal insufficiency due to suppression of the physiological hypothalamic-pituitary-
adrenal (HPA) axis by the pathological secretion of ACTH by the adenoma, for which 
hydrocortisone replacement therapy is needed. A significant number of these patients 
even need life-long replacement therapy, because of incomplete recovery of the 
HPA-axis either due to isolated downregulation of the adrenal glands or because of 
pituitary function loss, which is seen in 42% of patients after 5 years of follow-up 
(17). The incidence of adrenal crisis in the subset of patients with a history of 
hypercortisolism is unknown. Due to long-standing hypercortisolism, the activity of 
the HPA-axis may have altered the response to cortisol deficiency in patients treated 
for Cushing’s syndrome (including Cushing’s disease) compared to other adrenal 
insufficient patients. The history of hypercortisolism and potential occurrence of 
corticosteroid withdrawal syndrome and a phase of lowering replacement doses may 




may not recognize early symptoms of adrenal crisis in time. Corticosteroid 
withdrawal syndrome can occur in patients with previous hypercortisolism despite 
apparently acceptable cortisol concentrations, meaning that these patients need 
higher replacement doses of hydrocortisone than other adrenal insufficient patients. 
This may suggest that they are at higher risk of an adrenal crisis if they receive 
normal replacement doses that result in apparently acceptable cortisol 
concentrations (18).  
 
For clinical practice, it is important to know how often adrenal crisis occurs and what 
the possible risk factors are in the population of patients in the aftermath of an 
episode of endogenous hypercortisolism. 
 
Study aims 
The primary study aim was to summarize the incidence of adrenal crisis, defined as 
an acute impairment of general health requiring hospital admission (excluding 
emergency room visit only) and administration of intravenous glucocorticoids, with 
subsequent resolution of symptoms, in a population of patients with Cushing’s 
syndrome treated by transsphenoidal pituitary surgery or adrenalectomy during the 
time that they were adrenal insufficient. Secondary study aims were to find risk 
factors identifying patients with Cushing’s syndrome who may be at higher risk for an 
adrenal crisis after surgical treatment, to describe the course and underlying cause of 
adrenal crisis, and to assess a potential change in incidence of adrenal crises due to 





Study population  
Consecutive patients with Cushing’s disease and adrenal Cushing’s syndrome from the 
Leiden University Medical Center and the Charité Universitätsmedizin Berlin were 
included in this cohort study. Patients with an adrenal carcinoma were excluded. 
Patients were included between January 1
st
 2000 and December 31
st
 2015. Only 
patients with adrenal insufficiency and glucocorticoid dependency after 
transsphenoidal pituitary surgery or adrenalectomy were included, as this constitutes 
the population at risk for an adrenal crisis. There were no restrictions in prior or 
adjuvant treatment, such as reoperation, prior or adjuvant radiotherapy or pre-
operative cortisol-lowering medication. 
 
The diagnostic process for ACTH-dependent Cushing’s syndrome was described 
previously (19). For ACTH-independent Cushing’s syndrome, the same criteria were 
used, except that ACTH had to be suppressed, and that adrenal imaging was 
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performed by either magnetic resonance imaging (MRI) or computed tomography 
(CT). Due to the use of different assays, cut-off levels for the used tests varied 
between both study centers and over time.  
 
Transsphenoidal adenomectomy (TSA) was the first-choice treatment for Cushing’s 
disease. One patient underwent bilateral adrenalectomy, because no pituitary 
adenoma was visualized on MRI and no lateralization was present during inferior 
petrosal sinus sampling, but also no ectopic ACTH-producing source was found. For 
patients with adrenal Cushing’s syndrome, adrenalectomy was the first-choice 
treatment. Details of postoperative evaluation as well as definitions of remission, 
recurrence and persistent disease were presented previously (19). We included the 
time period that a patient was hydrocortisone dependent, as explained more 
extensively under “follow-up”. During disease recurrence, patients were excluded 
from our study, but they could re-enter the study if after further treatment, they 
were again hydrocortisone dependent. Starting from three months postoperatively, 
potential normalization of the HPA-axis was tested dynamically with synthetic ACTH, 
corticotropin-releasing hormone (CRH), or insulin tolerance test (ITT). The HPA-axis 
was considered normalized if the dynamic test showed a normal test result, and 
consequently hydrocortisone replacement was discontinued. 
 
Study outcomes and follow-up  
Primary outcome of interest was adrenal crisis. Further outcomes of interest were 
mortality, (surgical) outcome including recurrent disease, and complications. Unless 
otherwise specified, outcomes were reported in relation to the first surgery. 
 
Adrenal crisis was defined as an acute impairment of general health requiring 
hospital admission (not only emergency room, as emergency room adrenal crises 
could not be scored reliably) and administration of intravenous glucocorticoids, after 
which a resolution of symptoms followed (10). Self-treatment for adrenal crisis at 
home was not included as endpoint, as the accuracy of this diagnosis cannot be 
guaranteed. Regarding adrenal crisis, the total number of crises and the total number 
of patient-years at risk were summarized, as well as the number of crises per patient 
with at least one crisis, the type of hospital admission (regular ward or intensive 
care), duration of hospital stay in days, hydrocortisone dose before hospital 
admission for the adrenal crisis in mg/day (in case of a crisis before first hospital 
release after surgery, the last dose given before start of symptoms was entered), 
and, at hospital admission for the adrenal crisis, the number of patients with a 
subphysiological dose of hydrocortisone replacement (<20 mg/day), the number of 





Besides recurrent disease, the following variables were described: hydrocortisone 
release dose from the hospital after the first surgery in mg/day, number of patients 
with restoration of the HPA-axis within one year after first surgery, and adjuvant 
treatment (radiotherapy, transsphenoidal adenomectomy, adrenalectomy, and 
medical treatment).  
 
Complications (measured ≤3 months after first surgery) included diabetes insipidus 
(requiring medication at least once) and anterior pituitary deficiency other than 
ACTH requiring medication. Complications were described only for patients that 
underwent transsphenoidal adenomectomy. 
 
We followed patients from date of surgery for Cushing’s syndrome until death, loss to 
follow-up, or December 31
st
 2016, whichever came first. Patients were followed only 
during the period that they were at risk of having an adrenal crisis, i.e. from the 
moment they had adrenal insufficiency and glucocorticoid dependency until 
normalizing adrenal function, evidenced by clinical stop of hydrocortisone 
replacement and at least one normal dynamic test (ACTH, CRH or ITT). Patients were 
potentially included again after a period of normal adrenal function if they once 
more experienced adrenal insufficiency and glucocorticoid dependency after a repeat 
surgical procedure or radiotherapy.  
 
Presurgical information was collected regarding diagnosis, comorbidities 
(hypertension, diabetes mellitus, dyslipidemia), and cortisol-lowering medical 
treatment prior to surgery. Pituitary tumor size was divided into microadenomas (≤10 
mm) and macroadenomas (>10 mm). 
 
All eligible patients were included in this study to prevent selection bias. However, 
selective loss to follow-up could have led to selection bias. Confounding was assessed 
as a potential source of bias by comparing baseline characteristics between groups. 
 
Statistical analysis 
In the contingency tables, patients with at least one adrenal crisis were compared to 
patients without any adrenal crisis: 1) Demographic characteristics and medical 
history (age at diagnosis, sex, duration of follow-up, Cushing’s syndrome Severity 
Index (CSI) score (20), type of surgical treatment, comorbidities, tumor size for 
pituitary adenomas, and cortisol-lowering medical treatment prior to surgery), and 2) 
Adrenal crisis details, (surgical) outcome, and complications. The difference between 
the two study groups was tested with an unpaired T-test for continuous outcomes and 
with the two-sample test of proportions for outcomes reported as proportions. These 
tables were also stratified by study center. If data were missing for ≥5% of patients, 
this was marked in the tables. 
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The Andersen-Gill adaptation of the Cox proportional hazard model was used to 
analyze the effect of the following variables on occurrence of an adrenal crisis: study 
center (Leiden versus Berlin) and etiology of Cushing’s syndrome (21). Univariate and 
multivariate analyses were performed. Only hydrocortisone-dependent time was 
included in the model, because this was the patient-time at risk for an adrenal crisis. 
By using the Andersen-Gill model, we were able to include recurrent adrenal crisis 
and take into account time between crises. Hydrocortisone replacement dose before 
hospital admission for adrenal crisis was related to the time between last surgery and 
the occurrence of adrenal crisis. This was the only analysis in which time since last 
surgery before adrenal crisis was used, as only patients with at least one crisis were 
included in this analysis and we were specifically interested in time since last surgery 
for this outcome. Prior adrenal crisis was related to risk of recurrent adrenal crisis by 
calculating the risk ratio, which was performed by dividing risk of recurrent crisis for 
patients with a first adrenal crisis by the risk of a first adrenal crisis for all included 
patients. Number of adrenal crises per 100 patient-years at risk was stratified by time 
period (2000-2004, 2005-2009, 2010-2016), to assess a change in incidence due to 
better education in time.  
 
Statistical analyses were performed with IBM SPSS Statistics 23.0 (IBM Corp, Armonk, 
NY, USA), and with Stata 14.2 (Stata Corp., College Station, TX, USA) for the 
Andersen-Gill model and the two-sample test of proportions (command: prtesti) to 
calculate the difference between two proportions with 95% confidence interval (CI), 
as this was not provided by SPSS. Patients gave informed consent to use their data for 
scientific research. Permission was granted from the ethical committees in the LUMC 
and Charité Universitätsmedizin. The Strengthening the Reporting of Observational 





Study population  
In total, 106 patients were included in this study (66 from Leiden and 40 from Berlin), 
of whom nineteen patients (17.9%) suffered from at least one adrenal crisis. There 
was no difference in sex or age between both groups. For the nineteen patients with 
adrenal crisis, mean age was 46.2 years (range: 16-72), and most (n=14, 73.7%) were 
female. Of the 87 patients without adrenal crisis, mean age was 42.9 years (range: 
10-80), and 68 (78.2%) were female.  
 
At diagnosis of Cushing’s syndrome, patients with adrenal crises had more often 
diabetes mellitus (68.4% versus 24.1%), and more often macroadenomas (53.8% versus 




syndrome Severity Index score between both groups. Twenty patients were lost to 
follow-up after an average of 81.2 months (range 3-165), of whom four with at least 
one crisis (21% out of 19 patients with at least one crisis) and sixteen without any 
crisis (18% out of 87 patients without any crisis). For a detailed description of 
demographic characteristics, see Table 1. Results per study center can be found in 
Supplemental Data 1.  
 
In Leiden, patients received a lower hydrocortisone replacement dose at hospital 
discharge postoperatively than in Berlin (median of 20 mg/day [interquartile range 
(IQR): 20-40; mean 25 mg/day] versus 30 mg/day [IQR: 25-50; mean 35 mg/day]), in 
accordance with the institutional protocols. However, in Berlin, the hydrocortisone 
replacement dose at hospital discharge was higher in patients with an adrenal crisis 
(median 50 mg/day), which was not observed in patients from Leiden. 
 
Table 1: Demographic characteristics. 
 Adrenal crisis No adrenal crisis Tested difference (95% CI) 
 N % N %  
Total number of patients 19 100.0 87 100.0  
Age at diagnosis, years* 46.2 12.5 42.9 14.8 3.3 (-4.0 to 10.5) 
Sex (female) 14 73.7 68 78.2 4.5% (-17.1% to 26.1%) 
Duration of follow-up (years)^ 6.3 4.6-
11.3 
7.8 3.7-11.7 0.5 (-1.7 to 2.7) 
Cushing’s syndrome Severity 
Index score* 




14 73.7 64 73.6 0.1% (-21.8% to 22.0%) 





















7.5% (-15.3% to 30.3%) 
44.3% (21.5% to 67.1%) 
19.0% (-3.0% to 41.0%) 
Patients with pituitary 
microadenoma 
6 46.2 49 75.4 29.2% (0.1% to 58.3%) 
Prior medical treatment 8 44.4 50 58.1 13.7% (-11.5% to 38.9%) 
CI=confidence interval 
*mean + standard deviation; ^median + IQR 
 
Adrenal crisis  
There were 41 adrenal crises in nineteen patients during 457 patient-years at risk, 
measured in all 106 patients. This translates into 9.0 crises per 100 patient-years at 
risk (95% CI: 6.7-12.0). Patients had on average 2.2 crises with a range of 1 to 7 crises 
per patient. Time since last surgery until first crisis had a median of 2 months (IQR: 
1-22 months), and time since last surgery until any crisis had a median of 20 months 
(IQR: 1-57 months). This means generally patients with adrenal crises had their first 
crisis early after their last surgery, after which they remained at risk for recurrent 
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crises for at least 5 years. Five patients had a crisis during the same hospital 
admission in which the surgery was performed, most within one week after surgery, 
and one patient two weeks after surgery. For most adrenal crises, patients were 
admitted to a regular ward only. One patient was first admitted to the intensive care 
and afterwards to a regular ward. Median hospital stay duration was 5 days. The 
average hydrocortisone replacement dose used at home (or at least advised) just 
before hospital admission for adrenal crisis was 30 mg/d (range 0-100 mg/d). In seven 
cases of adrenal crisis, the used dose was <20 mg/d. There were 29 cases of adrenal 
crisis with documented infection, and two with clear psychological stress. For 
detailed results, see Table 2.  
 
 
Table 2: Adrenal crisis, (surgical) outcome, and complications. 
 Adrenal crisis No adrenal crisis Tested difference (95% CI) 
 N % N %  
Adrenal crisis 
Number of crises per patient# 
Type of hospital admission 
- Regular ward 
- Intensive care 
Duration of hospital stay 
(days)^ 
Hydrocortisone dose at 
hospital admission (mg/day)# 






















































Hydrocortisone dose (mg/day) 
at discharge^ 
Serum cortisol direct 
postoperatively (nmol/L)^° 
Serum cortisol 3 to 6 months 
postoperatively (nmol/L)^° 
Restoration of HPA-axis in the 
















































5 (-7.5 to 17.5) 
 
170 (-150 to 480) 
 
120 (-20 to 390) 
 
7.4% (-8.4% to 23.2%) 
 
3.3% (-12.3% to 18.9%) 
5.6% (-15.9% to 27.1%) 
Complications 
Diabetes insipidus°+ 
Anterior pituitary deficiency+ 
- One axis 
- Two axes 


























17.1% (-12.8% to 47.0%) 
26.2% (-4.0% to 56.4%) 
CI=confidence interval, HPA-axis=hypothalamus-pituitary-adrenal-axis 







As there were nineteen patients with at least one adrenal crisis out of 106 patients, 
the risk of an adrenal crisis at baseline was 17.9%. Risk of recurrent crisis for patients 
with at least one adrenal crisis was eight out of nineteen (42.1%). The risk ratio of 
having a recurrent crisis for patients with at least one crisis was 2.3 (95% CI: 1.2-4.6) 
compared to having a first adrenal crisis.  
 
Four patients experienced more than three adrenal crises (two patients with four 
crises, one with five crises, and one with seven crises). There is no clear pattern, 
which discriminates these patients from other patients in this study. All had Cushing’s 
disease, and three were female. One had multiple adjuvant treatments (repeat 
transsphenoidal surgery, radiotherapy, and bilateral adrenalectomy), whereas the 
others only had one surgical procedure. After surgery, one patient had diabetes 
insipidus, one had anterior pituitary deficiency (only thyroid axis deficient), and one 
had both (also only thyroid axis deficient). Two patients had a cortisol stimulation 
test within two weeks after surgery, showing peak cortisol concentrations of 10 and 
50 nmol/L. Their average hydrocortisone replacement dose before hospital admission 
for adrenal crisis was 30 mg/day, and in one case only, the patient received <20 
mg/day (17.5 mg/day). 
 
In Leiden, patients had 6.7 crises per 100 patient-years (95% CI: 4.5-10.0), which was 
14.7 crises per 100 patient-years (95% CI: 9.7-22.3) in Berlin. In Leiden, patients were 
admitted to hospital for adrenal crises using lower hydrocortisone replacement doses 
than in Berlin (20 mg/day versus 40 mg/day), and there were more patients with a 
hydrocortisone replacement dose <20 mg/d at hospital admission for adrenal crisis 
(six cases versus one in Berlin). In five cases, hydrocortisone replacement <20 mg/d 
was given during a hydrocortisone withdrawal schedule, whereas in two cases, a dose 
<20 mg/d was already given within one month postoperatively (one in Leiden and one 
in Berlin), due to suspicion of persisting disease. For patients with Cushing’s disease, 
there were 9.6 crises per 100 patient-years (95% CI: 7.0-13.3), versus 7.0 crises per 
100 patient-years (95% CI: 3.6-13.6) for adrenal Cushing’s syndrome. For more 
detailed results, see Supplemental Data 2. 
 
The hazard ratio for patients with adrenal Cushing’s syndrome compared to Cushing’s 
disease was 0.73 (95% CI: 0.32-1.65) in a univariate Andersen-Gill model, meaning the 
risk for adrenal crisis was lower in patients with adrenal Cushing’s syndrome. The 
hazard ratio for patients from Berlin compared to patients from Leiden was 2.00 (95% 
CI: 1.02-3.91). In a multivariate Andersen-Gill model using both etiology and research 
center, we found a hazard ratio for adrenal Cushing’s syndrome compared to 
Cushing’s disease of 0.59 (95% CI: 0.25-1.39) and a hazard ratio for patients from 
Berlin compared to patients from Leiden of 2.23 (95% CI: 1.13-4.42). Due to the low 
number of events, no further risk factor analyses were performed. 
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In Figure 1, the relation between hydrocortisone replacement dose before hospital 
admission for adrenal crisis and time from last surgery until adrenal crisis is shown. 
Patients with a short period between last surgery and adrenal crisis had higher 
replacement doses of hydrocortisone at the occurrence of adrenal crisis than patients 
with a long duration between last surgery and adrenal crisis. This means that, due to 
the corticosteroid withdrawal syndrome, shortly after surgery patients with Cushing’s 
syndrome need higher replacement doses of hydrocortisone than longer after surgery 
to prevent adrenal crisis. Despite in general higher dosing for withdrawal complaints, 
patients are at risk for adrenal crisis, pointing at an increased need for 































































































Time between surgery and adrenal crisis (months) 
Figure 1: Relation between hydrocortisone replacement dose at time of adrenal crisis and time between last 
surgery and occurrence of adrenal crisis. 
 
Stratified by time period, there were two crises in 44 patient-years at risk from 2000-
2004 (5 crises per 100 patient-years, 95% CI: 1-18), fourteen crises in 142 patient-
years at risk from 2005-2009 (10 crises per 100 patient-years, 95% CI: 6-16), and 25 







Surgical outcome and state of the HPA-axis  
From the patients without adrenal crisis, twelve experienced a recurrence (14.8% out 
of 81 initially in remission). From the patients with at least one adrenal crisis, two 
experienced recurrent disease, for which they underwent repeat surgery (12.5% out 
of 16 initially in remission). Adrenal crises only occurred after the final treatment in 
each patient.  
 
Postoperative serum cortisol concentrations were similar for patients with (median 30 
nmol/L, IQR: 20-600) and without adrenal crisis (median 40 nmol/L, IQR: 20-100). 
There was one patient (7.1%) with restoration of the HPA-axis in the first year 
postoperatively who had an adrenal crisis, whereas the HPA-axis restored within a 
year in ten patients (14.5%) without adrenal crisis. A detailed overview of surgical 
outcome results can be found in Table 2, and results stratified by study center in 
Supplemental Data 2. 
 
Overall survival  
Five patients died in the study period, three without any adrenal crisis, and two 
patients with at least one adrenal crisis. Both deaths in the latter group were not 
related to adrenal crisis. No further mortality analyses were performed due to the 
small number of deaths. 
 
Complications  
Postoperatively, patients with adrenal crises had additional anterior pituitary 
deficiency more often than patients without any adrenal crisis (50.0% versus 23.8%), 




In this exploratory study, we summarized the incidence of adrenal crisis in a 
population of patients with Cushing’s syndrome after treatment during the 
postoperative period that they were adrenal insufficient. We compared patients with 
and without any adrenal crisis regarding potential risk factors for adrenal crisis and 
characteristics of Cushing’s syndrome.  
 
The incidence of adrenal crisis was 9.0 crises per 100 patient-years at risk. The risk of 
adrenal crisis was higher for patients from Berlin than for patients from Leiden, and 
higher for patients with Cushing’s disease than for patients with adrenal Cushing’s 
syndrome. First adrenal crisis occurred early after cure despite high replacement 
doses of hydrocortisone, and was a risk factor for recurrent crisis. No decline in 
incidence of adrenal crisis in time, due to better education and increased general 
awareness across Europe for necessity of stress instruction, was observed. Additional 
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pituitary deficits are more often present in patients with adrenal crisis, and may 
therefore be a risk factor for the occurrence of adrenal crises.  
 
A strength of this study is the focus on adrenal crisis as primary outcome in a 
population of patients treated for Cushing’s syndrome, including a detailed 
description of the underlying disease and course of the adrenal crisis. Our incidence 
of adrenal crisis is in line – on the high end – with the incidences reported in the 
literature on adrenal insufficient populations (4.1-9.3 per 100 patient-years) (2-9), 
and especially with one systematic review about patients with Cushing’s syndrome 
after bilateral adrenalectomy (9.3 per 100 patient-years) (5). Our risk ratio for 
recurrent crisis is in line with the current literature (6). 
 
The following study limitations need to be taken into account when interpreting our 
results. Due to the low absolute number of adrenal crises in our study population, the 
planned extensive risk factor analysis could not be performed. High percentages of 
loss to follow-up in both study groups, though equally divided, may have led to 
selection bias. As loss to follow-up could have resulted from various reasons, 
including both excellent health as well as very poor health status, the direction in 
which the results may have been biased cannot be determined. However, since our 
main results are in line with the literature, selection due to high loss to follow-up is 
unlikely to have biased our results extensively.  
 
As should be discussed according to the STROBE guideline (22), this study is 
generalizable to all patients with Cushing’s disease and adrenal Cushing’s syndrome 
who are adrenal insufficient and glucocorticoid dependent after transsphenoidal 
pituitary surgery or adrenalectomy. 
 
Our risk ratio for recurrent crisis indicates that certain patients are at larger risk than 
others to develop (multiple) adrenal crises. This may be due to decreased 
glucocorticoid sensitivity at the tissue level caused by polymorphisms in the 
glucocorticoid receptor gene (23). For these patients, the increase in hydrocortisone 
replacement dose during stress, or maybe even regular hydrocortisone replacement 
doses, may not be sufficient to prevent adrenal crisis. A further explanation may be 
an insufficient understanding in these patients of the instructions how to adequately 
anticipate with increasing the dose of hydrocortisone during stress, or insufficient 
compliance in increasing the hydrocortisone replacement dose. Severity of Cushing’s 
syndrome (measured by CSI score) could not be related to occurrence of adrenal 
crisis. However, risk factors such as severity of Cushing’s syndrome can be difficult to 





The large difference in incidence of adrenal crisis between Leiden and Berlin may 
partially be explained by a different approach in hospital admission for patients 
presenting to the emergency room with signs and symptoms of early onset adrenal 
crisis. Patients in Leiden may preferably be treated in the emergency room, whereas 
patients in Berlin may rather be treated during hospital admission. On the other 
hand, the difference may partially be explained by different patient education 
strategies in the prevention of adrenal crises, possibly because in Berlin patients use 
higher hydrocortisone replacement doses, both at hospital discharge as well as prior 
to hospital admission for adrenal crisis. The difference in incidence of adrenal crisis 
between patients with Cushing’s disease and adrenal Cushing’s syndrome is small and 
may not represent a true difference. A difference might be explained by the different 
treatment methods for both etiologies. A higher risk of adrenal insufficiency and 
therefore adrenal crisis might be expected after adrenalectomy, which could have 
led to better patient education after adrenalectomy than after transsphenoidal 
surgery. Better awareness through education and thereby timely treatment of early 
symptoms of adrenal crisis could have resulted in the lower risk of adrenal crisis for 
patients with adrenal Cushing’s syndrome.  
 
The lack of difference in recurrence rates for Cushing’s syndrome between patients 
with and without adrenal crisis is most likely due to selection of our patient 
population, as only patients with at least one period of adrenal insufficiency and 
glucocorticoid dependency were included in this study. Patients with adrenal crisis 
more often had additional pituitary hormone deficiencies than patients without any 
adrenal crisis, which may indicate which patients are more vulnerable, and therefore 
at higher risk of adrenal crisis.  
 
The lack of improvement over time due to better education is supported by recent 
publications stating that patients with adrenal insufficiency are still threatened by 
the risk of adrenal crisis (24), that there is a clear mismatch between self-perceived 
understanding of adrenal insufficiency/adrenal crisis and objectively tested 
knowledge (9), and that definitive and timely diagnosis of adrenal crisis is often not 
possible before treatment needs to be initiated to prevent mortality in patients with 
adrenal crisis (25). Further research is needed to investigate the effects of various 
education methods in preventing adrenal crises and how often education should be 
repeated. Despite proper education, some patients may remain at higher risk of 
adrenal crisis due to e.g. altered glucocorticoid sensitivity (23). Furthermore, adrenal 
crisis occurring during hospital admission in which patients undergo surgery for 
Cushing’s syndrome cannot be prevented merely by educating the patient. Other 
ways to prevent crises need to be explored, e.g. education of the endocrine nursing 
staff in order to recognize early stages of adrenal crisis timely. A low threshold for 
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contact between patient and physician could cause overtreatment, but could also 
result in less severe cases of adrenal crisis (26). 
 
In conclusion, patients with a history of Cushing’s disease are at risk for adrenal 
crisis. Adrenal crisis tends to present early after institution of cure. Those patients 
that have experienced adrenal crisis are at increased risk for recurrent crisis. 
Although some risk factors tend to point towards increased risk for adrenal crisis (e.g. 
additional pituitary deficiencies), we believe more outcome data are necessary to 
identify groups at increased risk. Further research is needed to find effective 
education methods for preventing adrenal crisis, and to find ways to prevent the first 
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Cushing’s syndrome is characterized by glucocorticoid excess, which induces physical 
and mental symptoms, and impairments in quality of life. Biochemical cure improves 
symptoms, but quality of life and cognitive function may remain impaired. 
 
Objective 
To perform a systematic review and meta-analysis evaluating changes in health-




Eight electronic databases were searched in March 2017, and PubMed again in May 
2018, to identify potentially relevant articles. Eligible studies were (randomized 
controlled) trials, cohort studies, and cross-sectional studies assessing quality of life 
or cognitive functioning in patients treated for Cushing’s syndrome. Quality of life 
measures were standardized; differences were expressed as standardized mean 
difference, and reported with 95% confidence intervals. We compared patients before 




We included 47 articles with in total 2,643 patients. Most patients had Cushing’s 
disease and were in remission after treatment. Both quality of life and cognitive 
functioning improved after treatment in all studied domains. Compared to a healthy 
control population, quality of life did not normalize. Cognitive functioning normalized 
in part, but not all, of the studied domains. 
 
Conclusions 
Treatment of Cushing’s syndrome improves quality of life and cognitive functioning. 
As normalization was not achieved in quality of life and in some aspects of cognitive 
functioning, special and continuous attention should be given to these aspects for 
patients after treatment. Effective interventions for further improvement and 
possibly normalization are urgently needed.  





Cushing’s syndrome due to endogenous glucocorticoid excess is a rare condition and is 
either adrenocorticotropic hormone (ACTH)-dependent or ACTH-independent, both 
with a variety of underlying causes (1). Glucocorticoid excess causes osteoporosis, 
central obesity, insulin resistance, dyslipidemia, proximal muscle weakness, 
hypertension, hypercoagulability, and neuropsychiatric disorders. Patients report 
fatigue, a variety of mental and physical symptoms, and impairment in quality of life 
(2-3). Mortality and morbidity are increased even after long-term correction of 
glucocorticoid excess, including cognitive functioning, indicating irreversible adverse 
effects of previous hypercortisolism (4-6).  
 
Cushing’s disease resulting from an ACTH-secreting pituitary adenoma accounts for 
approximately 70% of cases of endogenous Cushing’s syndrome, and has a reported 
incidence of 1.2-1.7 patients per million each year (7). The other causes for 
endogenous Cushing’s syndrome are ectopic Cushing’s syndrome resulting from a non-
pituitary ACTH-producing source (approximately 5% of cases), and ACTH-independent 
Cushing’s syndrome that is caused by a cortisol-producing adrenal adenoma or 
carcinoma (approximately 25% of cases) (1, 8). First-choice treatment for Cushing’s 
disease is transsphenoidal pituitary surgery, selectively removing the corticotroph 
adenoma (9). Cushing’s syndrome is generally approached by removing the ACTH-
producing tumor in ectopic Cushing’s syndrome and by adrenalectomy in ACTH-
independent Cushing’s syndrome (10). If necessary to establish cure, repeat 
surgeries, radiotherapy, and pharmaceutical therapies are considered. After surgical 
treatment, many patients face a period of transient or permanent adrenal 
insufficiency and sometimes other hormone deficits (11). A particular issue after 
surgery, but sometimes also during medical therapy, is the steroid withdrawal 
syndrome with its severe musculoskeletal pains, fatigue, and emotional lability (12).  
 
In 2012, a literature review summarized the effects of Cushing’s disease on clinical 
symptoms, including health-related quality of life and cognitive functioning, stating 
that current treatment options may not completely reverse the effects of chronic 
hypercortisolism (13). In 2015, another systematic review summarized quality of life 
in patients with a pituitary adenoma, concluding that patients with Cushing’s disease, 
along with patients with acromegaly, demonstrated the greatest impairment in 
quality of life, and the smallest improvement (14). For Cushing’s disease, two 
disease-specific quality of life questionnaires have been developed: the Tuebingen 
Cushing’s disease quality of life inventory (Tuebingen CD-25), and the Cushing Quality 
of Life questionnaire (CushingQoL) (15-17). Also, a pituitary patient-specific 
questionnaire, the Leiden Bother and Needs Questionnaire, was developed for use in 




questionnaires should be combined with a generic questionnaire to assess health-
related quality of life. In addition, structural and functional brain abnormalities were 
shown to be persistent after biochemical cure of Cushing’s syndrome, which was 
related to both quality of life and cognitive functioning impairments in patients with 
Cushing’s syndrome (5). Until now, no meta-analysis has been performed to evaluate 
health-related quality of life or cognitive functioning in patients with Cushing’s 
syndrome before and after treatment. 
 
Study aims 
The aim of the present study is to evaluate improvement in, and normalization of, 
health-related quality of life and cognitive functioning in patients with Cushing’s 
syndrome. Improvement in health-related quality of life and cognitive functioning 
will be evaluated by comparing patients before treatment to patients after treatment 
of Cushing’s syndrome. Whether health-related quality of life and cognitive 
functioning can normalize will be evaluated by comparing patients with Cushing’s 






(Randomized controlled) trials, cohort studies (measuring at different time points) 
and cross-sectional studies (measuring at one point in time), assessing quality of life 
or cognitive functioning in patients with Cushing’s syndrome were eligible for 
inclusion. Comparative studies (before-after treatment comparisons, or patients with 
Cushing’s syndrome compared to healthy controls) and non-comparative studies were 
considered for inclusion. Eligible quality of life questionnaires were validated 
generic, disease-specific (for Cushing’s syndrome), and domain-specific 
questionnaires. Articles were excluded if no separate results for patients with 
Cushing’s syndrome were described, if the study included children only, or if no 
quantitative data of quality of life questionnaires or cognitive functioning tests were 
presented (e.g. only figure without numbers). There were no restrictions regarding 
treatment for Cushing’s syndrome. If multiple studies with (partially) overlapping 
populations described the same questionnaire or test, only the data from the largest 
cohort were included per analysis. To minimize risk of selection bias, at least ten 
patients had to be included per study group. Articles irretrievable online were 









PubMed, Embase, Web of Science, COCHRANE Library, CENTRAL, Emcare, LWW, and 
ScienceDirect were systematically searched in March 2017 in cooperation with a 
specialized librarian to identify potentially relevant articles (see Supplemental Data 1 
for the complete search strategy). In May 2018, the search was repeated in PubMed. 
References of included articles were searched for relevant eligible articles. 
 
Data extraction 
The identified articles were all entered in EndNote 8 (Thomson Reuters, Philadelphia, 
PA, USA). First, the studies were screened by title and abstract. Two independent 
reviewers reviewed potentially relevant articles in detail. For reporting, the Meta-
analysis Of Observational Studies in Epidemiology (MOOSE) guidelines were used (19). 
 
The following data were extracted from all included articles: study period, study 
center, study design, etiology of Cushing’s syndrome, number of patients, treatment 
of Cushing’s syndrome, age, sex, duration of follow-up, type and number of control 
subjects, quality of life questionnaires and cognitive functioning tests used, and 
outcomes of these tests. If available, separate outcomes were extracted for patients 
in remission and patients not in remission after treatment.  
 
If data were only presented according to categories (e.g., remission status or sex), 
the data were combined into one outcome score using a fixed effects meta-analysis 
for the main analyses. Combination scores were calculated from the subscale scores 
for the following questionnaires: CushingQoL (15), Symptom Rating Test (SRT) (20), 
Multidimensional Fatigue Inventory-20 (MFI-20) (21), Nottingham Health Profile (NHP) 
(22), and the Hospital Anxiety and Depression Scale (HADS) (22). For one article, the 
scores after treatment were calculated using the scores before treatment and the 
difference between before and after treatment, imputing the standard deviation (SD) 
from before treatment as the best estimate of the SD after treatment (23). If 
estimate and 95% confidence interval (CI), but not SD, were given for a single group, 
the following formula was used to calculate SD: ((CI)/2)/TINV(0.05;n-1)*SQRT(n), 
with n=number of patients. If data for two groups were combined as described above, 
SD was calculated using the following formula: SQRT((((n1-1)*SD1^2)+((n2-
1)*SD2^2))/((n1+n2)-2)), with n1=number of patients in group 1, SD1=SD in group 1, 
n2=number of patients in group 2, and SD2=SD in group 2. From one article two 
questionnaires were excluded (Short Form health survey-36 [SF-36] and Beck 
Depression Inventory [BDI]) (24), and from another article one questionnaire was 
excluded (State Trait Anxiety Inventory [STAI]) (25), due to highly improbable or 






Risk of bias assessment 
A component approach was used to assess risk of bias for all included studies. 
Components that could potentially bias a reported association between treatment for 
Cushing’s syndrome and quality of life or cognitive functioning were included as 
follows: 
 
1. Loss to follow-up <5% was considered low risk of bias for follow-up studies; 
similarly, missing quality of life or cognitive functioning data in <5% of 
patients was considered low risk of bias for cross-sectional studies. 
2. Inclusion of patients: consecutive inclusion of all eligible patients or a 
random sample was considered low risk of bias. 
3. Criteria for diagnosis of Cushing’s syndrome: at least one of the following 
biochemical parameters had to be increased for low risk of bias: 24-h urinary 
free cortisol or midnight salivary cortisol. 
4. Criteria for remission of Cushing’s syndrome: at least normalization of 
biochemical hypercortisolism had to be measured for low risk of bias. 
5. Test quality: number of cognitive domains assessed, validation of used 
questionnaires and tests, reporting of test instructions for cognitive tests, 
and reporting of sequence of cognitive tests were described for each study. 
Low risk of bias is considered use of only validated questionnaires and tests 
and reporting both test instructions and sequence of cognitive tests. 
 
Risk of bias assessment was used to explore potential heterogeneity. Confounding was 
assessed by comparing baseline characteristics (age, sex, duration of follow-up, and 
treatment methods) for all included studies, as well as by comparing study group 
characteristics per study with a direct comparison before versus after treatment, or 
between patients after treatment and healthy controls. These assessments were 
made based on study level data. 
 
Study endpoints  
Quality of life scores were pooled for generic, disease-specific, and domain-specific 
(per domain) questionnaires separately. Analysed domains were anxiety, depression, 
and fatigue, as these were the only domains with enough data for analysis. Cognitive 
functioning was analysed in the following categories: intelligence (including concept 
formation), executive functioning (i.e. visuomotor tracking, inhibition, and mental 
flexibility), attention (i.e. divided, sustained), and memory (i.e. auditory, visual). In 
the category intelligence, the following tests were analysed: 1. Wechsler Adult 
Intelligence Scale – Revised (WAIS-R), 2. Similarities, and 3. Raven's Progressive 
Matrices (RPM). In the category executive functioning, the following tests were 
analysed: 1. Trail Making Test (TMT, trail A-D), and 2. Fluency tests (Verbal fluency, 
Word fluency, and the FAS test). In the category attention, the following tests were 
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analysed: 1. Substitution tests (Digit Symbol [Substitution] Test [D(S)ST], Digit symbol 
coding, and Letter-Digit Substitution Test [LDST]), and 2. Digit span. For the category 
memory, no analyses could be performed due to the large variety in used memory 
tests.  
 
Per analysis, all quality of life questionnaires and cognitive functioning tests were 
included, with notifications for studies with (partially) overlapping populations using 
different questionnaires or tests. Separate analyses were performed per 
questionnaire or test (including subscales if provided) reported by at least two 
articles. Stratified analyses were performed for longitudinal and cross-sectional 
studies. Main analyses were performed in all included studies. Subgroup analyses 
were performed for patients with Cushing’s disease only, and for patients in 
remission and patients not in remission after treatment. 
 
Data were displayed separately for quality of life and cognitive functioning scores of 
patients before treatment for Cushing’s syndrome, after treatment for Cushing’s 
syndrome, and for a healthy control population. Notifications were added stating for 
which questionnaires and tests a higher score represents a lower quality of life or 
worse cognitive functioning. 
 
Statistical analysis 
Primary study outcomes were the standardized mean differences (SMD) before versus 
after treatment, as well as treated patients versus healthy controls, within studies. 
As a rule of thumb for the interpretation of the SMD, an effect size of 0.2 represents 
a small effect, 0.5 represents a moderate effect, and 0.8 represents a large effect 
(26). A random-effects model was used, as no fixed effect could be assumed due to 
the heterogeneity in questionnaires or tests; a fixed-effect model was used for 
analyses per questionnaire or test including <5 articles as in this case the between-
study variance cannot be estimated reliably. All SMD scores were accompanied by 95% 
CI. No overall scores were presented per analysis with various tests/questionnaires, 
because a different number of (sub)scales per included article resulted in 
unintentional inequality in assigned weights per study, leading to incorrect effect 
estimates and confidence intervals. For meta-analyses only, questionnaires and tests 
in which a higher score represents a lower quality of life or worse cognitive 
functioning were reversed by multiplying the outcome with -1, ensuring that all 
outcomes were in the same direction. For three articles, ‘±’ was interpreted as SD in 
the analyses, as this remained unclear after reading the articles (24, 27-28). The 
D(S)ST and LDST were included in the analyses in items/second, the TMT in seconds, 
and fluency tests in number/minute. All analyses were performed in Stata 14.2 (Stata 







Study selection  
The initial search yielded 717 potentially relevant articles. After searching through 
references of included articles and repeating the search in PubMed in May 2018, 
another nine articles were added, providing 726 articles. After screening the articles 
by title and abstract, 603 articles were excluded, leaving 123 articles for detailed 
review. In total, 47 articles were included in this review, of which 32 reported on 
quality of life only, ten on cognitive functioning only, and five reported on both 
quality of life and cognitive functioning. Reasons for excluding articles are 
summarized in Figure 1. 
Potentially relevant published 
articles identified (n=726), 
screened by title and abstract




- No original data: 189
- No Cushing’s syndrome: 239
- N<10: 41
- Language other than English: 73
- Children only: 4
- No human subjects: 13
- No relevant outcome: 44
Articles excluded (n=76)
- No relevant outcome: 48
- No separate results before and after 
treatment: 4
- No separate results for Cushing's 
syndrome: 6
- Double population without new 
data: 15
- N<10 with Cushing's syndrome: 1
- No original data: 2
 
Figure 1: Flow-chart of inclusion of articles in this systematic review. 
 
Study characteristics (Supplemental Data 2) 
We included 27 cross-sectional studies (6, 22, 24-25, 27, 29-50), sixteen cohort 
studies (28, 51-65), one article that included both a cross-sectional study part and a 
cohort study part (66), one single-arm trial (67), and two articles about the same 
randomized controlled trial (pasireotide 600 µg versus pasireotide 900 µg) (23, 68). 
Studies were published between 1985 and 2017. Of the included studies, 28 reported 
on Cushing’s disease only, one on adrenal Cushing’s syndrome only, seventeen 
described a mixed population, and one study included a cohort of patients with 
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Cushing’s disease only, as well as a mixed population cross-sectional study part. In 
total, the included studies described 2,643 patients, partially from overlapping 
populations.  
 
Seventeen articles included a healthy control group (n=2,335, also partially from 
overlapping populations), of which fifteen studies matched controls on at least age 
and sex, and nine articles used normative data from the general population or 
literature reference values. Studies comparing patients before and after treatment 
by design included the same population for both measurement times, reducing risk of 
confounding, although bias remains possible through loss to follow-up, as described 
below.  
 
Baseline characteristics varied between all included studies. As data were insufficient 
to estimate risk of confounding, and inclusion of articles for meta-analysis differed 
per analysis and per domain, baseline characteristics data were summarized for all 
articles. Average age was between 33.6 and 57.0 years. Percentage female patients 
varied between 40% and 100%. Average duration of follow-up for cohort studies was 6 
to 54 months. Four studies, which were not included in any meta-analysis, did not 
present data after treatment. Of the remaining 43 studies, 23 used multimodality 
treatment, fifteen used surgical procedures only, three only used pharmaceutical 
treatment, and two did not describe the nature of the treatment. 
 
Risk of bias assessment (Supplemental Data 2) 
Loss to follow-up was reported by fourteen out of twenty cohort studies and trials, 
with a range of 0-74% loss to follow-up. Only four studies reported a loss to follow-up 
<5%. Of the 27 cross-sectional studies, 6 (22%) reported missing data for quality of 
life or cognitive functioning ≥5%. Fourteen articles (30%) explicitly stated including 
consecutive patients. Criteria for diagnosis of Cushing’s syndrome were reported 
adequately by 21 studies (45%). Criteria for remission of Cushing’s syndrome were 
reported adequately by 26 studies out of 43 with postoperative measurements (61%). 
 
Study outcomes 
Quality of life was reported in 37 articles, using eleven different generic 
questionnaires, two disease-specific questionnaires (i.e., CushingQoL and Tuebingen 
CD-25), and 21 domain-specific questionnaires (including amongst others five anxiety, 
six depression, and five fatigue questionnaires). Twelve studies reported quality of 
life both before and after treatment. Quality of life data were reported for patients 
with Cushing’s syndrome before treatment by fifteen studies, for patients with 
Cushing’s syndrome after treatment by 34 studies, and for a healthy control 






Figure 2: Generic quality of life before versus after treatment for Cushing’s syndrome. 
 
Cognitive functioning was reported in fifteen articles, using 35 different tests 
(including four tests on intelligence and concept formation, six on executive 








































































































































SCL-90-R: positive symptom distress
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cognitive functioning both before and after treatment. Cognitive functioning scores 
were reported for patients with Cushing’s syndrome before treatment by eight 
studies, for patients with Cushing’s syndrome after treatment by thirteen studies, 
and for a healthy control population by twelve studies. Detailed study outcomes and 
an overview of all included questionnaires and tests with abbreviations can be found 
in Supplemental Data 2. 
 
Meta-analyses of improvement of quality of life and cognitive functioning  
Quality of life and cognitive functioning improved after treatment in all studied 
categories (generic, disease-specific, domain-specific: anxiety, and domain-specific: 
depression quality of life, and the cognitive functions intelligence, executive 
functioning and attention). Generic quality of life improved by a SMD of 0.11 to 1.75 
in all included studies (see Figure 2). Disease-specific quality of life improved by a 
SMD of 0.16 to 1.57 in all included studies (see Figure 3). For domain-specific quality 
of life and cognitive functioning, studies showed SMDs of 0.08 to 0.86, indicating 
improvement in all aspects of quality of life and cognitive functioning.  
 
Figure 3: Disease-specific quality of life before versus after treatment for Cushing’s syndrome. 
 
Table 1 shows a summary of all meta-analyses regarding improvement in quality of 
life and cognitive functioning, including subgroup analyses for patients with Cushing’s 
disease only, and analyses stratified by remission status after treatment. 
Supplemental Data 3-6 show the raw figures for the main analyses, analyses for 
patients with Cushing’s disease only, analyses according to remission status, and 

























Tuebingen CD-25: sexual activity
Tuebingen CD-25: environment
Tuebingen CD-25: eating behaviour
Tuebingen CD-25: bodily restrictions
Tuebingen CD-25: cognition
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Meta-analyses of normalization of quality of life and cognitive functioning  
Quality of life did not normalize after treatment for Cushing’s syndrome. For generic 
quality of life SMDs varied across included studies from 0.05 in favor of patients after 
treatment to 1.61 in favor of healthy controls (see Figure 4). For domain-specific 
quality of life, SMDs varied from 0.20 to 1.20, indicating that healthy controls 
















































































































































SCL-90-R: positive symptom distress












































































































Cognitive functioning partially normalized after treatment for Cushing’s syndrome. 
SMDs for intelligence varied across studies from 0.55 in favor of patients after 
treatment to 0.78 in favor of healthy controls. Executive functioning and attention 
were tested in both longitudinal as well as cross-sectional studies, which showed 
conflicting results. The longitudinal studies showed normalization of both domains of 
cognitive functioning, with SMDs varying between 0.48 in favor of patients after 
treatment and 0.31 in favor of healthy controls. The cross-sectional studies showed 
SMDs of 0.00 to 0.31 in favor of healthy controls, suggesting that no normalization of 
cognitive functioning had occurred. More detailed results regarding normalization of 
quality of life and cognitive functioning can be found in Table 1 and Supplemental 





The present systematic review and meta-analysis shows that quality of life and 
cognitive functioning improve after treatment for Cushing’s syndrome. However, 
quality of life does not normalize, and only partial normalization occurs in cognitive 
functioning. These results demonstrate that biomedical treatment of Cushing’s 
syndrome is the first step towards improvement in quality of life and cognitive 
functioning, but that room for further improvement remains in aiming to establish 
normalization of quality of life and cognitive functioning. 
 
The present observations are in line with the results of a previous literature review 
by Feelders et al., which described that health-related quality of life improved in 
patients with Cushing’s disease during biochemical remission, but that it remained 
impaired compared to healthy controls. The same study also found that cognitive 
functioning did not improve short-term, and suggested that there may be a delay 
between correction of hypercortisolism and recovery of impairments in cognitive 
functioning (13). This is in contrast with our findings, since we found improvement 
and partial normalization of cognitive functioning. However, no truly short-term 
studies with only patients up to one year follow-up were included in this review, 
preventing extensive analyses according to follow-up time for both cognitive 
functioning as well as quality of life. This might explain the different findings 
regarding cognitive functioning improvement, and it would also support the 
suggestion of a delay between correction of hypercortisolism and recovery of 
impairments in cognitive functioning. Our findings are in accordance with another 
systematic review, which described quality of life in patients with a pituitary 
adenoma in general, and found that patients with Cushing’s disease showed the 
smallest improvement and no normalization after treatment. They also reported 
room for further improvement in quality of life, potentially by psychosocial 
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interventions as well as optimal medical treatment (14). Two articles were published 
after our last search in May 2018. Our results were in accordance with the first one 
by Valassi et al., which demonstrated that quality of life, as assessed with the EQ-5D 
and CushingQoL, improved after treatment for Cushing’s syndrome (69). The second 
article by Osswald et al. compared quality of life, as assessed with the SF-36, 
CushingQoL, and Tuebingen CD-25, between patients in remission of ectopic 
Cushing’s syndrome and patients with remitted Cushing’s disease, and observed that 
female patients with ectopic Cushing’s syndrome reported a better quality of life 
compared to female patients with Cushing’s disease. This difference was not 
observed in male patients. Comparing the quality of life scores of these patients to 
the quality of life scores reported in our included studies, it can be observed that the 
patients in the study of Osswald et al. scored better on all three questionnaires. As 
this study included a small population (n=69), their results would have meant a small 
change towards better quality of life in the average that we found for analyses 
including these questionnaires after treatment for Cushing’s syndrome only (70). 
 
Although quality of life and cognitive functioning have been addressed before 
separately in systematic reviews, this is the first study investigating both quality of 
life as well as cognitive functioning. Furthermore, not only patients with Cushing’s 
disease were included, but all patients with Cushing’s syndrome. The following study 
limitations need to be taken into account when interpreting the results. Included 
studies showed heterogeneity regarding etiology of Cushing’s syndrome, treatment 
strategy, and remission status after treatment. Results were consistent across the 
subgroup analyses for Cushing’s disease only and the subgroup analyses stratified by 
remission status. Due to lack of sufficient data per category, no separate analyses 
stratified by treatment strategy could be performed. As longitudinal studies were 
expected to differ less in treatment strategy and follow-up time between individual 
patients than cross-sectional studies, analyses were performed separately for 
longitudinal versus cross-sectional studies. Only two cognitive functioning domains 
were tested by enough longitudinal and cross-sectional studies to perform and 
compare both analyses, hindering extensive comparison between the two study 
designs. Studies directly comparing different treatment strategies should be 
performed to determine the effect of treatment strategy on quality of life and 
cognitive functioning improvement and normalization. 
 
As there were already few articles included per category, no sensitivity analysis with 
only low risk of bias studies could be performed. Only two of the included articles 
had low risk of bias on all components. Most of the included articles were not low risk 
of bias because they had too high loss to follow-up or because they selected patients 
based on remission status. High loss to follow-up could have caused bias in 




important to participate in quality of life research, our results may be too 
pessimistic, meaning that the improvement after treatment is actually larger than we 
observed. Publication bias was minimized by searching for otherwise unpublished 
meeting abstracts in Embase, Web of Science, and COCHRANE Library. This did not 
lead to additional data. 
 
As glucocorticoid excess is known to cause not only physical symptoms, but also 
reduced quality of life and cognitive symptoms (2-3), improvement in quality of life 
and cognitive functioning after treatment of Cushing’s syndrome could be explained 
by the normalization of cortisol concentrations with accompanying reduction in 
physical symptoms of Cushing’s syndrome. Lack of normalization of quality of life and 
cognitive functioning after treatment might be explained by the structural and 
functional brain abnormalities observed in patients with active Cushing’s syndrome, 
that even persist after long-term remission of Cushing’s syndrome (5). The partial 
normalization in cognitive functioning found in this study has not been described 
previously. Only the results from two small cohort studies showed clear normalization 
in cognitive functioning (54, 59). Larger cohort or cross-sectional studies, or 
(randomized controlled) trials comparing different treatment methods, are necessary 
to confirm the normalization in cognitive functioning observed in these two small 
cohort studies. Theoretically, partial normalization in cognitive functioning might be 
explained by the involvement of different brain regions in cognitive functioning tasks 
that showed normalization, than the brain regions affected by structural and 
functional abnormalities as described above. 
 
In conclusion, treatment of Cushing’s syndrome is the first effective step in improving 
quality of life and cognitive functioning. However, the most effective treatment 
regimen for Cushing’s syndrome regarding improvement in quality of life and 
cognitive functioning is still unknown, and probably consists of a multidisciplinary 
approach of at least endocrinology, surgery, and psychology, as well as early 
diagnosis to minimize permanent structural and functional brain abnormalities. As no 
normalization could be achieved in quality of life and part of the cognitive 
functioning domains, patients require special attention from the clinician for quality 
of life as well as for cognitive functioning after effective treatment for Cushing’s 
syndrome. Interventions for further improvement and possibly normalization of 
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Hypercortisolism is the cause of numerous and potentially severe complications, 
which are often underestimated and not well recognized in clinical practice (1-3). 
There are two main causes for hypercortisolism. Firstly, exogenous hypercortisolism 
through corticosteroid use, which is highly prevalent, since around 1% of the general 
population uses corticosteroids (4, 5). Secondly, endogenous Cushing’s syndrome, 
which is a rare condition, but the disease burden is considerable through its increased 
morbidity and mortality risks (2, 3, 6). To increase our knowledge on the effects of 
endogenous hypercortisolism, large-scale studies are necessary, as single-center 
cohort studies often have insufficient power due to the small patient population. In 
this thesis, we present several meta-analyses, one population-based cohort study 
from Denmark, and combined data from two single-center cohorts from tertiary 
referral centers in Leiden and Berlin. 
 
 
Part I: Complications of corticosteroid use 
 
Corticosteroids are widely used for various conditions, such as inflammatory disease, 
malignancies, and organ transplantation, in order to suppress an inflammatory 
response, although many complications and side effects are known (5, 7). In this 
thesis, Chapter 2, Chapter 3, and Appendix I discuss potential complications of 
exogenous hypercortisolism due to corticosteroid use.  
 
Corticosteroid use is the most common cause of adrenal insufficiency, by suppression 
of the hypothalamus-pituitary-adrenal (HPA) axis. Adrenal insufficiency is a serious 
and potentially life-threatening situation (8). In Chapter 2 and Appendix I, the 
proportion of patients that develop adrenal insufficiency after use of corticosteroids 
was studied in a systematic review. Results were stratified by route of 
administration, underlying disease, treatment dose, and treatment duration, to 
identify patients with high risk of adrenal insufficiency. From the literature, 74 
articles with 3,753 patients were included in this meta-analysis. Percentage of 
adrenal insufficiency varied widely, from 4.2% for nasal administration to 52.2% for 
intra-articular administration. There was no administration form, treatment dose, 
treatment duration, or underlying disease for which adrenal insufficiency could 
certainly be excluded. The lowest risk of adrenal insufficiency (1.4%) was for patients 
after short-term use of corticosteroids, and the highest risk (60.0%) for patients with 
hematological malignancies. Therefore, in clinical practice, both patients and 
clinicians should be informed of the risk and symptoms of adrenal insufficiency after 
use of corticosteroids, and the threshold to test corticosteroid users for adrenal 
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insufficiency should be low. However, how to test for adrenal insufficiency in a 
population of corticosteroid users, and when to expect improvement, remains 
difficult, especially if the dose of corticosteroids is reduced but not withdrawn. The 
importance of testing for adrenal insufficiency and the need for treatment, despite 
imperfect tests, is discussed further in Appendix II. 
 
To identify a potentially increased mortality risk in patients using corticosteroids 
compared to non-users, patients with the same disease should be compared to 
minimize an effect of the underlying disease per se on mortality risk. Chapter 3 
describes a population-based cohort study, situated in Denmark (n=5,289,261), on 
mortality risk in patients with perforated diverticular disease comparing patients that 
use corticosteroids with non-users. The study included 4,640 patients with perforated 
diverticular disease, of whom 19.3% had used corticosteroids for various underlying 
diseases. Mortality risk was doubled for patients with recent corticosteroid use after 
full adjustment for potential confounders. Highest mortality risk was 52.5% mortality 
within one year for patients who started using corticosteroids within 90 days before 
hospital admission. To assess potential confounding by indication for corticosteroid 
use on mortality, several sensitivity analyses were performed excluding high-risk 
patient populations, e.g. patients with malignancies. These sensitivity analyses 
showed similar results to the main analysis, suggesting confounding by indication was 
not fully explaining mortality risk after corticosteroid use in patients with perforated 
diverticular disease. Hence, use of corticosteroids should be regarded as an 
important risk factor for mortality in clinical practice among patients with perforated 
diverticular disease. 
 
It was already well known that corticosteroid use is the cause of various 
complications and side effects (1). Our studies added information to the knowledge 
of complications of corticosteroid use regarding adrenal insufficiency and mortality 
risk. However, it is a common misconception that low-dose, short-term use of 
corticosteroids, or the use of only inhalation corticosteroids, is risk-free (9). Risk of 
adrenal insufficiency exceeds 50% in long-term (>1 year), high-dose corticosteroid 
use, and is higher in systemic use rather than inhalation use only, but even patients 
with short-term (<1 month), low-dose use, or inhalation only, are at risk of adrenal 
insufficiency. Mortality risk in patients with perforated diverticular disease is 
increased similarly regardless of corticosteroid dose, and it is increased in inhalation 
corticosteroid use only as well, although less pronounced. Given the mechanism of 
action of corticosteroids, it is likely that this increased mortality risk is not restricted 
to patients with perforated diverticulitis. 
 
Besides adrenal insufficiency and increased mortality risk, patients using 




cardiovascular disease, myopathy, cataracts and glaucoma, neuropsychiatric 
disturbances, and immunosuppression (10). Considering these risks of severe 
complications, all corticosteroid-using patients should be monitored adequately, 
which includes periodical physical check-ups and (laboratory) measurements (e.g. 
lipids, glucose) for adults every 3-6 months in the first year, and subsequently every 
12 months (10). Currently, there is no clinical guideline available specifically for the 
evaluation of possible adrenal insufficiency after use of corticosteroids, and 
therefore, clear guidance on recovery of the HPA-axis is lacking. In general, screening 
for adrenal insufficiency should be performed at least 18-24 hours after last short-
acting corticosteroid dose (i.e. hydrocortisone) by measuring early morning serum 
cortisol, and by performing an adrenocorticotropic hormone (ACTH) stimulation test 
if morning cortisol concentration is between 3 and 15 µg/dL (i.e. 83-414 nmol/L) 
(11). We suggest screening at least those patients with nonspecific symptoms after 
cessation of corticosteroid use. Because recognition and screening of complications of 
corticosteroid use in clinical practice is currently insufficient, the use of 
corticosteroids should be minimized if clinically feasible. 
 
 
Part II: Treatment outcome in Cushing’s syndrome 
 
In contrast to exogenous hypercortisolism, endogenous hypercortisolism is very rare, 
with an incidence of 1.2-2.4 per million persons each year (12). Cushing’s disease, 
caused by a pituitary adenoma, and other causes of endogenous Cushing’s syndrome, 
most often caused by an adrenal adenoma or an ectopic ACTH-producing tumor, are 
characterized by severe hypercortisolism with increased morbidity and mortality 
rates, if left untreated (2, 3, 6). Therefore, patients should be treated without delay 
(13). Chapters 4 to 6 describe the results of our studies on treatment options for 
Cushing’s disease and other causes of endogenous Cushing’s syndrome. 
 
Cushing’s disease is the most prevalent underlying cause of endogenous 
hypercortisolism (12). For Cushing’s disease, the first-choice treatment option is 
transsphenoidal selective adenomectomy (14). For this surgical procedure, two 
techniques are in use: microscopy and endoscopy. Microscopic surgery is the older 
procedure, in which the neurosurgeon observes a direct, three-dimensional image of 
the pituitary by looking through the microscope (15). Endoscopic surgery is newer, 
and, by means of a camera attached to the end of the endoscope, allows the 
neurosurgeon a closer look at the pituitary, including angles that are impossible to 
visualize with the microscope, however losing the three-dimensional vision (16). In 
Chapter 4, we described both techniques in our cohort of patients treated in the 
Leiden University Medical Center (LUMC) to assess potential differences regarding 
remission rate, mortality risk, or short- and long-term complications. We included 
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137 patients, of whom 87 were treated microscopically, and 50 endoscopically. We 
found no clear advantage of either technique for the treatment of Cushing’s disease. 
When the results were stratified by tumor size, patients with macroadenomas had a 
lower risk of recurrence after microscopic surgery than after endoscopic surgery. 
Theoretically however, endoscopic surgery is expected to perform better, especially 
in patients with large or invasive tumors, because the entire tumor can be visualized, 
which is not always possible with microscopy. Possibly, the advantage of microscopic 
surgery for patients with macroadenomas found in our study was due to the selected 
population of patients with macroadenomas, as patients with large and invasive 
tumors may have been more often referred to our center than patients with non-
invasive macroadenomas. Patients with large and invasive tumors have a worse 
prognosis despite treatment, and they are more often treated endoscopically than 
patients with non-invasive and smaller tumors, which can lead to biased results. 
Selective patient referral resulted in eight endoscopically treated (50%) versus five 
microscopically treated (28%) patients with macroadenomas and cavernous sinus 
invasion in our cohort. However, excluding these patients in a sensitivity analysis did 
not largely alter the results.  
 
To compare the results from our center to the results reported in literature, in 
Chapter 5, we performed a systematic review and meta-analysis on the same topic, 
microscopic versus endoscopic transsphenoidal adenomectomy. We included 97 
articles with 6,695 patients in total, of whom 5,711 were treated microscopically and 
984 endoscopically. We found no clear differences in remission, recurrence, or 
mortality rates. Most complications occurred similarly in both surgical techniques. 
Cerebrospinal fluid leakage occurred more often in endoscopic surgery, whereas 
transient diabetes insipidus occurred more often in microscopic surgery. If only 
microadenomas were considered, no difference between both techniques regarding 
remission or recurrence rate was found, in accordance with our cohort study. 
However, for macroadenomas only, we found a higher remission rate and lower 
recurrence rate after endoscopy compared to microscopy, opposing the results from 
our cohort study. The difference in outcome between our cohort study and 
systematic review underlines the importance of standardized outcome measures, 
internationally shared definitions, and combining data from multiple centers before 
making recommendations for clinical practice.  
 
As endoscopic surgery is the newer technique, there is on average less experience 
with this technique than with microscopic surgery. Especially in the first years after 
switching to endoscopy in a specific center, worse results may be expected, which 
will improve with increasing experience (17-20). This should be taken into account in 
interpreting comparisons between both techniques. In Chapter 4, we assessed this 




with subsequent years. However, no learning curve was found for endoscopic surgery, 
which may be due to the small population size and thus low statistical power. For 
clinical practice, the results of Chapter 5 suggest that endoscopic surgery is the 
preferred method for treating patients with Cushing’s disease and a macroadenoma. 
Microscopic surgery can be used based on neurosurgeon’s preference, but for 
macroadenomas referral to a center specialized in endoscopic surgery should be 
considered. No transient worsening of outcomes was seen in our center during the 
transition to endoscopic surgery, which may be reassuring for other centers 
considering transitioning, although evaluation of this new method should be 
performed per treatment center. 
 
Although transsphenoidal adenomectomy is the preferred treatment method for 
Cushing’s disease, other treatment options are in practice for patients with a 
contraindication for transsphenoidal surgery, persistent or recurrent disease, and for 
patients who refuse surgery. These treatment options include cortisol-lowering 
medical therapy (steroidogenesis inhibitors, glucocorticoid receptor antagonists, 
cabergoline, and pasireotide), radiotherapy, and bilateral adrenalectomy, and can 
likewise be used for patients with endogenous Cushing’s syndrome (13, 21). Bilateral 
adrenalectomy always leads to complete adrenal insufficiency, necessitating life-long 
hydrocortisone and fludrocortisone replacement therapy (8). A common complication 
of radiotherapy is hypopituitarism with corresponding hormone replacement therapy, 
and additionally radiotherapy usually takes several months before the first beneficial 
effects become apparent (13). Therefore, both bilateral adrenalectomy and 
radiotherapy are not recommended as first-line treatment options (13), and medical 
treatment is increasingly initiated. To estimate the effectiveness of medical 
treatment, we performed a systematic review and meta-analysis in Chapter 6. We 
included 35 articles with 1,520 patients with Cushing’s disease or other causes of 
endogenous Cushing’s syndrome using six different kinds of cortisol-lowering medical 
treatment. Average duration of follow-up per study was 2 weeks to 11.5 years, with a 
majority of short-term studies. Cortisol secretion normalization ranged from 35.7% 
(cabergoline) to 81.8% (mitotane). However, medical agents with higher effectiveness 
regarding cortisol normalization also led to a higher percentage of patients with side 
effects, and vice versa. Patients using multiple medical agents simultaneously, or 
consecutively, showed a higher percentage of cortisol normalization (65.7%) than 
patients on monotherapy (49.4%). The percentage of patients with Cushing’s disease 
with normalized cortisol is lower than after first-line transsphenoidal surgery, but it 
is comparable with remission rates after repeat transsphenoidal surgery, as described 
in Chapter 5. This suggests that medical treatment is a valuable alternative to 
transsphenoidal surgery for patients with a contraindication for surgery, persistent or 
recurrent disease, and for patients who refuse surgery. However, long-term 
effectiveness and side effects have not been investigated in detail, including the 
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effects on quality of life. This is relevant for these patients, as they will need life-
long cortisol-lowering medication if this treatment strategy is considered necessary. 
Even after the introduction of a treatment method or medical agent, assumptions 
about effectiveness and side effects or complications should be confirmed or 
rejected. For Cushing’s disease, our meta-analysis suggests that the presumed 
advantage of endoscopic surgery exists only for macroadenomas, but not for 
microadenomas. We also found that medical treatment is as effective and safe as 
repeat transsphenoidal surgery, extending the range of reasonable treatment options 
for patients with Cushing’s disease. However, medical treatment must be 
administered life-long and will never normalize pulsatile hormone secretion, which 
may be important for long-term morbidity and quality of life of these patients. 
Knowledge on the optimal treatment method as well as a broad range of effective 
treatment options are essential in reducing the high disease burden due to the 
severity of untreated Cushing’s disease and Cushing’s syndrome. To optimize use of 
existing treatment methods in clinical practice, future studies could investigate 
which cortisol-lowering medical agent should be administered first, and which 
combination of medical agents is most effective and safe in the treatment of 
Cushing’s disease and Cushing’s syndrome. Furthermore, patient registries with 
longer-term follow-up are needed to investigate long-term effectiveness and safety 




Part III: Clinical outcome in Cushing’s syndrome 
 
The clinical consequences of Cushing’s disease and Cushing’s syndrome, both before 
and after effective treatment, can be severe, and it is often unknown which patients 
are at a higher risk of specific morbidities. Chapters 7 to 9 describe a range of 
clinical outcomes in patients with Cushing’s disease and Cushing’s syndrome. To 
determine which patients are at risk of specific clinical outcomes, prediction models 
can be used to find risk factors and stratified analysis can be performed to compare 
categories of patients. We decided to investigate sex as a potential risk marker for 
specific clinical outcomes. Sex-based differences were hypothesized due to the 
different clinical pictures for males and females encountered in clinical practice. 
After investigating a potential risk marker for clinical outcomes, we studied two 
clinical outcomes known to be affected before treatment: quality of life and 
cognitive functioning. We were interested if successful treatment of Cushing’s 
syndrome is also effective in improving, or even normalizing, quality of life and 
cognitive functioning. Furthermore, we chose to investigate the occurrence of 
adrenal crisis after treatment, as this is a severe potential complication after 




occurrence of adrenal crisis may differ between patients previously exposed to 
hypercortisolism and other adrenal insufficient patients. Due to the previous 
hypercortisolism, the activity of the HPA-axis may have altered the ability to respond 
to cortisol deficiency in patients with treated Cushing’s syndrome. Furthermore, 
previous hypercortisolism can facilitate the occurrence of the corticosteroid 
withdrawal syndrome in the presence of acceptable cortisol concentrations, meaning 
that these patients need higher hydrocortisone replacement doses than other adrenal 
insufficient patients (22). This may lead to a higher incidence of adrenal crises in 
patients with treated Cushing’s syndrome due to reduced awareness of symptoms, 
and insufficient replacement doses in case of a withdrawal syndrome.  
 
For Cushing’s syndrome, different treatment methods are recommended per etiology, 
but no further individualized treatment is currently implemented in clinical practice. 
However, Cushing’s disease is more prevalent in females than males, and males are 
thought to have a higher risk of ectopic Cushing’s syndrome (23). Whether treatment 
decisions should therefore be sex-specific is uncertain. In Chapter 7, we performed a 
cohort study of patients with ACTH-dependent Cushing’s syndrome from Leiden and 
Berlin, comparing males and females before and after surgery, to assess sex as a risk 
marker for disease severity and complications. We included 130 patients, of whom 37 
were male and 93 female patients. Although both sexes had similar serum and urinary 
cortisol concentrations, ACTH concentrations were higher in males than females at 
time of diagnosis. Given previous reports in the literature of high ACTH in male 
patients with Cushing’s syndrome (24-27), a higher proportion of ectopic Cushing’s 
syndrome and/or pituitary macroadenomas was expected in male patients, as these 
have also been associated with high ACTH concentrations (28, 29). However, we 
found no differences regarding etiology of Cushing’s syndrome (i.e. Cushing’s disease 
or ectopic Cushing’s syndrome) or pituitary tumor size between both sexes, nor did 
we find a difference in diagnostic or therapeutic strategy, or surgical outcome 
including remission and recurrence rate. Males had more often osteoporosis both 
before and after surgery, with accompanying vertebral fractures, and more often 
anemia directly after surgery than females. In view of the similar surgical outcome 
and lack of differences regarding etiology and pituitary tumor size, no sex-based 
diagnostic strategy or treatment for Cushing’s disease or Cushing’s syndrome is 
recommended. However, extra attention should be given to bone mineral density in 
male patients to diagnose osteoporosis in time, in order to prevent (further) 
complications, such as vertebral fractures. This may be equally important for males 
with hypercortisolism due to other causes than endogenous Cushing’s syndrome, e.g. 
corticosteroid use. 
 
In evaluating treatment effect for Cushing’s disease, normalization of cortisol 
concentrations, and if possible, cortisol secretion, is generally considered the most 
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important treatment outcome. However, comorbidity and complications due to 
hypercortisolism before treatment may persist after and despite treatment. 
Therefore, presence of comorbidity and occurrence of complications (e.g. 
osteoporosis) should also be considered as important markers for successful 
treatment. Mortality risk is high in patients with untreated Cushing’s disease (6). 
Even after successful treatment, mortality risk in patients with Cushing’s disease 
remains increased compared to the general population (30). One of the reasons for 
the increased mortality risk after successful treatment for Cushing’s disease may be 
the occurrence of an adrenal crisis. Adrenal crisis is a potentially life-threatening 
complication of adrenal insufficiency due to acute and severe glucocorticoid 
deficiency, which can develop after any illness or psychological stress (31). Patients 
with previous hypercortisolism due to Cushing’s syndrome are at risk of adrenal crisis 
if they are adrenal insufficient after successful surgery, but the extent of this risk is 
unknown. Furthermore, the diagnosis of adrenal crisis is inconsistent in existing 
literature due to lack of a common definition, which decreases comparability 
between existing studies. Chapter 8 describes a cohort study including patients with 
Cushing’s disease and Cushing’s syndrome due to an adrenal adenoma with adrenal 
insufficiency after successful surgical treatment from Leiden and Berlin. We included 
106 patients, of whom 19 had a total of 41 adrenal crises. Nine adrenal crises (95% 
confidence interval: 6.7-12.0) occurred per 100 patient-years at risk. The risk of 
adrenal crisis was higher for patients with previous Cushing’s disease than for 
patients with adrenal Cushing’s syndrome. As a higher risk of adrenal insufficiency 
and therefore adrenal crisis might be expected after adrenalectomy, the lower risk 
suggests greater awareness in patients with adrenal Cushing’s syndrome, and thereby 
timely treatment of early symptoms of adrenal crisis. This may be due to better 
education after adrenalectomy than after transsphenoidal surgery. Another 
explanation may be the presence of other pituitary hormone deficiencies in patients 
treated for Cushing’s disease, which seemed to increase the vulnerability for adrenal 
crisis in our study. The risk of adrenal crisis in previous Cushing’s disease may 
partially explain the increased mortality risk after successful treatment for Cushing’s 
disease, although in the current study we did not investigate mortality due to the low 
number of deaths. This also means that mortality due to adrenal crisis is relatively 
low in patients with treated Cushing’s syndrome. A systematic review found six 
deaths related to adrenal crisis among 203 patients during 29-235 months of follow-
up (32). However, mortality risk due to adrenal crisis in patients with treated 
Cushing’s syndrome needs to be investigated further in larger patient registries. 
Previous crisis was a risk factor for recurrent crisis. Patients with at least one adrenal 
crisis had more complications after surgery than patients without any adrenal crisis, 
including anterior pituitary hormone deficiencies and diabetes insipidus. Effectively 
educating patients and endocrine nursing staff is essential in preventing adrenal crisis 




adrenal crisis in patients with previous hypercortisolism can aid focusing education in 
preventing adrenal crisis on the proper patients. 
 
Considering that patients with previous hypercortisolism are at risk of developing new 
complications (i.e. adrenal crisis) after successful treatment, and that mortality risk 
is still increased after treatment, other clinical outcomes may remain equally 
impaired after treatment. The glucocorticoid excess in patients with Cushing’s 
disease and Cushing’s syndrome is associated with impaired quality of life and 
reduced cognitive functioning (3, 33, 34). In Chapter 9, we performed a systematic 
review and meta-analysis evaluating quality of life and cognitive functioning after 
treatment for Cushing’s disease and Cushing’s syndrome. We compared scores after 
treatment with scores before treatment to assess improvement, and we compared 
scores after treatment with scores from a healthy control population to assess 
normalization of quality of life and cognitive functioning. We included 47 articles 
with a total of 2,643 patients. Both quality of life and cognitive functioning improved 
after treatment. However, quality of life did not normalize, and cognitive functioning 
only partially normalized after treatment compared to a healthy control population, 
which may be explained by long-lasting, or even irreversible effects of 
hypercortisolism on the brain (33). Considering the lack of normalization of quality of 
life and partially of cognitive functioning, further research is required to develop 
effective interventions for further improvement, and possibly normalization. Until 
then, clinicians should pay extra attention to quality of life and cognitive functioning 
after treatment of Cushing’s disease and Cushing’s syndrome. 
 
The before described outcomes and risk marker for adverse clinical outcomes were 
selected based on the literature, clinical experience, and known biological rationale. 
Although we selected these carefully, our expectations were not always confirmed in 
a clinical study, e.g. sex-based diagnostic and treatment decisions for Cushing’s 
syndrome could not be recommended based on our study results. Besides etiology and 
sex, more risk factors for adverse clinical outcomes in Cushing’s syndrome should be 
investigated to increase the potential for individualized treatment. In the case of 
Cushing’s disease, potential risk factors could be the size of the pituitary adenoma 
and preoperative comorbidity, such as diabetes mellitus. However, even if 
differences between study groups are confirmed, this does not automatically mean 
that different treatment strategies should be recommended. Whereas it is not always 
predictable on which characteristics clinical outcomes depend, treatment of 
hypercortisolism does not seem to completely resolve morbidity and mortality rate 
seen without treatment. Therefore, treatment of patients with Cushing’s syndrome 
should expand beyond treatment of hypercortisolism to further reduce morbidity and 
mortality rates. 
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Future research perspectives 
 
The studies in this thesis on various aspects of hypercortisolism emphasize the 
importance of suppressing cortisol secretion to physiological ranges. Both 
hypercortisolism and adrenal insufficiency have enormous, and sometimes 
deleterious, impact, both on physical and psychological functioning. Treatment of 
hypercortisolism and adrenal insufficiency attempting to restore normal cortisol 
concentrations representing the physiological circadian rhythm does not eliminate 
risk of adverse outcomes.  
 
To provide patients with rare endocrine conditions, such as Cushing’s syndrome, with 
equal expert specialized care throughout Europe, the European Reference Network 
on Rare Endocrine Conditions (Endo-ERN) was recently established (35). Via an Endo-
ERN reference center, a multidisciplinary expert team can be consulted to provide an 
advice based on combined specialist expertise throughout Europe (Figure 1) (36). This 
facilitates the correct identification of the underlying disease in hypercortisolemic 
patients, thereby reducing delay in the diagnostic process, and promoting earlier 
referral to a specialized center. Furthermore, the multidisciplinary team can aid with 
treatment decisions, e.g. for patients with persistent or recurrent Cushing’s disease, 
or ectopic Cushing’s syndrome without a clear source of ACTH-production. 
 
What Endo-ERN represents for patient care, international patient registries are for 
clinical research. For improvement of knowledge and expertise on rare endocrine 
conditions, international exchange of information through these patient registries is 
crucial. This increases the population size and therefore accuracy of gained 
knowledge through research compared to single-center cohort studies. Unfortunately, 
awareness of and participation rate in these international registries is relatively low. 
Recently, the European Registries for Rare Endocrine Conditions (EuRRECa, 
https://eurreca.net/), which will be fed by, and coupled to, Endo-ERN, was also 
funded by the European Union’s health programme. Besides developing new 
international registries for endocrine conditions that are not covered in a registry 
yet, awareness of and participation in existing registries should increase to optimize 
functioning of both the Endo-ERN and patient registries, which is a process under 
development (37). Patient registries provide information on specific rare diseases, 
which can be supplemented with knowledge from the Endo-ERN on unusual cases 
regarding clinical picture, diagnosis or treatment. Combined, they contribute 






Figure 1: Consultation of a multidisciplinary team (MDT) by an European Reference Network on rare 
endocrine conditions (Endo-ERN) reference center on behalf of the patient, bringing expert specialized care 
to all patients in Europe through the Clinical Patient Management System (CPMS), derived from the Endo-
ERN website (36). 
 
To effectively increase our knowledge concerning hypercortisolism, it is of paramount 
importance to clearly define and recognize all states of cortisol excess and cortisol 
deficiency, as well as all clinical outcomes considered. For some diagnoses 
classification is especially challenging, e.g. in case of adrenal insufficiency, 
considering the non-specific symptoms, and the multiple steps necessary for 
establishing the correct diagnosis (presence of hypocortisolism, level of HPA-axis 
dysfunction, and exact cause of adrenal insufficiency). Only if all research groups use 
the same definitions, data can be compared to each other, both directly in meta-
analyses, and indirectly in separate trials and cohort studies. Furthermore, 
definitions used in research should match clinical definitions, to ensure study 
outcomes are applicable to clinical practice. Future studies should focus on which 
combination of tests (serum cortisol, urinary cortisol, salivary cortisol, cortisol 
suppression tests, and -stimulation tests) is ideal for diagnosing Cushing’s syndrome, 
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and what the diagnostic consequences are of inconsistent test results. Moreover, 
future research should also concentrate on how to differentiate between Cushing’s 
syndrome and pseudo-Cushing states, which show increased cortisol concentrations as 
well as varying degrees of symptoms associated with Cushing’s syndrome. These 
results can be used in collectively deciding on an improved definition for Cushing’s 
syndrome that can be used in both research settings as well as clinical practice. 
Future meta-analyses, which include only studies that use the same definitions for 
diagnosis of disease and clinical outcomes, will be more valuable and easy to 
interpret than the presently available meta-analyses. However, as this is currently 
impossible due to use of various definitions in individual studies, authors of meta-
analyses should consider carefully which conclusions can be drawn from the data and 
to which patients these conclusions are applicable, which we were able to do in all 
meta-analyses presented in this thesis. 
 
Consistent definitions are essential for the optimal functioning of research and 
patient care. International patient registries supply a large collection of data on rare 
diseases that is impossible for a single center to assemble. If consistent definitions 
are used by all participating centers, these registries provide an excellent 
opportunity to perform large-scale investigations on rare diseases with rare 
outcomes, e.g. to find risk factors for adrenal crisis after treatment for Cushing’s 
syndrome. However, data collection should match potential research questions, and 
addition of data should be possible. E.g. in the European Register on Cushing’s 
Syndrome (ERCUSYN) no data on adrenal crisis are available, and retrospective 
addition of data is difficult, if not impossible (23). Furthermore, current patient 
registries are only suited to investigate a specific rare disease, such as Cushing’s 
syndrome, whereas a registry for comparing patients with different underlying 
diseases but similar clinical presentations is still lacking. Such a registry could allow 
us to compare patients with hypercortisolism from various etiologies. Understanding 
of differences and similarities between the underlying diseases can lead to a more 
accurate adaptation of clinical guidelines for specific patient categories with various 
forms of hypercortisolism. Future research on patients with Cushing’s syndrome using 
these large-scale patient registries should primarily aim to directly compare cortisol-
lowering medical agents and look into long-term effectiveness and side effects. 
Furthermore, randomized controlled trials should be performed to directly compare 
the most promising medical agents with the highest effectiveness and lowest risk of 
side effects. Knowledge on preferred medical agent, or combination of agents, can 
improve treatment options for patients with persistent or recurrent Cushing’s 






Finally, increasing knowledge on the effects of both endogenous Cushing’s syndrome 
and exogenous hypercortisolism is likely to improve patient care beyond the 
endocrinology department, as these conditions serve as a model for long-term 
exposure to stress, which is a highly prevalent condition. Insight into the potential 
consequences of long-term stress exposure, both during periods of stress as well as 
after abrogation of the stress-inducing situation, can aid all individuals exposed to 
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Hypercortisolisme veroorzaakt veel en mogelijk ernstige complicaties, die in de 
klinische praktijk vaak onderschat en slecht herkend worden (1-3). Er zijn twee 
belangrijke oorzaken voor hypercortisolisme. Ten eerste, exogeen hypercortisolisme 
door gebruik van glucocorticoïden, met een hoge prevalentie doordat ongeveer 1% 
van de bevolking glucocorticoïden gebruikt (4, 5). Ten tweede, het endogene 
syndroom van Cushing, een zeldzame aandoening met een hoge ziektelast door de 
verhoogde risico’s op morbiditeit en mortaliteit (2, 3, 6). Om onze kennis over de 
effecten van endogeen hypercortisolisme te vergroten zijn grootschalige studies 
nodig, want monocentrische cohortstudies hebben vaak onvoldoende bewijskracht 
door de kleine patiëntenpopulatie. In dit proefschrift presenteren wij enkele meta-
analyses, een cohortstudie op bevolkingsniveau uit Denemarken en gecombineerde 
data van twee cohortstudies van tertiaire referentiecentra uit Leiden en Berlijn. 
 
 
Deel I: Complicaties door gebruik van glucocorticoïden 
 
Glucocorticoïden worden veelvuldig gebruikt voor de behandeling van patiënten met 
een inflammatoire ziekte, maligniteit of orgaantransplantatie om een inflammatoire 
respons te onderdrukken, ondanks de bekende hoeveelheid complicaties en 
bijwerkingen (5, 7). In Hoofdstuk 2, Hoofdstuk 3 en Appendix I van dit proefschrift 
worden potentiële complicaties van exogeen hypercortisolisme als gevolg van 
glucocorticoïdgebruik besproken. 
 
Gebruik van glucocorticoïden onderdrukt de hypothalamus-hypofyse-bijnier (HPA) as 
en is de meest voorkomende oorzaak van bijnierschorsinsufficiëntie. Bijnier-
schorsinsufficiëntie is een ernstige en potentieel levensbedreigende situatie (8). In 
Hoofdstuk 2 en Appendix I bestudeerden wij de proportie patiënten met 
bijnierschorsinsufficiëntie na gebruik van glucocorticoïden in een systematische 
review. De resultaten zijn gestratificeerd per toedieningsvorm, onderliggende ziekte, 
behandelduur en behandeldosis, om patiënten te identificeren met een verhoogd 
risico op bijnierschorsinsufficiëntie. Wij includeerden 74 artikelen uit de literatuur in 
deze meta-analyse met in totaal 3.753 patiënten. Het percentage patiënten met 
bijnierschorsinsufficiëntie varieerde per toedieningsvorm van 4,2% bij nasale 
toediening tot 52,2% bij intra-articulaire toediening. Er was geen toedieningsvorm, 
behandelduur, behandeldosis of onderliggende ziekte waarvoor bijnierschors-
insufficiëntie met zekerheid uitgesloten kon worden. Het laagste risico op 
bijnierschorsinsufficiëntie (1,4%) hadden patiënten die glucocorticoïden gedurende 
korte termijn gebruikten en het hoogste risico (60,0%) patiënten met hematologische 
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maligniteiten. In de klinische praktijk zouden zowel patiënten als artsen 
geïnformeerd moeten worden over de risico’s en symptomen van bijnierschors-
insufficiëntie ten gevolge van glucocorticoidgebruik. De drempel om gebruikers van 
glucocorticoïden te testen op bijnierschorsinsufficiëntie zou laag moeten zijn. 
Echter, hoe te testen op bijnierschorsinsufficiëntie in een populatie gluco-
corticoïdgebruikers, en wanneer verbetering te verwachten is, blijft lastig, vooral als 
de dosis glucocorticoïden verlaagd is zonder volledig te stoppen. Het belang van 
testen op bijnierschorsinsufficiëntie en de noodzaak van behandeling, ondanks 
imperfecte tests, wordt verder bediscussieerd in Appendix II. 
 
Om een potentieel verhoogd mortaliteitsrisico op te sporen bij patiënten die 
glucocorticoïden gebruiken ten opzichte van niet-gebruikers, moeten patiënten met 
dezelfde ziekte bestudeerd worden om een effect van de onderliggende ziekte zelf 
op mortaliteitsrisico te minimaliseren. Hoofdstuk 3 beschrijft een cohortstudie op 
populatieniveau uit Denemarken (n=5.289.261), waarin mortaliteitsrisico voor 
patiënten met geperforeerde divertikelziekte vergeleken wordt tussen patiënten die 
glucocorticoïden gebruikten en niet-gebruikers. Deze studie bevatte 4.640 patiënten 
met geperforeerde divertikelziekte, van wie 19,3% glucocorticoïden gebruikten voor 
uiteenlopende onderliggende ziekten. Na correctie voor potentiële verstorende 
variabelen bleek het mortaliteitsrisico verdubbeld voor patiënten die recent 
glucocorticoïden gebruikten. Het hoogste mortaliteitsrisico was 52,5% mortaliteit 
binnen een jaar voor patiënten die met glucocorticoïdgebruik begonnen in de laatste 
90 dagen voor ziekenhuisopname. Om mogelijke verstoring van het effect door de 
indicatie voor glucocorticoïdgebruik te beoordelen hebben wij verschillende 
sensitiviteitsanalyses uitgevoerd, waarbij we hoog-risico populaties hebben 
uitgesloten, bijvoorbeeld patiënten met maligniteiten. De resultaten van deze 
sensitiviteitsanalyses waren vergelijkbaar met de hoofdanalyse, wat suggereert dat 
verstoring van het effect door indicatie voor glucocorticoïdgebruik geen afdoende 
verklaring is voor mortaliteitsrisico bij patiënten met geperforeerde divertikelziekte. 
Daarom moet gebruik van glucocorticoïden beschouwd worden als een belangrijke 
risicofactor voor mortaliteit in de klinische praktijk bij patiënten met geperforeerde 
divertikelziekte. 
 
Het was al bekend dat gebruik van glucocorticoïden leidt tot verschillende 
complicaties en bijwerkingen (1). Onze studies hebben informatie toegevoegd over 
complicaties van glucocorticoïdgebruik wat betreft bijnierschorsinsufficiëntie en 
risico op mortaliteit. Echter, het is een veelvoorkomend misverstand dat gebruik van 
glucocorticoïden in lage doseringen, of het gebruik van alleen inhalatiegluco-
corticoïden, geen risico’s zou opleveren (9). Het risico op bijnierschorsinsufficiëntie 
overstijgt 50% bij lange-termijn gebruik (>1 jaar) van hoog gedoseerde gluco-




maar toch houden zelfs mensen met korte-termijn (<1 maand) gebruik van laag 
gedoseerde glucocorticoïden, of alleen inhalatieglucocorticoïden, risico op 
bijnierschorsinsufficiëntie. De verhoging van het mortaliteitsrisico bij patiënten met 
geperforeerde divertikelziekte is onafhankelijk van de gebruikte dosis glucocorti-
coïden. Het mortaliteitsrisico is tevens verhoogd bij patiënten met geperforeerde 
divertikelziekte die alleen inhalatieglucocorticoïden gebruiken, alhoewel minder 
uitgesproken. Gegeven het werkingsmechanisme van glucocorticoïden is het 
waarschijnlijk dat het verhoogde mortaliteitsrisico niet beperkt is tot patiënten met 
geperforeerde divertikelziekte. 
 
Naast bijnierschorsinsufficiëntie en een verhoogd mortaliteitsrisico hebben patiënten 
die glucocorticoïden gebruiken risico op osteoporose en fracturen, diabetes mellitus, 
cardiovasculaire ziekte, myopathie, cataract en glaucoom, neuropsychiatrische 
klachten en immuunsuppressie (10). Gezien deze risico’s op ernstige bijwerkingen 
zouden alle patiënten die glucocorticoïden gebruiken adequaat gemonitord moeten 
worden, wat voor volwassenen inhoudt dat periodieke controles door een arts 
inclusief (lab)metingen (bijvoorbeeld lipiden en glucose) plaatsvinden, iedere 3-6 
maanden in het eerste jaar en daarna jaarlijks (10). Op dit moment is er geen 
klinische richtlijn voor de evaluatie van mogelijke bijnierschorsinsufficiëntie na 
gebruik van glucocorticoïden en daardoor is er geen duidelijk advies over herstel van 
de HPA-as. In het algemeen moet screening op bijnierschorsinsufficiëntie ten minste 
18-24 uur na de laatste dosis kortwerkende glucocorticoïden, zoals hydrocortison, 
plaatsvinden door het meten van het serumcortisol in de vroege ochtend en een 
adrenocorticotroop hormoon (ACTH) stimulatietest bij een serumcortisol tussen de 3 
en 15 µg/dL (dit is 83-414 nmol/L) (11). Wij stellen voor in ieder geval de patiënten 
met aspecifieke symptomen na afbouw van de glucocorticoïden te screenen. Omdat 
herkenning van en screening op complicaties van glucocorticoïdgebruik op dit 
moment onvoldoende is in de klinische praktijk, zou gebruik van glucocorticoïden 
moeten worden geminimaliseerd indien klinisch haalbaar. 
 
 
Deel II: Behandeluitkomsten bij het syndroom van 
Cushing 
 
In tegenstelling tot exogeen hypercortisolisme is endogeen hypercortisolisme extreem 
zeldzaam, met een incidentie van 1,2-2,4 per miljoen personen per jaar (12). De 
ziekte van Cushing, veroorzaakt door een hypofyseadenoom, en andere oorzaken van 
het endogene syndroom van Cushing, meestal veroorzaakt door een bijnieradenoom 
of een ectopische ACTH-producerende tumor, worden gekenmerkt door ernstig 
hypercortisolisme met verhoogde mortaliteit en morbiditeit indien onbehandeld (2, 3, 
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6). Daarom moeten deze patiënten zo snel mogelijk behandeld worden (13). 
Hoofdstukken 4 tot 6 beschrijven de resultaten van onze studies over behandelopties 
voor de ziekte van Cushing en andere oorzaken van het endogene syndroom van 
Cushing. 
 
De ziekte van Cushing is de meest voorkomende oorzaak van endogeen 
hypercortisolisme (12). Voor de ziekte van Cushing is transsfenoïdale selectieve 
adenomectomie de eerste keus behandeloptie (14). Voor deze chirurgische 
behandeling zijn twee technieken in gebruik: microscopie en endoscopie. 
Microscopische chirurgie is de oudere techniek, waarbij de neurochirurg een direct, 
driedimensionaal beeld van de hypofyse krijgt door te kijken door de microscoop 
(15). Endoscopische chirurgie is nieuwer en levert een beeld op dichterbij de 
hypofyse middels een camera aan het uiteinde van de endoscoop, waarbij echter het 
driedimensionale beeld verloren gaat. Met de endoscoop kan de hypofyse ook onder 
hoeken bekeken worden die met de microscoop onmogelijk zijn (16). In Hoofdstuk 4 
beschreven wij beide technieken in ons cohort patiënten uit het Leids Universitair 
Medisch Centrum (LUMC) om potentiële verschillen te beoordelen wat betreft 
remissie, mortaliteit en korte- en lange-termijn complicaties. We includeerden 137 
patiënten, van wie 87 microscopisch en 50 endoscopisch behandeld werden. We 
vonden geen duidelijk voordeel van een van beide technieken voor de behandeling 
van de ziekte van Cushing. Bij stratificatie van de resultaten naar tumorgrootte bleek 
dat patiënten met macroadenomen een lager risico op recidief hadden na 
microscopische chirurgie dan na endoscopische chirurgie. Echter, in theorie zou 
endoscopie betere resultaten moeten opleveren, vooral bij grote of invasieve 
tumoren, omdat de volledige tumor in beeld kan worden gebracht, wat met 
microscopie niet altijd mogelijk is. Mogelijk was in onze studie microscopische 
chirurgie een voordeel voor patiënten met macroadenomen door selectie, omdat 
patiënten met grote en invasieve tumoren mogelijk vaker naar ons centrum verwezen 
werden dan patiënten met niet-invasieve macroadenomen. Patiënten met grote en 
invasieve tumoren hebben een slechtere prognose ondanks behandeling en zij worden 
vaker endoscopisch behandeld dan patiënten met niet-invasieve en kleinere tumoren, 
wat kan leiden tot vertekende resultaten. Selectieve verwijzing van patiënten 
resulteerde in acht endoscopisch behandelde (50%) en vijf microscopisch behandelde 
(28%) patiënten met macroadenomen en invasie van de sinus cavernosus in ons 
cohort. Echter, het excluderen van deze patiënten in een sensitiviteitsanalyse 
veranderde de resultaten niet wezenlijk. 
 
Om de resultaten van ons centrum te vergelijken met de resultaten gerapporteerd in 
de literatuur hebben we in Hoofdstuk 5 een systematische review en meta-analyse 
uitgevoerd over hetzelfde onderwerp, microscopische versus endoscopische 




patiënten, van wie 5.711 microscopisch en 984 endoscopisch behandeld waren. We 
vonden geen duidelijk verschil in remissie, recidief of mortaliteit. De meeste 
complicaties kwamen bij beide technieken ongeveer even vaak voor. Liquorlekkage 
kwam vaker voor na endoscopie, terwijl tijdelijke diabetes insipidus vaker voorkwam 
na microscopie. Als alleen naar patiënten met microadenomen gekeken werd, was er 
geen verschil tussen beide technieken wat betreft remissie of recidiefkans, conform 
de bevindingen van onze cohortstudie. Echter, als alleen naar patiënten met 
macroadenomen gekeken werd, vonden we een hoger percentage patiënten in 
remissie en een lagere recidiefkans na endoscopie dan na microscopie, wat 
tegenstrijdig is met de resultaten van onze cohortstudie. Het verschil in uitkomst 
tussen onze cohortstudie en systematische review benadrukt het belang van 
gestandaardiseerde uitkomstmaten, internationaal geaccepteerde definities en het 
combineren van data uit verschillende centra voordat aanbevelingen worden gedaan 
voor de klinische praktijk. 
 
Doordat endoscopie nieuwer is, is er minder ervaring met deze techniek dan met 
microscopische chirurgie. Vooral in de eerste jaren na overstappen op endoscopie in 
een bepaald centrum kunnen slechtere resultaten geanticipeerd worden, die zullen 
verbeteren met een toename aan ervaring (17-20). Hier dient rekening mee gehouden 
te worden bij de interpretatie van vergelijkingen tussen beide technieken. In 
Hoofdstuk 4 onderzochten we deze potentiële leercurve in ons cohort door 
endoscopie in de vroegere jaren te vergelijken met navolgende jaren. We vonden 
echter geen leercurve voor endoscopische chirurgie, mogelijk door de kleine 
populatie en daardoor lage statistische bewijskracht. Voor de klinische praktijk 
suggereren de resultaten van Hoofdstuk 5 dat endoscopische chirurgie de beste 
behandelmethode is voor patiënten met de ziekte van Cushing en een 
macroadenoom. Microscopie kan gebruikt worden als de neurochirurg hier een 
voorkeur voor heeft, maar dan moet overwogen worden patiënten met een 
macroadenoom te verwijzen naar een ander centrum gespecialiseerd in 
endoscopische chirurgie. In ons centrum zagen wij geen tijdelijke verslechtering van 
de resultaten gedurende de transitie naar endoscopische chirurgie, wat voor andere 
centra die deze overstap overwegen geruststellend kan zijn, alhoewel deze nieuwe 
methode per behandelcentrum geëvalueerd moet worden. 
 
Alhoewel transsfenoïdale adenomectomie de eerste keus behandelmethode is voor 
patiënten met de ziekte van Cushing, zijn er andere methoden beschikbaar voor 
patiënten met een contra-indicatie voor transsfenoïdale chirurgie, persisterende 
ziekte of recidief, en voor patiënten die chirurgie weigeren. Deze behandelopties zijn 
cortisolverlagende medicatie (steroïdgenese-remmers, glucocorticoïdreceptor-
antagonisten, cabergoline en pasireotide), radiotherapie en bilaterale adrena-
lectomie, en deze kunnen ook gebruikt worden voor patiënten met het syndroom van 
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Cushing (13, 21). Bilaterale adrenalectomie leidt altijd tot volledige bijnierschors-
insufficiëntie, waardoor levenslange substitutietherapie met hydrocortison en fludro-
cortison nodig is (8). Een veelvoorkomende complicatie van radiotherapie is 
hypofyseuitval, waardoor hormoonsubstitutietherapie noodzakelijk is. Bovendien 
duurt het normaal gesproken enige maanden voordat de eerste gunstige effecten van 
radiotherapie bemerkt worden (13). Daarom worden zowel bilaterale adrenalectomie 
als radiotherapie niet aanbevolen als eerstelijns behandeloptie (13), en wordt 
behandeling met medicatie steeds vaker geïnitieerd. Om de effectiviteit van 
cortisolverlagende medicatie te schatten hebben we een systematische review en 
meta-analyse uitgevoerd in Hoofdstuk 6. We includeerden 35 artikelen met 1.520 
patiënten met de ziekte of andere oorzaken van het endogene syndroom van Cushing, 
die zes verschillende soorten cortisolverlagende medicijnen gebruikten. Gemiddeld 
per studie werden de patiënten 2 weken tot 11,5 jaar gevolgd, met een meerendeel 
aan korte-termijn studies. Normalisatie van de cortisolsecretie varieerde van 35,7% 
(cabergoline) tot 81,8% (mitotane). Echter, medicijnen met een grotere effectiviteit 
wat betreft normalisatie van de cortisolsecretie leidden tot een hoger percentage 
patiënten met bijwerkingen en vice versa. Patiënten die meerdere medicijnen 
tegelijkertijd of achtereenvolgens gebruikten lieten vaker normalisatie van de 
cortisolsecretie zien (65,7%) dan patiënten die slechts één medicijn gebruikten 
(49,4%). Het percentage patiënten met de ziekte van Cushing met een 
genormaliseerd cortisol door cortisolverlagende medicatie is lager dan na eerstelijns 
transsfenoïdale chirurgie, maar is vergelijkbaar met het percentage patiënten in 
remissie na herhaalde transsfenoïdale chirurgie, zoals beschreven in Hoofdstuk 5. Dit 
suggereert dat medicatie een waardevol alternatief is voor transsfenoïdale chirurgie 
voor patiënten met een contra-indicatie voor chirurgie, persisterende ziekte of 
recidief, en voor patiënten die chirurgie weigeren. Echter, lange-termijn effectiviteit 
en bijwerkingen zijn nog niet in detail onderzocht, inclusief de effecten op kwaliteit 
van leven. Dit is relevant voor deze patiënten, aangezien zij levenslang 
cortisolverlagende medicijnen nodig zullen hebben als deze behandelstrategie 
noodzakelijk geacht wordt. 
 
Ook na de introductie van een nieuwe behandelmethode of medicijn moeten 
aannames over effectiviteit en bijwerkingen of complicaties bevestigd of weerlegd 
worden. Voor de ziekte van Cushing suggereert onze meta-analyse dat het verwachte 
voordeel van endoscopische chirurgie alleen bestaat voor macroadenomen, maar niet 
voor microadenomen. Tevens vonden wij dat medicamenteuze behandeling net zo 
effectief en veilig is als herhaalde transsfenoïdale chirurgie, wat de behandel-
mogelijkheden voor patiënten met de ziekte van Cushing uitbreidt. Echter, 
cortisolverlagende medicatie moet levenslang gebruikt worden en zal nooit de 
pulsatiele hormoonafgifte normaliseren, wat belangrijk kan zijn voor lange-termijn 




behandelmethode en een breed aanbod aan effectieve behandelopties zijn essentieel 
in het verminderen van de hoge ziektelast van onbehandelde ziekte van Cushing en 
syndroom van Cushing. Om het gebruik van bestaande behandelmethoden in de 
klinische praktijk te optimaliseren kunnen toekomstige studies onderzoeken welk 
cortisolverlagend medicijn als eerst toegediend zou moeten worden en welke 
combinatie van medicijnen het meest effectief en veilig is in de behandeling van de 
ziekte en het syndroom van Cushing. Bovendien zijn patiëntenregisters die patiënten 
langdurig vervolgen nodig om de lange-termijn effectiviteit en veiligheid van 
cortisolverlagende medicijnen te onderzoeken, inclusief het effect op lange-termijn 
morbiditeit en kwaliteit van leven. 
 
 
Deel III: Klinische uitkomsten bij het syndroom van 
Cushing 
 
De klinische consequenties van de ziekte en het syndroom van Cushing kunnen ernstig 
zijn, zowel voor als na behandeling, en het is vaak onbekend welke patiënten een 
hoger risico op specifieke morbiditeit hebben. Hoofdstukken 7 tot 9 beschrijven een 
reeks klinische uitkomsten bij patiënten met de ziekte en het syndroom van Cushing. 
Om te bepalen welke patiënten risico lopen op specifieke klinische uitkomsten 
kunnen predictiemodellen gebruikt worden om risicofactoren te vinden en met 
gestratificeerde analyses kunnen categorieën patiënten vergeleken worden. We 
besloten geslacht te onderzoeken als potentiële risicomarker voor specifieke klinische 
uitkomsten. Geslachtsafhankelijke verschillen werden verondersteld op basis van het 
verschillende klinische beeld dat bij mannen en vrouwen gezien wordt in de kliniek. 
Na het bestuderen van een potentiële risicomarker voor klinische uitkomsten, 
onderzochten we twee klinische uitkomstmaten die voorafgaand aan behandeling 
aangedaan zijn: kwaliteit van leven en cognitief functioneren. We wilden weten of 
succesvolle behandeling van het syndroom van Cushing ook effectief is in het 
verbeteren, of zelfs normaliseren, van kwaliteit van leven en cognitie. Daarnaast 
kozen we ervoor het optreden van Addisonse crisis na behandeling te onderzoeken, 
aangezien dit een ernstige mogelijke complicatie na effectieve behandeling van de 
ziekte of het syndroom van Cushing is. Theoretisch kan het optreden van Addisonse 
crisis verschillen tussen patiënten met voormalig hypercortisolisme en andere 
bijnierschorsinsufficiënte patiënten. Door het voormalige hypercortisolisme is 
mogelijk het vermogen van de activiteit van de HPA-as om te reageren op 
cortisoldeficiëntie veranderd bij patiënten die behandeld zijn voor het syndroom van 
Cushing. Bovendien kan voormalig hypercortisolisme het optreden van het 
glucocorticoïdonttrekkingssyndroom faciliteren in aanwezigheid van acceptabele 
cortisolconcentraties, waardoor deze patiënten hogere hydrocortisonsubstitutiedoses 
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nodig hebben dan andere bijnierschorsinsufficiënte patiënten (22). Dit kan leiden tot 
een hogere incidentie van Addisonse crisen bij patiënten die behandeld zijn voor het 
syndroom van Cushing door een verminderde gewaarwording van de symptomen en 
onvoldoende substitutie in het geval van het onttrekkingssyndroom. 
 
Voor het syndroom van Cushing worden verschillende behandelmethoden aanbevolen 
per etiologie, maar momenteel wordt er geen verdere individualisatie van 
behandeling toegepast in de klinische praktijk. Echter, de ziekte van Cushing komt 
vaker voor bij vrouwen dan bij mannen en van mannen wordt gedacht dat zij een 
groter risico hebben op het ectopische syndroom van Cushing (23). Of als gevolg 
daarvan behandelkeuzes geslachtsafhankelijk zouden moeten zijn is onbekend. In 
Hoofdstuk 7 hebben wij een cohortstudie gedaan naar patiënten met ACTH-
afhankelijk syndroom van Cushing uit Leiden en Berlijn, waarbij we mannen en 
vrouwen voor en na chirurgische behandeling hebben vergeleken om te beoordelen of 
geslacht een risicomarker is voor ernst van de ziekte en complicaties. We hebben 130 
patiënten geïncludeerd, waaronder 37 mannen en 93 vrouwen. Alhoewel beide 
geslachten vergelijkbare cortisolconcentraties in het serum hadden, waren bij 
diagnose de ACTH-concentraties hoger bij mannen dan bij vrouwen. Gezien onze 
bevindingen overeenkomen met vermeldingen in de literatuur van hoog ACTH bij 
mannelijke patiënten met het syndroom van Cushing (24-27), verwachtten wij tevens 
een hogere proportie van het ectopische syndroom van Cushing en/of hypofysaire 
macroadenomen bij mannen, aangezien deze ook geassocieerd worden met hoge 
ACTH-concentraties (28, 29). Echter, wij vonden geen verschil wat betreft etiologie 
van het syndroom van Cushing (in dit geval de ziekte van Cushing of het ectopische 
syndroom van Cushing) of tumorgrootte van het hypofyseadenoom tussen beide 
geslachten. Ook vonden wij geen verschil in diagnostische of therapeutische strategie 
of in uitkomst van chirurgie inclusief remissie en recidief. Mannen hadden vaker 
osteoporose, zowel voor en na chirurgie, met begeleidende vertebrale fracturen, en 
ze hadden vaker anemie direct na chirurgie dan vrouwen. Vanwege de vergelijkbare 
behandeluitkomst en het gebrek aan verschil in etiologie en tumorgrootte van het 
hypofyseadenoom, wordt geen geslachtsafhankelijke diagnostiek of behandeling 
aanbevolen voor de ziekte of het syndroom van Cushing. Echter, er zou extra 
aandacht geschonken moeten worden aan de botdichtheid bij mannelijke patiënten 
om osteoporose tijdig te diagnosticeren, zodat (verdere) complicaties zoals 
vertebrale fracturen voorkomen kunnen worden. Dit is mogelijk ook belangrijk voor 
mannen met hypercortisolisme door andere oorzaken dan endogeen syndroom van 
Cushing, zoals gebruik van glucocorticoïden. 
 
Bij de evaluatie van de effectiviteit van behandeling voor de ziekte van Cushing 
wordt normalisatie van de cortisolconcentraties, en indien mogelijk, cortisolsecretie, 




comorbiditeit en complicaties door hypercortisolisme voorafgaand aan behandeling 
kunnen persisteren na en ondanks behandeling. Daarom zouden aanwezigheid van 
comorbiditeit en optreden van complicaties (zoals osteoporose) ook als belangrijke 
markers voor succesvolle behandeling moeten worden beschouwd. Mortaliteitsrisico is 
hoog in patiënten met onbehandelde ziekte van Cushing (6). Zelfs na succesvolle 
behandeling blijft het mortaliteitsrisico verhoogd in patiënten met de ziekte van 
Cushing in vergelijking met de algemene bevolking (30). Een van de redenen voor de 
verhoogde mortaliteit na succesvolle behandeling voor de ziekte van Cushing zou het 
optreden van een Addisonse crisis kunnen zijn. Een Addisonse crisis is een potentieel 
levensbedreigende complicatie van bijnierschorsinsufficiëntie door acute en ernstige 
glucocorticoïddeficiëntie, wat zich kan ontwikkelen na elke ziekte of psychologische 
stress (31). Patiënten met voormalig hypercortisolisme door het syndroom van 
Cushing lopen risico op een Addisonse crisis als zij bijnierschorsinsufficiënt zijn na 
succesvolle chirurgische behandeling, maar de rijkwijdte van dit risico is onbekend. 
Bovendien wordt Addisonse crisis inconsistent gediagnosticeerd in de bestaande 
literatuur door gebrek aan een algemeen geaccepteerde definitie, wat de 
vergelijkbaarheid tussen bestaande studies vermindert. Hoofdstuk 8 beschrijft een 
cohortstudie bestaande uit patiënten uit Leiden en Berlijn met de ziekte van Cushing 
en patiënten met het syndroom van Cushing door een bijnieradenoom, die 
bijnierschorsinsufficiënt zijn na succesvolle chirurgische behandeling. We 
includeerden 106 patiënten, van wie 19 in totaal 41 Addisonse crisen meemaakten. 
Negen Addisonse crisen (95% betrouwbaarheidsinterval: 6,7-12,0) deden zich voor per 
100 patiëntjaren met risico op Addisonse crisis. Het risico op Addisonse crisis was 
hoger voor patiënten met de ziekte van Cushing dan voor patiënten met het 
syndroom van Cushing door een bijnieradenoom. Aangezien een hoger risico op 
bijnierschorsinsufficiëntie en daardoor Addisonse crisis verwacht kan worden na 
adrenalectomie, suggereert het lagere risico een grotere gewaarwording bij 
patiënten met het syndroom van Cushing door een bijnieradenoom en daardoor 
tijdige behandeling van vroege symptomen van een Addisonse crisis. Dit kan komen 
door een betere educatie na adrenalectomie dan na transsfenoïdale chirurgie. Een 
andere mogelijke verklaring zou de aanwezigheid van andere hypofysehormoon-
deficiënties kunnen zijn bij patiënten die behandeld zijn voor de ziekte van Cushing, 
wat de kwetsbaarheid voor Addisonse crisis in onze studie leek te vergroten. Het 
risico op een Addisonse crisis in patiënten met voorheen de ziekte van Cushing 
verklaart mogelijk deels de verhoogde mortaliteit na succesvolle behandeling voor de 
ziekte van Cushing, alhoewel we in de huidige studie mortaliteit niet onderzocht 
hebben door een laag aantal overlijdens. Dit betekent ook dat mortaliteit door 
Addisonse crisis relatief laag is in patiënten behandeld voor het syndroom van 
Cushing. Een systematische review vond zes overlijdens gerelateerd aan Addisonse 
crisis onder 203 patiënten gedurende 29-235 maanden follow-up (32). Echter, 
mortaliteit door Addisonse crisis in patiënten behandeld voor het syndroom van 
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Cushing zou verder onderzocht moeten worden in grotere patiëntenregisters. Eerdere 
Addisonse crisis was een risicofactor voor een recidief crisis. Patiënten met ten 
minste één crisis hadden meer complicaties na chirurgie dan patiënten zonder crisis, 
namelijk hypofysevoorkwabsdeficiënties en diabetes insipidus. Effectieve educatie 
van patiënten en endocrinologieverpleegkundigen is essentieel in het voorkomen van 
Addisonse crisis bij patiënten behandeld voor hypercortisolisme. Toekomstig 
onderzoek naar risicofactoren voor Addisonse crisis bij patiënten met voormalig 
hypercortisolisme kan helpen de educatie om Addisonse crisis te voorkomen op de 
juiste patiënten te richten. 
 
Aangezien patiënten met voormalig hypercortisolisme risico lopen op het ontwikkelen 
van nieuwe complicaties (zoals Addisonse crisis) na succesvolle behandeling, en 
aangezien mortaliteit verhoogd blijft na behandeling, blijven andere klinische 
uitkomsten mogelijk evenzeer aangedaan na behandeling. Het teveel aan 
glucocorticoïden bij patiënten met de ziekte en het syndroom van Cushing is 
geassocieerd met verminderde kwaliteit van leven en verlaagd cognitief functioneren 
(3, 33, 34). In Hoofdstuk 9 beschrijven wij een systematische review en meta-
analyse, waarin kwaliteit van leven en cognitief functioneren na behandeling voor de 
ziekte en het syndroom van Cushing geëvalueerd worden. We vergelijken scores na 
behandeling met scores voor behandeling om eventuele verbetering te beoordelen en 
we vergelijken scores na behandeling met scores van een gezonde controlepopulatie 
om eventuele normalisatie van kwaliteit van leven en cognitief funtioneren te 
beoordelen. We includeerden 47 artikelen met in totaal 2.643 patiënten. Zowel 
kwaliteit van leven als cognitief functioneren verbeterde na behandeling. Echter, 
kwaliteit van leven normaliseerde niet, terwijl cognitief functioneren slechts 
gedeeltelijk normaliseerde na behandeling in vergelijking met een gezonde 
controlepopulatie, wat mogelijk verklaard kan worden door langdurige of zelfs 
irreversibele effecten van hypercortisolisme op het brein (33). Gezien het gebrek aan 
normalisatie van kwaliteit van leven en gedeeltelijk ook van cognitief functioneren, is 
vervolgonderzoek noodzakelijk om effectieve interventies te ontwikkelen voor 
verdere verbetering en mogelijk normalisatie. Vooralsnog moeten clinici extra 
aandacht schenken aan kwaliteit van leven en cognitief functioneren na behandeling 
van de ziekte en het syndroom van Cushing. 
 
De hiervoor beschreven uitkomsten en risicomarker voor negatieve klinische 
uitkomsten zijn geselecteerd op basis van de literatuur, klinische ervaring en 
bekende biologische rationale. Alhoewel we ze zorgvuldig geselecteerd hebben, 
werden onze verwachtingen niet altijd bevestigd in een klinische studie, bijvoorbeeld 
geslachtsafhankelijke diagnostiek en behandelkeuzes voor het syndroom van Cushing 
konden niet worden aanbevolen gebaseerd op onze studieresultaten. Naast etiologie 




syndroom van Cushing moeten worden onderzocht om het potentieel voor 
geïndividualiseerde behandeling te vergroten. Bij de ziekte van Cushing zouden 
potentiële risicofactoren de grootte van het hypofyseadenoom en preoperatieve 
comorbiditeit, zoals diabetes mellitus, kunnen zijn. Echter, zelfs als verschillen 
tussen studiegroepen bevestigd worden betekent dit niet automatisch dat 
verschillende behandelstrategieën aanbevolen moeten worden. Alhoewel het niet 
altijd voorspelbaar is van welke factoren klinische uitkomsten afhankelijk zijn, lijkt 
behandeling van hypercortisolisme risico op morbiditeit en mortaliteit niet volledig 
weg te nemen. Daarom zou behandeling van patiënten met het syndroom van Cushing 
zich verder moeten uitstrekken dan alleen behandeling van hypercortisolisme om 





De studies in dit proefschrift over verschillende aspecten van hypercortisolisme 
benadrukken het belang van suppressie van de cortisolsecretie tot in het fysiologische 
bereik. Zowel hypercortisolisme als bijnierschorsinsufficiëntie hebben enorme, en 
soms zeer schadelijke, impact op zowel fysiek als psychisch functioneren. 
Behandeling van hypercortisolisme en bijnierschorsinsufficiëntie met als doel het 
herstellen van normale cortisolconcentraties met een fysiologisch circadiaan ritme 
sluit het risico op ongunstige uitkomsten niet uit. 
 
Om patiënten met zeldzame endocriene stoornissen, zoals het syndroom van Cushing, 
gelijkwaardige deskundige gespecialiseerde zorg te bieden in heel Europa, is recent 
het Europees Referentie Netwerk voor zeldzame endocriene ziekten (Endo-ERN) 
opgericht (35). Via een Endo-ERN referentiecentrum kan een multidisciplinair team 
van experts geconsulteerd worden voor een advies gebaseerd op gecombineerde 
specialistische expertise vanuit heel Europa (Figuur 1) (36). Dit ondersteunt de 
correcte identificatie van de onderliggende ziekte bij patiënten met hyper-
cortisolisme, waarmee vertraging in het diagnostische proces vermindert, en 
vroegere verwijzing naar een gespecialiseerd centrum kan worden bevorderd. 
Bovendien kan het multidisciplinaire team helpen bij behandelkeuzes, zoals bij 
patiënten met persisterende ziekte of recidief, of bij patiënten met het ectopische 
syndroom van Cushing zonder duidelijke bron van ACTH-productie. 
 
Wat Endo-ERN is voor patiëntenzorg, zijn internationale patiëntenregisters voor 
klinisch onderzoek. Voor het verbeteren van kennis en expertise wat betreft 
zeldzame endocriene ziekten is internationale uitwisseling van informatie middels 
deze patiëntenregisters cruciaal. Dit vergroot de populatie en daarmee de 
nauwkeurigheid van de verworven kennis door onderzoek vergeleken met 
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monocentrische cohortstudies. Helaas is bewustzijn van en deelname aan deze 
internationale registers relatief laag. Recent is het Europese register voor zeldzame 
endocriene ziekten (EuRRECa, https://eurreca.net/), wat gevoed zal worden door, 
en gekoppeld zal worden aan, Endo-ERN, mede gefinancierd door het 
gezondheidsprogramma van de Europese Unie. Naast het ontwikkelen van nieuwe 
internationale registers voor endocriene ziekten waarvoor tot nu toe nog geen 
register bestaat, moet bewustzijn van en deelname aan bestaande registers 
vergroten om optimaal functioneren van zowel Endo-ERN als patiëntenregisters te 
garanderen, wat een proces in ontwikkeling is (37). Patiëntenregisters bieden 
informatie over specifieke zeldzame ziekten, wat kan worden aangevuld met kennis 
vanuit de Endo-ERN over buitengewone gevallen wat betreft klinisch beeld, diagnose 
of behandeling. Gecombineerd kunnen zij effectief bijdragen aan onderzoek over 
zeldzame endocriene ziekten. 
 
Figuur 1: Consultatie van een multidisciplinair team (MDT) door een referentiecentrum van het Europees 
Referentie Netwerk voor zeldzame endocriene ziekten (Endo-ERN) namens een patiënt, waarmee deskundige 
gespecialiseerde zorg naar alle patiënten in Europa wordt gebracht middels het Klinische Patiënt 




Om onze kennis wat betreft hypercortisolisme effectief te vergroten is het uiterst 
belangrijk om alle statussen van cortisolexces en cortisoldeficiëntie, evenals alle 
klinische uitkomsten, duidelijk te definiëren en herkennen. Voor sommige diagnosen 
is de classificatie extra uitdagend, bijvoorbeeld in het geval van bijnierschors-
insufficiëntie, gezien de aspecifieke symptomen en de combinatie van stappen die 
nodig zijn om een juiste diagnose te stellen (aanwezigheid van hypocortisolisme, 
niveau van dysfunctie van de HPA-as en precieze oorzaak van bijnier-
schorsinsufficiëntie). Alleen als alle onderzoeksgroepen dezelfde definities gebruiken 
kunnen data met elkaar vergeleken worden, zowel direct in meta-analyses, als 
indirect in losstaande klinische studies. Bovendien moeten definities gebruikt in 
onderzoek overeenkomen met klinische definities om te verzekeren dat 
studieuitkomsten toepasbaar zijn in de klinische praktijk. Toekomstige studies 
zouden moeten kijken naar welke combinatie van testen (serumcortisol, 
urinecortisol, speekselcortisol, cortisol suppressietesten en -stimulatietesten) 
optimaal is voor het diagnosticeren van het syndroom van Cushing en wat de 
diagnostische consequenties zijn van inconsistente testresultaten. Verder zou 
toekomstig onderzoek zich ook moeten concentreren op hoe te differentiëren tussen 
het syndroom van Cushing en pseudo-Cushing, waarbij verhoogde cortisol-
concentraties gezien worden, evenals verschillende gradaties van symptomen die 
passen bij het syndroom van Cushing. Deze resultaten kunnen gebruikt worden bij het 
collectief kiezen voor een verbeterde definitie van het syndroom van Cushing, die in 
zowel onderzoek als de klinische praktijk gebruikt kan worden. Toekomstige meta-
analyses, die alleen studies meenemen waarin dezelfde definities voor diagnose en 
klinische uitkomsten zijn gebruikt, zullen waardevoller en makkelijker te 
interpreteren zijn dan bestaande meta-analyses. Echter, aangezien dit op het 
moment niet uitvoerbaar is door gebruik van verschillende definities in individuele 
studies, moeten auteurs van meta-analyses zorgvuldig zijn bij het bepalen welke 
conclusies getrokken kunnen worden uit de data en voor welke patiënten deze 
conclusies geldig zijn, wat wij hebben kunnen doen in alle meta-analyses 
gepresenteerd in dit proefschrift. 
 
Consistente definities zijn essentieel voor het optimaal functioneren van onderzoek 
en patiëntenzorg. Internationale patiëntenregisters leveren een grote hoeveelheid 
data over zeldzame ziekten, die onmogelijk door een enkel centrum verzameld kan 
worden. Als consistente definities door alle deelnemende centra gebruikt worden, 
bieden deze registers een uitstekende mogelijkheid grootschalige studies naar 
zeldzame ziekten met zeldzame uitkomsten uit te voeren, zoals het vinden van 
risicofactoren voor Addisonse crisis na behandeling voor het syndroom van Cushing. 
Echter, dataverzameling moet in overeenstemming zijn met potentiële onderzoeks-
vragen en data achteraf toevoegen moet mogelijk zijn. Bijvoorbeeld in het Europees 
Register voor het Syndroom van Cushing (ERCUSYN) zijn geen data beschikbaar over 
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Addisonse crisis en retrospectief data toevoegen is vrijwel onmogelijk (23). 
Bovendien zijn huidige patiëntenregisters alleen geschikt voor het onderzoeken van 
een specifieke zeldzame ziekte, zoals het syndroom van Cushing, terwijl een register 
voor het vergelijken van patiënten met verschillende onderliggende ziekten maar 
vergelijkbare klinische presentatie ontbreekt. Een dergelijk register zou ons in staat 
kunnen stellen patiënten met hypercortisolisme door verschillende onderliggende 
ziekten met elkaar te vergelijken. Kennis over de verschillen en overeenkomsten 
tussen de onderliggende ziekten kan leiden tot een zorgvuldigere bewerking van 
klinische richtlijnen voor specifieke patiëntengroepen met verschillende vormen van 
hypercortisolisme. Toekomstig onderzoek naar patiënten met het syndroom van 
Cushing kan deze grootschalige patiëntenregisters gebruiken voor een directe 
vergelijking van verschillende cortisolverlagende medicijnen, waarbij tevens gekeken 
wordt naar lange-termijn effectiviteit en bijwerkingen. Bovendien zouden 
gerandomiseerde gecontrolleerde studies moeten worden uitgevoerd om de 
veelbelovendste medicijnen met de hoogste effectiviteit en laagste risico op 
bijwerkingen direct te kunnen vergelijken. Kennis omtrent medicijn, of combinatie 
van medicijnen, van voorkeur kan de behandelopties verbeteren voor patiënten met 
persisterende ziekte of recidief, of voor diegenen met een contra-indicatie voor 
chirurgie.  
 
Tot slot kan extra kennis over de effecten van zowel endogeen syndroom van Cushing 
als exogeen hypercortisolisme waarschijnlijk de patiëntenzorg ook buiten de afdeling 
Endocrinologie verbeteren, aangezien deze aandoeningen model staan voor lange-
termijn blootstelling aan stress, wat een veelvoorkomende conditie is. Inzicht in de 
potentiële consequenties van lange-termijn blootstelling aan stress, zowel tijdens 
perioden van stress als na opheffing van de stressinducerende situatie, kan alle 
individuen blootgesteld aan lange-termijn stress helpen, inclusief patiënten met 
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Het schatten van het risico op bijnierschorsinsufficiëntie na behandeling met 
glucocorticoïden, en het stratificeren van de resultaten naar toedieningsvorm, 
ziekte, behandelduur en dosering. 
 
Opzet 
Systematische review en meta-analyse. 
 
Methode 
In PubMed, MEDLINE, Embase, Cochrane, CENTRAL, Web of Science, CINAHL en 
Academic Search Premier zochten we naar relevante studies. We includeerden 
originele artikelen die bijnierschorsinsufficiëntie diagnosticeerden bij volwassen 
gebruikers van glucocorticoïden. 
 
Resultaten 
We includeerden 74 artikelen met in totaal 3.753 deelnemers. Gestratificeerd naar 
toedieningsvorm varieerde het percentage patiënten met bijnierschorsinsufficiëntie 
van 4,2% bij nasale toediening (95%-betrouwbaarheidsinterval [BI]: 0,5%-28,9%) tot 
52,2% bij intra-articulaire toediening (95%-BI: 40,5%-63,6%). Gestratificeerd naar 
ziekte varieerde het percentage patiënten met bijnierschorsinsufficiëntie van 6,8% 
bij astmapatiënten die alleen inhalatieglucocorticoïden gebruikten (95%-BI: 3,8%-
12,0%) tot 60,0% bij patiënten met hematologische maligniteiten (95%-BI: 38,0%-
78,6%). Bij astmapatiënten varieerde het risico op bijnierschorsinsufficiëntie per 
dosering van 2,4% bij een lage dosering (95%-BI: 0,6%-9,3%) tot 21,5% bij een hoge 
dosering (95%-BI: 12,0%-35,5%), en per behandelduur van 1,4% bij een behandelduur 




Bijnierschorsinsufficiëntie komt vaak voor bij patiënten die glucocorticoïden hebben 
gebruikt. Er is geen toedieningsvorm, dosering, behandelduur of onderliggende ziekte 
waarbij bijnierschorsinsufficiëntie met zekerheid kan worden uitgesloten, hoewel 
hogere doses en een langere behandelduur een hoger risico geven. In de klinische 
praktijk moeten gebruikers van glucocorticoïden laagdrempelig getest worden op 
bijnierschorsinsufficiëntie, zeker patiënten met aspecifieke symptomen na het staken 
van glucocorticoïden. 
  





Glucocorticoïden worden gebruikt voor de behandeling van patiënten met een 
inflammatoire ziekte, maligniteit of orgaantransplantatie. Behandeling met 
glucocorticoïden is gericht op inhibitie van een inflammatoire respons (1-3). Het 
gebruik van deze medicijnen is gerelateerd aan talloze bijwerkingen en het is de 
meest voorkomende oorzaak van bijnierschorsinsufficiëntie (4, 5). Bijnierschors-
insufficiëntie kan ontstaan doordat chronisch gebruik van glucocorticoïden via 
negatieve feedback de hypothalamus-hypofyse-bijnier-as remt (4, 6).  
 
Bijnierschorsinsufficiëntie is een ernstige, mogelijk levensbedreigende bijwerking van 
het gebruik van glucocorticoïden. Om die reden hebben patiënten glucocorticoïd-
vervangende therapie nodig ten tijde van stress, zoals bij trauma, operaties of acute 
ziekte, totdat de functie van de bijnierschors volledig hersteld is. Soms is chronische 
vervangende therapie met fysiologische doses glucocorticoïden geïndiceerd (7-9). 
 
Noch de dosering en behandelduur, noch de toedieningsvorm lijken accurate 
voorspellers voor het ontstaan van bijnierschorsinsufficiëntie na gebruik van 
glucocorticoïden (10, 11). Daarnaast is niet duidelijk hoe groot het risico is op het 
ontstaan van deze bijwerking. Omdat veel patiënten glucocorticoïden gebruiken, is 
het klinisch relevant om kennis te vergaren over het risico dat het gebruik van deze 
medicijnen geeft op het ontwikkelen van bijnierschorsinsufficiëntie. 
 
Het doel van deze studie was inzicht te krijgen in het risico op bijnierschors-
insufficiëntie na glucocorticoïdgebruik. Dit deden we met een systematische review 
van de beschikbare literatuur en een meta-analyse van het percentage patiënten dat 
bijnierschorsinsufficiëntie ontwikkelt na gebruik van glucocorticoïden. Nevendoelen 
waren het stratificeren van de onderzoeksresultaten naar toedieningsvorm, 





Inclusie van artikelen  
We zochten in PubMed, MEDLINE, Embase, Cochrane, CENTRAL, Web of Science, 
CINAHL en Academic Search Premier naar mogelijk relevante studies uit de periode 
1975-februari 2014. Originele studies die bijnierschorsinsufficiëntie diagnosticeerden 
bij volwassen gebruikers van glucocorticoïden waren geschikt voor inclusie. De 
diagnose ‘bijnierschorsinsufficiëntie’ moest gesteld zijn op basis van een van de 




of 250 μg), de corticotropine-‘releasing’-hormoon (CRH)-test of de metyrapontest. Er 
waren geen restricties in dosis, behandelduur, type glucocorticoïd of toedienings-
vorm, met uitzondering van intraveneuze toediening. 
 
Definitie van bijnierschorsinsufficiëntie  
De afkapwaarde van de serumcortisolconcentratie voor het definiëren van bijnier-
schorsinsufficiëntie was ≤500 nmol/l of hoger, bijvoorbeeld ≤550 nmol/l (12-14). Bij 
de metyrapontest moest de concentratie 11-deoxycortisol ten minste 200 nmol/l zijn 
(12). We voerden een sensitiviteitsanalyse uit voor artikelen waarin ≥24 uur na de 
laatste dosering glucocorticoïden getest was op bijnierschorsinsufficiëntie (12). 
 
Risico op bias  
Voor alle geïncludeerde studies werd het risico op bias beoordeeld. Artikelen met een 
hoog risico op bias werden niet geëxcludeerd, aangezien dat zou leiden tot een klein 
aantal beschikbare studies voor de systematische review en meta-analyse. 
 
Statistische analyse  
De primaire uitkomstmaten van deze meta-analyse waren de gepoolde percentages 
patiënten die bijnierschorsinsufficiëntie kregen na gebruik van glucocorticoïden. 
Hierbij werd gestratificeerd naar toedieningsvorm, ziekte, dosering en behandelduur. 
De percentages werden gepoold in een logistisch regressiemodel. 
 
De analyse waarin werd gestratificeerd naar toedieningsvorm was gebaseerd op de 
toedieningsvorm die gebruikt werd, op het moment dat de bijnierschorsfunctie werd 
getest. 
 
Bij stratificatie naar ziekte werden de volgende ziektegroepen of indicaties 
onderscheiden: astma, inclusief chronische obstructieve longziekte (COPD), waarbij 
de behandeling bestond uit alleen inhalatieglucocorticoïden; astma, inclusief COPD, 
met ook andere toedieningsvormen; allergische rhinitis en rinosinusitis; 
dermatologische ziekten, zoals psoriasis, atopisch eczeem en lichen planus; 
reumatische ziekten, waaronder artrose en reumatoïde artritis; niertransplantatie; 
hematologische maligniteiten, waaronder myeloom, lymfoom, acute lymfatische 
leukemie en de ziekte van Hodgkin; nasale polypose; cystische fibrose; en de ziekte 
van Crohn. Ziektes of indicaties die slechts bestudeerd waren in een enkele studie, 
werden niet geïncludeerd in de analyse waarin naar ziekte werd gestratificeerd. 
 
De behandelduur werd als volgt gecategoriseerd: <28 dagen gebruik als ‘korte 
termijn’, 28 dagen-1 jaar als ‘gemiddelde termijn’ en >1 jaar als ‘lange termijn’. De 
dosering werd gecategoriseerd aan de hand van de aanbevolen doseringen, waarbij 
doses tussen de onderste en bovenste grens van de aanbeveling werden gecodeerd als 
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‘gemiddelde dosis’, doses onder de onderste grens als ‘lage dosis’ en doses boven de 
bovenste grens als ‘hoge dosis’. Aangezien de meeste doses die gebruikt werden 
suprafysiologisch waren, werden deze niet geclassificeerd naar fysiologische en 
suprafysiologische dosis. Voor de gebruikte grenzen voor het bepalen van de 
dosiscategorie verwijzen wij naar het originele artikel (15). 
 
De analyses van het risico op bijnierschorsinsufficiëntie per dosering en per 
behandelduur werden alleen bij astmapatiënten uitgevoerd om zo een homogene 
patiëntenpopulatie te creëren. Studiegroepen waarbij herhaaldelijk tests werden 
uitgevoerd na het staken van glucocorticoïden werden eveneens apart geanalyseerd. 
 
Voor verdere details omtrent inclusiecriteria, definitie van bijnierschorsinsufficiëntie 
en beschouwing van het risico op bias, en voor informatie over de zoekstrategie, 






De initiële zoekstrategie leverde 3.600 unieke artikelen op. Door in de referenties 
van belangrijke artikelen te zoeken, vonden we nog 16 artikelen. Dit leidde tot een 
totaal van 3.616 artikelen. Na het screenen op titel en samenvatting bleven er 365 
artikelen over voor een gedetailleerde beschouwing. De redenen voor exclusie staan 
in het originele artikel (15). Uiteindelijk includeerden we 74 artikelen in de meta-
analyse, met gegevens van 136 studiegroepen. Voor referenties van de geïncludeerde 
studies, zie het originele artikel (15). 
 
Studie-eigenschappen  
Uitgebreide informatie over de studie-eigenschappen staat genoemd in het originele 
artikel (15). De geïncludeerde studies waren gepubliceerd in de periode 1975-februari 
2014. Van de 74 artikelen waren er 36 gerandomiseerde gecontroleerde trials, 23 
cohortstudies en 15 dwarsdoorsnedeonderzoeken. De 74 studies bestonden uit in 
totaal 136 studiegroepen en 3.753 deelnemers, onder wie 124 gezonde vrijwilligers. 
 
Risico op bias  
Een gedetailleerde beschouwing van het risico op bias per studie is te vinden in het 
originele artikel (15). 
 
Uitkomsten van de studies  
Van de 3.753 deelnemers werd bij 1.190 de diagnose ‘bijnierschorsinsufficiëntie’ 




Bij 79 studiegroepen was de tijd tussen de laatste gift glucocorticoïden en de test op 
bijnierschorsinsufficiëntie ≥24 uur. Bij 7 studiegroepen, met in totaal 199 patiënten, 
was het gebruik van glucocorticoïden als comedicatie toegestaan. Voor details over 
de studie-uitkomsten en de gebruikte testen, zie het originele artikel (15). 
 
Symptomen van bijnierschorsinsufficiëntie  
Voor slechts 10 studiegroepen werden de symptomen van bijnierschorsinsufficiëntie 
gerapporteerd. In totaal meldden 10 van de 521 patiënten (1,9%) symptomen van 
bijnierschorsinsufficiëntie. Deze symptomen werden in geen van de artikelen 
systematisch gescoord. Na het testen op bijnierschorsinsufficiëntie werd de diagnose 
bij 98 patiënten (18,8%) uit de 10 studiegroepen gesteld. Zodoende zouden 88 
patiënten (89,8%) gemist zijn als alleen patiënten met symptomen van 
bijnierschorsinsufficiëntie waren getest. 
 
Gepoolde analyses  
We stratificeerden de onderzoeksresultaten naar toedieningsvorm, onderliggende 
ziekte, dosering, behandelduur en naar studies die meerdere keren op 
bijnierschorsinsufficiëntie testten. 
 





Van de patiënten die werden behandeld met orale glucocorticoïden had 48,7% (95%-
betrouwbaarheidsinterval [BI]: 36,9%-60,6%) bijnierschorsinsufficiëntie (Tabel 1). De 
risico’s op bijnierschorsinsufficiëntie bij gebruik van andere toedieningsvormen 
waren: 7,8% (95%-BI: 4,2%-13,9%) bij inhalatie, 4,7% (95%-BI: 1,1%-18,5%) bij dermale 
toediening, 4,2% (95%- BI: 0,5%-28,9%) na nasale toediening en 52,2% (95%-BI: 40,5%-
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die glucocorticoïden in meerdere toedieningsvormen tegelijkertijd gebruikten, had 
42,7% bijnierschorsinsufficiëntie (95%-BI: 28,6%-58,0%). 
 
Ziekte  
De gepoolde percentages bijnierschorsinsufficiëntie per ziekte of indicatie staan in 
Tabel 2. De gepoolde percentages varieerden van 6,8%-60,0%. Van de astmapatiënten 
had 11,1% (95%-BI: 6,8%-17,7%) bijnierschorsinsufficiëntie. Dit percentage was lager 
voor astmapatiënten die alleen inhalatieglucocorticoïden gebruikten (6,8%; 95%-BI: 
3,8%-12,0%) dan voor astmapatiënten die andere toedieningsvormen gebruikten 
(43,7%; 95%-BI: 27,3%-61,6%). 
 
Dosering en behandelduur  
De analyse per dosering en behandelduur werd alleen uitgevoerd bij astmapatiënten, 
zodat de populatie relatief homogeen was (Tabel 3). Het gebruik van 
glucocorticoïden in een lage, gemiddelde en hoge dosering leidde tot 
bijnierschorsinsufficiëntie bij respectievelijk 2,4% (95%-BI: 0,6%-9,3%), 8,5% (95%-BI: 
4,2%-16,8%) en 21,5% van de astmapatiënten (95%-BI: 12,0%-35,5%). Gebruik van 
glucocorticoïden gedurende korte, gemiddelde of lange termijn veroorzaakte 
bijnierschorsinsufficiëntie bij respectievelijk 1,4% (95%-BI: 0,3%-7,4%), 11,9% (95%-BI: 
5,8%-23,1%) en 27,4% van de astmapatiënten (95%-BI: 17,7%-39,8%). 
 

























































Na opnieuw testen  
We splitsten de onderzoeksresultaten in studies die opnieuw op bijnier-
schorsinsufficiëntie testten na 4 weken bij patiënten die voornamelijk gedurende een 
korte termijn hoge doses glucocorticoïden gebruikten, en studies die opnieuw testten 
na 6 maanden bij patiënten die voornamelijk gedurende een lange termijn 
gemiddelde doses glucocorticoïden gebruikten (Tabel 4). Bij studies die opnieuw 
testten na 4 weken had 38,7% van de patiënten (95%-BI: 21,7%-58,8%) 
bijnierschorsinsufficiëntie na de eerste test. Na 4 weken was dit percentage 
afgenomen tot 14,9% (95%-BI: 6,8%-29,5%). Studies die opnieuw testten na 6 maanden 
lieten zien dat 56,4% van de patiënten (95%-BI: 38,2%-72,9%) bijnierschors-
insufficiëntie had na de eerste test. Na 6 maanden was het percentage nog steeds 
25,3% (95%-BI: 19,4%-32,3%). 
 
Tabel 3: Absolute risico op bijnierschorsinsufficiëntie bij astmapatiënten na glucocorticoïdgebruik, 





Voor de sensitiviteitsanalyses combineerden we alle studies met astmapatiënten als 
referentiegroep; hierbij was het percentage bijnierschorsinsufficiëntie 11,1% (95%-BI: 
6,8%-17,7%). Als alleen studies werden geïncludeerd die expliciet vermeldden dat de 
tijd tussen de laatste dosis glucocorticoïden en het moment van testen ≥24 uur was, 
was het percentage patiënten met bijnierschorsinsufficiëntie iets lager (6,6%; 95%-BI: 
2,2%-18,3%). Als alleen studies werden geanalyseerd die gebruikmaakten van de 































  0 25 50 75 100
Bijnierschorsinsufficiëntie bij gebruik glucocorticoïden 
227 
 







Wij voerden een systematische review en meta-analyse uit om het percentage 
patiënten te schatten dat bijnierschorsinsufficiëntie ontwikkelt na gebruik van 
glucocorticoïden. Afhankelijk van de toedieningsvorm varieerde het percentage 
patiënten met bijnierschorsinsufficiëntie van 4,2% bij nasaal toegediende 
glucocorticoïden tot 52,2% bij intra-articulaire glucocorticoïden. Gestratificeerd naar 
ziekte varieerde het percentage van 6,8% bij astmapatiënten die alleen 
inhalatieglucocorticoïden gebruikten tot 60% bij patiënten met hematologische 
maligniteiten. Bij astmapatiënten varieerde het percentage bijnierschors-
insufficiëntie afhankelijk van de dosis van 2,4% (lage dosis) tot 21,5% (hoge dosis), en 
afhankelijk van de behandelduur van 1,4% (<28 dagen) tot 27,4% (>1 jaar). Dit 
betekent dat er geen toedieningsvorm, ziekte, dosering of behandelduur was waarbij 
het risico op bijnierschorsinsufficiëntie veilig kon worden uitgesloten. Hoewel het 
percentage patiënten met bijnierschorsinsufficiëntie na gebruik van glucocorticoïden 
in de tijd afnam, hield een substantieel aantal patiënten bijnierschorsinsufficiëntie 
na 6 maanden. 
 
Dit is de eerste meta-analyse die een brede blik biedt op het risico op 
bijnierschorsinsufficiëntie na gebruik van verschillende typen glucocorticoïden bij 
verschillende ziekten. Er is slechts 1 eerdere meta-analyse gepubliceerd over 
bijnierschorsinsufficiëntie bij astmapatiënten; deze studie rapporteert percentages 
bijnierschorsinsufficiëntie van 5,5%-13,3% (16). Dit komt overeen met de resultaten 
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uit onze meta-analyse, namelijk het percentage bijnierschorsinsufficiëntie van 6,8% 
bij astmapatiënten die alleen inhalatieglucocorticoïden gebruikten. 
 
De geïncludeerde studies vertoonden heterogeniteit in type glucocorticoïd, 
onderliggende ziekte, dosering, behandelduur en toedieningsvorm. Het is belangrijk 
te beseffen dat deze heterogeniteit de klinische praktijk weerspiegelt. Men moet er 
ook rekening mee houden dat de ziekte, dosering, behandelduur en toedieningsvorm 
onderling gerelateerd zijn. In onze gestratificeerde analyses hebben wij niet 
gecorrigeerd voor alle onderling afhankelijke factoren, met name omdat deze 
factoren ook in de klinische praktijk gerelateerd zijn, maar ook omdat meta-
regressietechnieken deze factoren niet uit elkaar kunnen halen zonder de 
beschikbaarheid van individuele-patiëntengegevens. 
 
Een hogere dosis van en een langere behandelduur met glucocorticoïden veroorzaken 
een hogere serumconcentratie hiervan en daarmee een hoger risico op 
bijnierschorsinsufficiëntie (17). Zo resulteert het gebruik van orale glucocorticoïden 
in hogere systemische concentraties glucocorticoïden dan het gebruik van 
inhalatieglucocorticoïden, of dermale of nasale glucocorticoïden, waardoor patiënten 
die orale glucocorticoïden gebruiken een hoger risico hebben op bijnierschors-
insufficiëntie (18). 
 
Ook intra-articulaire glucocorticoïden worden in hoge doses toegediend en hiervan is 
bekend dat zij binnen 24-48 uur de cortisolsecretie onderdrukken, die pas herstelt na 
1-4 weken (19). Dit vormt mogelijk een verklaring voor het frequente voorkomen van 
bijnierschorsinsufficiëntie bij deze patiënten. Het hoge risico op bijnierschors-
insufficiëntie wordt mogelijk ook verklaard doordat glucocorticoïdinjecties depots 
vormen. Hierdoor zijn er in het lichaam continu glucocorticoïden aanwezig en deze 
hoeveelheid neemt geleidelijk af, niet abrupt. 
 
De meeste studies die we includeerden gaven geen informatie over de therapietrouw. 
Hierdoor was het niet mogelijk om te kijken naar de impact van therapietrouw of 
therapieontrouw op het risico op bijnierschorsinsufficiëntie. De geïncludeerde studies 
toonden ook heterogeniteit in de bepaling van de cortisolconcentratie en in het type 
test dat gebruikt werd voor evaluatie van de cortisolreserve. De sensitiviteitsanalyses 
toonden geen wezenlijk verschil in het percentage bijnierschorsinsufficiëntie als 
alleen artikelen werden geïncludeerd die radio-immunoassay gebruikten, of als alleen 
artikelen geïncludeerd werden waarin de stimulatietest met ACTH 250 μg was 
gebruikt. 
 
Glucocorticoïden worden gebruikt door ten minste 1% van de bevolking (3). Onze 
meta-analyse toont dat het risico dat deze patiënten bijnierschorsinsufficiëntie 
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ontwikkelen 1,4%-60,0% is. Verschijnselen van lichte tot matige bijnierschors-
insufficiëntie, zoals vermoeidheid en buikklachten, zijn aspecifiek en worden dus niet 
zonder meer toegeschreven aan bijnierschorsinsufficiëntie. Daarnaast ontbreken 
accurate voorspellers om onderscheid te maken tussen patiënten die 
bijnierschorsinsufficiëntie zullen ontwikkelen en zij die dat niet ontwikkelen. Ook is 
er onvoldoende bewijs dat enig afbouwschema na gebruik van glucocorticoïden 
efficiënt of veilig is (20). 
 
Daarom is het aan te bevelen alle patiënten met onverklaarde symptomen na het 
afbouwen van glucocorticoïden te testen op mogelijke bijnierschorsinsufficiëntie. 
Patiënten met een onvoldoende cortisolrespons moeten worden behandeld met 





Alle patiënten die behandeld worden met glucocorticoïden lopen risico op het 
ontwikkelen van bijnierschorsinsufficiëntie. In de eerste plaats impliceert dit dat 
behandelaars patiënten die glucocorticoïden gebruiken moeten informeren over het 
risico op en de symptomen van bijnierschorsinsufficiëntie. Daarnaast moeten 
behandelaars overwegen patiënten te testen op bijnierschorsinsufficiëntie na het 
staken van hoge doses glucocorticoïden of een langetermijnbehandeling met deze 
medicijnen. Ten slotte moet met name laagdrempelig op bijnierschorsinsufficiëntie 






1. Bijnierschorsinsufficiëntie is een veelvoorkomende bijwerking na het gebruik 
van glucocorticoïden. 
2. Van de ten minste 1% van de bevolking die glucocorticoïden gebruikt, 
ontwikkelt 1,4%-60% bijnierschorsinsufficiëntie, waarbij het risico afhangt 
van de behandelduur, toedieningsvorm, dosering en onderliggende ziekte. 
3. Als een patiënt met glucocorticoïden wordt behandeld, is er geen enkele 
toedieningsvorm, ziekte, dosering of behandelduur waarbij het risico op 
bijnierschorsinsufficiëntie kan worden uitgesloten. 
4. Patiënten dienen bij het begin van een behandeling met glucocorticoïden 





5. Vanwege de aspecifieke symptomen die bijnierschorsinsufficiëntie kan 
veroorzaken, is het raadzaam om patiënten met onverklaarde symptomen na 
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We thank Dr. Lindholm for his interest in our paper and for drawing attention to two 
important issues: first, the definition of adrenal insufficiency; and second, the 
association between the result of a biochemical test for adrenal insufficiency and the 
need for hormone replacement. 
 
Adrenal insufficiency could be defined as insufficient cortisol secretion in response to 
stress, of which medical emergencies clearly pose the highest risk. At present we can 
only assess adrenal function through biochemical measurements and dynamic tests. It 
is well known that no test — including the ACTH test — is infallible. It might also be 
that tests perform differently according to the specific condition (pituitary or adrenal 
disease, glucocorticoid users, patients on intensive care, etc.). Also, cutoff values 
can be debated (1). When performing a systematic review, one has to be pragmatic, 
and it is an empirical fact that the ACTH test is the most frequently used; for that 
simple reason, our study relies largely on the ACTH test. 
 
We fully agree that an inadequate response to the ACTH test does not automatically 
demand glucocorticoid replacement. For good reasons, there are limited data on the 
risk of glucocorticoid not being replaced, and pharmaco-epidemiological studies 
should therefore be undertaken to address this important clinical issue. For the time 
being, the decision about glucocorticoid replacement is therefore at the discretion of 
the physician in charge. 
 
The main clinical message from our study is that some degree of secondary 
adrenocortical failure is detectable in many former glucocorticoid users (2). This is 
the reason that in glucocorticoid users admitted to the intensive care unit, high-dose 
glucocorticoid replacement is started immediately (3). But we argue that knowledge 
of this risk is also of relevance apart from the medical emergencies because adrenal 
insufficiency is directly related to a decreased quality of life, which will improve 
after substitution. Awareness of this risk in glucocorticoid users is important, given 
the high prevalence of such users and the nonspecificity of symptoms of adrenal 
insufficiency that can be difficult to disentangle from symptoms of underlying 
diseases or treatment. Physicians should therefore utilize a low threshold to test for 
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